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Management 
ABSTRACT 
We performed three distinct studies of low back pain treatment using a generalizable 
database of medical and pharmaceutical claims paid by multiple commercial payers. 
Objectives: 
(1) Evaluate the cost-utility, from the US commercial payer perspective, of Cognitive 
Behavioral Therapy (CBT) to manage chronic non-specific low back pain (LBP); 
(2) Identify unique subgroups of people with incident LBP based on health care 
utilization; (3) Specify the distribution of costs for people with intervertebral disc 
herniation (IDH). 
Methods: 
(1) We constructed and validated a Markov model with 1-year and 10-year time horizons. 
We applied rates of service utilization and recovery from a randomized controlled trial 
assessing CBT to treat chronic LBP, estimated standardized costs from the claims 
database, and derived utilities and recurrence rates from the literature. (2) Using Latent 
vi 
Class Analysis, we identified four subgroups (classes) of people with LBP based on 
utilization over 27 months (9 quarters). We modeled increasing numbers of classes and 
service combinations to build the final model. (3) We compared empirical cost data to 
four candidate distributions. 
Results: 
(1) The incremental cost-utility ofCBT, compared to education, was $7197 per QALY in 
the first year and $5833 per QAL Y over ten years. (2) We identified four mutually 
exclusive subgroups of patients. Two groups were very likely to receive services in each 
quarter (Pr>0.70 for 7% and >0.40 for 33%), implying continuing symptoms or frequent 
relapse. The extremely high utilization group (8%) had >85% likelihood of receiving 
services, >70% painkillers, in each quarter after the first. Differences in types of service 
received imply the groups were characterized by pain or disability. Just over half the 
patients recovered, not receiving services after the frrst quarter. (3) Lognormal 
distribution fit costs ofiDH more closely than Weibull, Gamma, or Exponential. Results 
for all studies were robust across numerous sensitivity analyses. 
Conclusions: 
(1) CBT is a cost-effective approach to managing NSLBP among commercial health 
plans members, regardless of plan structure. (2) Almost half of people with low back pain 
are at high risk of continuing symptoms or repeated relapse over 27 months. (3) Costs for 
IDH follow a Lognormal distribution. 
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1 BACKGROUND 
1.1 Current knowledge 
The fundamental challenge facing low back pain researchers is the need to define "low 
back pain." The term is used to describe actual pain, sometimes but not always specified 
as being the costal margin and gluteal fold, but is also used to describe radiculating pain -
that which extends to the leg or foot- or disability resulting from structural changes to 
the spine, with or without pain. With no universally agreed upon definition, there are 
many ways to measure low back pain, including pain scales, disability metrics, quality of 
life scores, and perceived "bothersomeness," which summarizes the other attributes[!] 
and is increasingly used as an outcome.[2-5] 
With no single definition, diagnosis is a significant challenge for clinicians. The 
presence of pain in the leg or foot aids diagnosis.[6, 7] The three defmitive causes of low 
back pain involve such pain. 
1. Intervertebral disc herniation (IDH) is the breakdown ofthe cushioning 
structure between two vertebrae such that protrudes, extrudes, or sequesters, 
putting pressure on the spinal cord. In addition to radicular pain, clinical 
evidence includes nerve root compression, manifesting as a positive nerve 
root tension sign (positive straight leg raise test or femoral tension sign), 
reflex (asymmetric depressed reflex), sensory (asymmetric decreased 
sensation in a dermatomal distribution), or motor (asymmetric weakness in a 
myotomal distribution) deficit with positive nerve root tension signs. 
Although responsible for less than 5% of all low back problems, IDH is the 
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most common cause of nerve root pain and surgical interventions. 
2. Spinal stenosis is a narrowing of the central spinal canal, lateral recesses, or 
neural foramina due to encroachment on the neural structures by the 
surrounding bone and soft tissue, resulting in pressure on spinal cord and 
pseudoclaudication (bilateral pain in the buttock, thigh, or leg on ambulation 
that improves with rest). 
3. Degenerative spondylolisthesis, the degenerative forward slippage of one 
vertebral body on another, typically L3 relative to L4 or L4 relative to L5, 
possibly resulting in either pseudoclaudication or radicular pain. [8-12] 
These three mechanical causes are present in a small proportion of people with 
low back pain, as many as 15% of cases, and approximately a third of cases overlap. [ 13] 
The remainder of cases, "non-specific low back pain," (NSLBP) remains more a 
symptom than a diagnosis.[14] Some non-specific causes are considered "mechanical," in 
that they are also presumed to arise from from spinal structures such as bone, ligaments, 
discs, joints, nerves, and meninges.[15] However, the mechanism by which 
zygapophysial joint pain, disco genic pain, sacroiliac joint pain, and myofascial pain 
actually result in pain are not well understood. 
NSLBP may be due to strains or sprains of musculature. In some cases, such as a 
strain in the erector spinae that the patient clearly associates with an instance of heavy 
lifting, the pain is expected to abate within a few days. Other muscular strains, however, 
are easily confused with mechanical low back pain. For example, a strain of the 
piriformis muscle, a lateral rotator that attaches to the sacrum and femur, can result in a 
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"vicious cycle of pain and spasm."[16] The sciatic nerve passes either above, below, or 
even through the piriformis muscle before it travels down the leg, so inflammation of the 
piriformis can mimic the effects ofiDH. 
Adding to the complexity of defining NSLBP is the varying terminology used: 
NSLBP with the same presentation may be called lumbago by general practitioners, 
hyperextension by physical therapists, facet joint disorder by chiropractors and 
degenerative disc disorder by orthopedists.[17] 
For the purposes of this document, "NSLBP" is all manifestations of pain in lower 
back, or of"disability," defined as limitations on functionality, other than the three 
specific causes of low back pain and disability defined above. In some cases, research 
cited will also include those three causes, which may or may not be clear in the 
documentation of that research. When possible, this document will clarify whether the 
research is ofNSLBP alone or NSLBP including one or more of the three causes. 
Because NSLBP is "characterized by variability and change rather than 
predictability and stability,"[18] there is no clear definition of an episode of low back 
pain, of its duration,[19] or ofrecovery.[20-24] We consider an incident case to be one 
with no evidence of low back pain- from any cause - during the six months prior to a 
person's index diagnosis oflow back pain. Prior research has defined incident cases 
based on pain-free durations, if any, ranging from three months[4, 25] to a "lifetime 
history of no significant LBP problem."[26] 
Many NSLBP patients receive diagnostic services, particularly MRI, that do not 
result in diagnostic clarity.[27] Perceived structural problems identified by MRI are not 
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correlated with pain intensity or recovery, whether analyzed for specific indicators[28-
30] or a score incorporating multiple elements.[31] MRis do not discriminate between 
those who will or will not get surgery.[32] Among people with incident low back pain, 
MRis do not identify subsequent structural changes.[26] 
Many NSLBP patients also receive treatments that may not help.[33-35] Although 
evidence is good that epidural steroid injections manage disc herniation, it is limited to 
fair that it is effective in the absence of herniation or stenosis, regardless of specific 
procedure.[36-38] A paucity of strong research on percutaneous lumbar laser disc 
decompression results in limited support for its use,[39] while an abundance of evidence 
suggests that lumbar fusion should not be used. [ 40] 
Ironically, while evidence-based guidelines are not followed,[41, 42] some 
physicians report fmding low back pain "uninteresting" and "clinically 
unchallenging." [ 4 3] In a perhaps related finding, in visits with providers ranging from 
chiropractors to neuro- and orthopedic surgeons, patients' backs are often not visually 
inspected (43%) or palpitated (20%).[44] 
There is a great need for low back pain services. Annual prevalence of acute pain 
among adults is 15 to 45%, with 25-30% point prevalence;[45-47] prevalence of pain 
lasting at least three months is 5-8% of all adults and 19% of working adults. [ 48] 
Approximately 6% to 9% of adults receive health care services for low back pain 
annually.[49] Per capita costs are increasing: from 1997 to 2006, the mean adjusted per-
user expenditures increased 37% (from $13,040 to $17,909) for inpatient hospitalizations, 
139% (from $166 to $397) for prescription medications, and 84% (from $81 to $149) for 
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emergency department visits.[34] Low back pain is responsible for as much as 75% of 
the costs due to sick leave and disability and affects presenteeism.[50, 51] 
The modified Andersen model in Figure 1.1 demonstrates that need is influenced 
by risk factors such as age, prior episodes of low back pain, and psychological factors. 
Depression and anxiety are known to have a complex relationship with low back 
pain.[52-55] Emotional and cognitive factors such as fear-avoidance, health literacy, 
cultural factors, and prior management of adversity also affect perceived need.[56-60] 
Risk markers, particularly education, have a poorly understood relationship with 
low back pain. Need alone is not sufficient to result in getting health care services.[61] 
Having health insurance is an enabling resource that can influence a person's decision to 
seek health care for low back pain. Other enabling resources, such as having flexibility 
and control over one's time, may also contribute. Finally, people may seek services in 
order to attain narcotics, with or without actual pain.[62, 63] 
The heterogeneity displayed in the figure and discussion above presents 
challenges to defining a specific research subject, determining appropriate inclusion and 
exclusion criteria, and defining, measuring, and assessing success. The three aspects of 
low back pain that will be addressed in this dissertation are highlighted in the figure: the 
contribution of psychological factors, the risk factor of having prior low back pain 
(specifically, the lack of it), and (lumbar) Intervertebral Disc Herniation. 
1.1.1 Patient involvement and psychological contributors to NSLBP 
Patients seek clarity and solutions. A meta-analysis of 12 qualitative and 8 
quantitative studies of patient satisfaction of, and expectations for, treatment finds that 
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Figure 1.1. Conceptual Framework 
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patients expect an explanation and "sickness certification" (i.e., a diagnosis and 
emotional confirmation), specific advice on managing their pain, and pain relief. They 
get frustrated when they get no diagnosis, inadequate diagnosis, or conflicting 
diagnoses.[64] Those who participate in their own care tend to be more satisfied and 
experience better outcomes.[65] However, many patients feel they don't have the tools 
for self-management. [ 6] 
Clinical understanding is shifting to recognize that low back pain may best be 
treated using a chronic care model; that it can be treated but not cured, and that patient 
self-care strategies are essential to managing pain, alleviating symptoms, and preventing 
relapse.[27] A patient-centered approach puts classic medical interventions, with their 
technical focus, in a theoretical framework that includes the patients' psychological as 
well as physical characteristics. [ 66] 
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Psychological factors have a strong influence on a patient's experience with low 
back pain. Fear-based avoidance predicts impairment[67] and directly contributes to 
improved function,[68] "catastrophizing" mediates both depression and pain following 
treatment.[69] Lowering the level of anxiety and depression can directly decrease low 
back pain severity.[70] Of psychological factors, "pain-related distress factor" was found 
to have the strongest association to LBP patients' outcomes, accounting for 34.6% ofthe 
variance in pain intensity and 51.1% of the variance in disability. [71] 
Cognitive Behavioral Therapy (CBT) has emerged as a very promising 
psychology-based approach because it targets modifiable risk factors.[72]. CBT, a 
multidisciplinary biopsychosocial approach to rehabilitation, aims to teach patients to 
address their problems using specific psychological and practical skills. CBT directly 
addresses common psychological characteristics such as stress, maladaptive pain coping 
behaviors, fear-avoidance, catastrophizing, depression, and anxiety.[55, 67, 73-75] 
CBT is particularly effective relative to wait-list controls; its effectiveness relative 
to physical therapy or exercise, information/education, biofeedback, operant behavioral 
treatment, lumbar spinal fusion surgery, and relaxation training is less clear. The 
variation in the strength of the eviqence is attributed to variations in study quality and in 
implementation of CBT, including variations in amount of contact time, provider 
expertise, components included, and method of delivery.[76, 77] The American College 
of Physicians and the American Pain Society guidelines include a "strong 
recommendation [with] high-quality evidence" for physicians to consider CBT for 
patients with nonradicular low back pain while European guidelines indicate that CBT is 
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"most promising" for managing NSLBP.[78, 79] 
As CBT is increasingly used to treat low back pain, there is interest in whether it 
is cost-effective.[80, 81] 
1.1.2 Identifying subgroups 
Researchers have called for better classification of patients with NSLBP despite decades 
of efforts including methods based on musculoskeletal, biomechanical, psychosocial, 
neurosensory, and behavioral dimensions.[82, 83] Defining and refming subgroups is 
critical for three reasons. First, researchers must be able to specify patient selection 
criteria that will minimize heterogeneity in order to produce interpretable effects. 
Incorrect classification can result in null fmdings because sub-groups may have opposite 
features relative to the comparison group. 
Second, clinicians must better understand the course of low back pain in order to 
make appropriate recommendation for, and referrals to, care. Physicians report wanting to 
know which patient characteristics are relevant to treatment choices and recovery.[84] 
Being able to distinguish among clinically meaningful subgroups will result in more 
effective use of diagnostic tools and upstream decision-making. Those patients whose 
condition becomes disabling account for a disproportionate share of services, and 
therefore costs, associated with LBP.[47, 67, 85, 86] Knowing whether, and when, the 
condition becomes severe could help clinicians time intervention to avoid that outcome. 
Ultimately, accurate classification could contribute to better prediction rules, reduced 
variation in practice, and improved outcomes.[87-94] 
Third, patients' anticipation ofthe potential duration and intensity of symptoms 
8 
contributes to their desire for treatment. Currently, many patients with NSLBP get 
surgery but do not benefit, because it is inappropriate for them.[27, 95] Many have 
recurrent episodes, recurrent sciatica, or re-operation; both orthopedic and chiropractic 
evidence-based guidelines now exclude surgery from all but tightly specified cases.[17, 
18, 96, 97] Better classification could result in better patient education and more realistic 
expectations. 
Two studies have used latent cluster analysis to identify cohorts such as 
"fluctuating" or "persistent" at mild, moderate, or severe levels ofpain.[9, 98] Each study 
uses a different methodology and has a fairly small sample that reflects some selection 
bias. Dunn (2006) recruited patients with low back pain from general practitioners' 
offices.[9] Of776 subjects who both completed a questionnaire and consented to be 
included, only 342 (44%) completed at least four of six monthly questionnaires. Using 
latent cluster analysis with pain as an outcome, Dunn identified four classes: recovering, 
mild persistent, severe persistent, and fluctuating. Although they collected data for 12 
months, the clusters were based on the first 6 months' data. 
Tamcan (2010) sought to examine the "natural course" oflow back pain by 
recruiting from the "general population," specifically participants in a Swiss cross-
sectional study of musculoskeletal health, rather than from people who had sought care. 
Tamcan identified three persistent classes - mild, moderate and severe - as well as a 
fluctuating class. Pain was self-reported using weekly pain diaries, which may be subject 
to recall bias. Despite many and early email and paper mail reminders, the study required 
only 50% completed diaries; the final sample had 305 subjects. Tamcan also determined 
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whether subjects changed clusters across four three-month time periods. 
The results of these two studies overlap, but also demonstrate differences that are 
due to the different cohorts. Additional research, using a third, larger cohort and ensuring 
no missing data, could refine the cohorts and lead to analysis of biomechanical, clinical, 
or psychosocial differences between the groups. Research using administrative data could 
analyze health care services received as implicit measures of pain or disability. 
1.1.3 Costing care for IDH 
New and existing technologies are increasingly tested for cost-effectiveness as well as 
clinical effectiveness. Cost-effectiveness studies often use one of four methods. 
1. Directly measure costs, and use the exact costs in the model.[75, 99] 
2. Estimate costs, and use those costs in the model. For example, Lambeek 
collected questionnaires covering a 3-month recall period at each of 3, 6, 9, 
and 12 months after randomization, applied the estimated totals. Tosteson et 
al. had patients recall use of services, missed work, and need for unpaid 
caregiving over less time, 4- or 6-week recall periods, at 6 weeks and 3, 6, 12, 
and 24 months (2008), and 36 and 48 months (2011), extended the results 
across the uncovered time periods, applied discount rates, then applied the 
estimated totals. [ 100-1 02] 
3. Assume that patients will continue receiving treatment in subsequent years at 
the same rates, which is appropriate for interventions intended to affect 
subsequent care-seeking. [ 1 02, 103] 
4. Assess costs using individual patient data from randomized clinical or 
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behavioral trials, integrating both the health gains and the financial costs into 
one summative estimate.[l04] 
As some spine disorders become more accurately diagnosed, randomized clinical 
trials (RCT) compare the effect of treatment on those with a specific condition. RCTs are 
often shorter than the time period desired for cost-effectiveness analysis. Researchers 
need to know the expected distribution of costs over a longer time period. Modeling the 
tail is particularly challenging, as it will typically be highly skewed and drive the 
population mean. A second challenge is determining whether a truncation point should be 
applied, after which costs are not included. Meeting these challenges requires two 
elements: a large sample, in order to mute the effect of individual high-cost subjects, and 
a long follow-up period to account for all relevant costs. 
Intervertebral disc herniation (IDH), in particular, is increasingly studied as a 
distinct, treatable spine disorder,[l05-lll] and some have called its cost-effectiveness to 
be determined.[ll2] As noted above, imaging can document the presence of disc 
herniation congruent with symptoms, confirming that IDH is the cause of the symptoms. 
It is not clear, however, whether imaging leads to more accurate assessment and, 
therefore, more appropriate treatment and better outcomes, or detects a wider range of 
abnormalities, resulting in higher rates of surgery and subsequent higher costs.[ll3] 
Jarvik randomly assigned patients with suspected IDH (specifically, low back 
pain with or without radiating leg pain) to radiograph (x-ray) or rapid magnetic resonance 
imaging (rMRI) and measured costs accrued over 12 months as well as outcomes.[ll3] 
They found that subjects in the rMRI arm did have higher rates of specialist consultations 
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and surgical procedures, but the economic effect remained "ambiguous." 
Two other sets of researchers used Jarvik's data to attempt to assess the cost-
effectiveness of their results, in part by determining the appropriate theoretical 
distribution to apply.[104, 114] Thompson and Nixon found that mean estimated costs 
applying the Lognormal distribution were approximately $450 higher in the control group 
relative to applying the Gamma distribution. (The distribution did not affect the MRI 
group's estimated costs.) Choice of model would strongly affect the interpretation of cost 
effectiveness of the diagnostic tools. 
Not being able to determine whether data points in the sample of 328 were true 
outliers or, in a larger data set, would have been part of a tail, Thompson and Nixon 
modeled various truncation points, both within and beyond the actual data range. They 
found that the models were very sensitive to the truncation point. They argue that a log-
logistic model (which they did not estimate), with its heavy tail, would produce even 
higher cost estimates. As they note, "there is no underlying theory that determines what 
might be a suitable choice of distribution for cost data"(p.422); more robust data are 
necessary. 
Conigliani and Tancredi extended this analysis by using Bayesian model 
averaging, which takes into account the inferences obtained with the set of plausible 
models that have a non-zero posterior probability. The set of models includes lognormal, 
gamma, generalized Pareto, Weibull, log-logistic, and inverse Gaussian distributions. 
Conigliani and Tancredi also find that the estimation of the relative weight of the right-
hand tail has a strong influence on the models, so "it is very difficult to decide which 
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results one should believe" (p.814) A much larger sample is required to do that. 
1.2 Study Objectives 
I performed three studies, each of which addresses a different aspect of spine disorders, 
studies a different population of patients, and benefits different stakeholders. Each 
addresses a different gap in the literature, which is detailed in the study-specific sections. 
The first study expands upon the increasing body of evidence supporting the 
clinical effectiveness of Cognitive Behavioral Therapy (CBT) in helping patients manage 
their pain.[78, 79, 115, 116] It assesses whether CBT is cost-effective in the U.S. 
commercial context. 
The second study adds to the classification literature by analyzing patterns of care 
received among people who sought it over a 27-month period. Using latent class analysis, 
we identify subgroups based on multiple types of service received. The few studies that 
have assessed patterns in a population-based sample using longitudinal design have 
demonstrated overlapping, but not congruent, groups, with variations resulting from the 
cohort.[9, 98] With a third cohort, we add another data point towards understanding 
actual clinical subgroups. 
The third study produces accurate cost estimation of one specific cause of LBP, 
intervertebral disc herniation (IDH). It compares the cost distribution of health care 
utilization by patients with intervertebral disc herniation who do, or do not, receive 
diagnostic magnetic resonance. Previous attempts have been limited by relatively small 
sample sizes, so the choice of model was influenced by outliers.(104, 117] We uniquely 
perform univariate analysis of the empirical data, so produce results uninfluenced by 
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covariates. Table 1.1 summarizes the studies. 
Table 1.1. Summary of proposed studies 
Contribution to the Benefit to Study subjects 
literature 
Study One: Assess cost- Payers, who are interested Patients with 
Cost- effectiveness of CBT in effective treatments to NSLBP, 
Effectiveness to teach patients to replace the ineffective randomized to 
of Cognitive manage low back pain, ones being excluded from education alone 
Behavioral in the U.S. commercial evidence-based or with CBT. 
Therapy context. guidelines.[27, 118, 119] (Secondary 
(CBT) for Patients, who need analysis.) 
Low Back effective treatments. 
Pain Impact: If CBT is cost-
effective for US insurers, it 
may be made available to 
more people who could 
benefit from it 
Study Two: Contribute to ongoing Researchers, who must Adults with 
Classification classification of low identify and select diagnosed low 
of patients back pain into discrete, homogeneous groups and back pain and no 
with low back defmable, and understand how sample alternative causes 
pain. diagnosable groups. selection affects findings. forLBP. 
Efforts to classify Clinicians, who need new 
patients based on approaches to 
clinical presentation understanding and 
have not resulted in predicting the course of 
valid predictive models low back pain. 
or the ability to specify Patients, who desire 
study inclusion and distinct diagnoses and 
exclusion criteria effective treatment. 
sufficient to minimize 
heterogeneity. 
Study Three: Researchers Researchers, who require Adults with 
Treatment performing clinical appropriate models to diagnosed 
cost trials on intervertebral produce accurate results . intervertebral 
distributions disc herniation need to Funders, as shorter studies disc herniation, 
extrapolate results are more affordable. with X-ray or 
beyond study time Clinicians, who need rMRI, and no 
frame. results to inform alternative 
diagnostic and therapeutic potential causes 
decisions. forLBP. 
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2 DATA 
2.1 Data Source 
This section describes the source of the data that will be used in the three proposed 
studies and the overall inclusion and external criteria. Each study will use a different sub-
set ofthis data, as described in that study's section. 
The Ingenix Impact Research Database includes adjudicated medical and 
pharmaceutical claims over sixty million lives from multiple large U.S. insurance 
companies. The Database, which is updated every three months, includes demographic 
and emollment information, inpatient and outpatient diagnoses, surgical procedures, and 
prescription records. The data are nationally representative, quality controlled, and meet 
HIP AA (Health Insurance Portability and Accountability Act of 1996) compliant. The 
data contributor (health plan) is not included. Standard unit prices have been applied to 
all services in the database, removing any proprietary financial information from data 
contributors. The health plan members in the Database are distributed throughout the 
country approximately proportionate to the population, with the exception of relatively 
high representation from New England and relatively low representation from the Pacific 
region. The Database is currently used to support different research projects including 
methods development, health services research, benchmarking, and research on 
pharmaceutical agents. It has been used for numerous peer-reviewed studies. 
Permission was granted to use this data and a data use agreement was signed on 
July 29, 2011. The data extraction was coded in Statistical Analysis Software (SAS) 
version 9.2 by the author. 
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The source database had a claims date range of July 1, 2008 through June 30, 
2011, with cost data collected through September 30, 2011 to account for payment lag. 
People with low back pain were identified, and all claims data for up to 30 months 
following their index diagnosis collected. The specific steps are as follows. 
2.2 Overall inclusion criteria 
Adult men and women (age 18-64) of commercial insurance plans, including subscribers 
and others covered under the subscribers' plan, are included. Subjects will include men 
and women, as both are affected by low back pain. 
In order to ensure that all relevant data are available, we included only people 
with concurrent medical and pharmacy benefits and no gaps in coverage. This approach 
will ensure that, in Study Two, time periods with no data accurately reflect no utilization, 
rather than missing data, and, in Study Three, all reimbursed costs are captured. 
We identified people who, during the three month time period: 
1. had at least one diagnosis indicating non-mechanical low back pain. The 
benefit of requiring just one diagnosis is that it will capture people who have a 
brief episode that seems important enough to merit seeking care, but resolves 
quickly. However, it also risks capturing false positives with miscoded 
diagnoses. Other studies of utilization, particularly of musculoskeletal 
conditions, have also used just one claim.[l20-123] 
2. had no indication of other plausible causes of low back pain. 
The timeline in Figure 2.1 broadly demonstrates the six months prior to the 
subject's index diagnosis in which there is no evidence oflow back pain ("clean period") 
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or is evidence (blue), the patient identification period (orange), and the full data 
extraction period (yellow). Note that the 180-day clean period and 27 -month follow-up 
will be specific to each subject. A person whose first spine disorder diagnosis is on 
January 1 (Member A) will have a clean period starting July 1, whereas a subject whose 
first spine disorder diagnosis is on March 1 (Member B) will have a clean period starting 
September 1. 
Using this example, Member B can have no more than 27 months of claims to 
analyze subsequent to the index diagnosis. Member A's follow-up period will be 
truncated to 27 months to ensure that every subject has the amount of data contributing to 
Studies Two and Three. 
Figure 2.1: Data Extraction Period 
2008 2009 I 2010 I 2011 
J lA IS IO IN ID J IF IM lA IM IJ IJ lA IS IO IN ID IJ IF IM lA IM IJ IJ lA IS IO IN ID IJ IF IM lA IM IJ 
Clean Period Claim 10 1 Claim analysis 
As a first step toward determining how to define the sample, we looked to prior research. 
Table 7.1 in Appendix 1 lists International Classification of Diseases, 9th Revision (I CD-
9) diagnosis codes that were used in previous research to identify patients with spine 
disorders. Cherkin et al. first used ICD-9 codes to identify spine disorders.[124] This list 
was subsequently used in numerous other studies, some of which, because their data 
source was limited to the frrst three digits of the codes, could not achieve the same level 
ofspecificity. [34, 35, 96, 125, 126] 
Our objective was to identify people with (a) NSLBP (for study one) and 
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(b) specific diagnoses of intervertebral disc herniation (IDH) (for study three), spinal 
stenosis, or degenerative spondylolisthesis (for study two). Therefore, we rejected codes 
on this list which: 
• identify causes of back pain that we are explicitly not addressing, such as 
fractures and sequelae of previous surgery (e.g., 722.8, postlaminectomy 
syndrome). 
• refer to the thoracic only, cervical, or unspecified regions of the spine (e.g. , 
722.30, Schmorl's nodes, unspecified region). 
• indicate a systemic, rather than spine-specific, problem (e.g., 715 .0, 
Osteoarthritis, generalized). 
In cases where there was only moderate agreement between researchers, we 
weighted Cherkin et al.'s usage more heavily than the other sources (see Table 7.1). 
2.2.1 Overall exclusion criteria 
Children (age less than 18) are excluded because the objective is to classify spine 
disorders in adults. The elderly (age 65 and older) are excluded for two reasons. First, the 
source database is of people with commercial insurance, so the number of elderly is too 
small to ensure x. Second, Medicare data are more appropriate for analyses of low back 
pain in the elderly, as it is the most common source of insurance. 
Some cases of back pain can be attributed to existing conditions, such as 
neoplasm, trauma, inflammation, infection, or the temporary structural changes of 
pregnancy.[124] We identified people who have at least two claims indicating any of 
these conditions during the six months prior to the subject' s index diagnosis oflow back 
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pain. In some cases, the back pain may result in a diagnostic investigation that finds such 
a cause. Therefore, we also excluded people who had neoplasm, inflammation or 
infection diagnoses within 90 days of their first low back pain claim. The rationale for 90 
days has clinical and statistical support. Kay Schwebke, MD, MPH, MA, who has over 
eight years of experience defining medical conditions using administrative data for 
Optum, including selecting time periods, recommended using 90 days. In our data, claims 
meeting exclusion criteria were found, on average, 26.6 days (SD 21.4 days) after the 
anchor diagnosis and all but 1% was within 81 days. 
See Table 7.2 for the list ofiCD-9 codes used as exclusion criteria. 
2.2.2 Data Extraction 
We extracted all claims lines for all people in the final sample, including ICD-9 codes (up 
to 4), procedure codes, type of service, place of service, and provider specialty. Every 
claim line has a unique member ID with no personal data. Age was calculated from the 
date of birth in the source data. All medical, pharmaceutical, and admission data are 
included. From this dataset, we created three separate samples for the three studies, as 
described in each study's section. 
2.3 Sample numbers 
Figure 2.2 demonstrates the process of generating the sample. Figure 2.3 demonstrates 
the study sample in terms of type of low back pain - with a specific, identifiable cause 
versus NSLBP - and existing (chronic) or incident. 
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Figure 2.2. Sample generation 
INCLUSION 
Low back pain 
criterion. 
Identify 
people with 
LBP claims 
4/1/2009-
6/30/2009. 
n = 1,173,230. 
~ 
Age, sex, and enrollment 
criteria. 
Identify male or 
female members, 
age 18-64, with 
continuous 
coverage. 
n = 4,674,814. 
Create 
dataset of 
potential 
subjects. 
I 
n= 241,846 
4) Determine 
whether subject 
had existing LBP. 
n = 106,771 
people 
4) Append variable indicating eligible 
subject had existing LBP. n = 241,846 
106,771 (44.1%) with existing LBP . 
Figure 2.3. Typology of low back pain 
Existing: 
STUDY 1 INCLUSION 
Evidence of pre-
existing LBP. 
4) Select LBP 
claims 9/1/2008-
6/30/2009. 
26,747,907 
Incident : 
LBP in 6 months prior 
to index LBP claim. 
No LBP in 6 months prior 
to index LBP claim . 
I 
~ 
Specific: ~ IDH II ss il OS .. 
. 
Non-specific :mechanical, including Spondylosis 
-
. 
. Cause: 
EXCLUSION 
Person has other 2+ claims with plausible cause 
of low back pain 11+ for trauma). 
Identify claims 
indicating plausible 
nonmechanical 
causes of LBP in the 
subject-specific 
time period. 
1,657,997 claims. 
ID subjects 
w/plausible 
cause of LBP 
during person-
specific time 
period. 
For each 
cause, 
identify 
~ people with 
only 1 claim 
for it. 
n = 61,251 n = 11,952 
Dataset of people to be excluded (n = 
61,251) with variables indicating: (a) 
whether the member had only one 
claim during the member-specific time 
period, n = 12,720 (20.8%); 
(b) whether the member had only one 
claim for a given cause during the 
member-specific time period. 
Final dataset of all members who will 
be eligible for at least one study. 
n = 193,315 
IDH = Intervertebral drsk hernratron; SS = Sprnal stenosrs; OS = Degeneratrve spondylolisthesis 
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2.4 Effect of time period 
Very small spikes in the number of diagnoses of spine conditions occur every Monday 
following a decline from Friday to Saturday to Sunday. The spikes are slightly larger 
after long weekends such as Labor Day and Memorial Day. The pattern reflects the 
availability of non-emergency services. 
Some selection bias may have occurred if potential subjects chose to wait for a 
new insurance year, i.e., January 1, to seek services so the costs would be covered by 
their deductible. However, the spike on January 1 each year is only slightly higher than 
the spikes after shorter holidays. 
There is no selection bias of people being newly insured since we require 6 month 
of prior enrollment. 
Table 2.1. Effect on sample of enrollment requirements 
%Female 
Age (SD) 
Continuously enrolled 
51.3% 
39.74 (12.53) 
2.5 Comorbidities 
Not continuously enrolled 
51.9% 
40.12 (12.89) 
p-value 
<0.0001 
<0.0001 
To generate comorbidities, the data was processed through the Episode Treatment 
·Grouper®, a patented case-mix adjustment and episode-building system that uses 
routinely collected inpatient and ambulatory claims data to produce clinically 
homogeneous groups. The ETG methodology is reviewed frequently by Optum (formerly 
Ingenix) staff to ensure it reflects code changes and current pharmaceuticals. 
• ETGs are used by numerous commercial clients and therefore receive 
extensive external review of their content validity. Researchers not affiliated 
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with its developer have described how it achieves clinical homogeneity and 
applies condition-specific duration and required clean periods.[127] 
• ETGs have been used in prior research to identify people with specific 
conditions from claims data.[127-132] 
A review of the literature produced no coherent set of comorbidities to be 
included, other than depression and anxiety. Those studies that included lists of 
comorbidities, rather than simply reporting the number of comorbidities, used different 
terminology and unclear (often unwritten) methodology, rendering it challenging to 
directly compare them. For example, Ritzwoller[133] includes "Asthma/COPD" and 
"Stomach Problem" while Cassidy[134] includes "Respiratory disorders" and "Cancer 
Disorders," Cummins[135] includes "Blood Vessel Disease." 
To select comorbidities, we compared the lists of comorbidities deemed important 
by two major low back pain researchers, Richard Deyo and the SPORT research team. 
For each comorbidity, we identified, with the assistance of the Medical Director for the 
Episode Treatment Grouper, the most appropriate ETGs to use to identify it (Table 7.3). 
In some cases, such as liver disease, an ETG was considered appropriate for a broad 
definition. There were very minor differences in the proportion of subjects identified 
using the broad or narrow definition; we applied the broad definition. 
For chronic conditions, the ETG grouper assigns the start date as the beginning of 
the report year- in our case, July 1. Therefore, comorbidities identified "at baseline" 
could have been diagnosed during the 6-9 months before the index LBP episode, or 
during the 3-6 months after the index LBP episode. This is acceptable as they are, by 
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definition, chronic, so would have some clinical or biological affect at baseline. 
2.6 Limitations of administrative data 
Administrative data have numerous, well documented limitations.[136] Claims databases 
are designed to track expenditures, not medical care. Interpretation of results must be 
grounded with the caveat that they are based on data from people who sought care, and 
were insured, whose care was accurately reported, and whose claims were accepted by 
the insurer. Paid claims are an underestimate of underlying pain or disability. 
Any analysis of administrative data is, of course, susceptible to miscoding, 
whether intentional or due to error, and "upcoding," a practice that resulted in inflated 
costs.[137] 
Administrative data lack clinical complexity, such as severity, and context. 
However, our need was to track utilization or cost of essential services rather than 
develop complex clinical models. 
Other concerns that generically apply to administrative data are not relevant in our 
case. We required continuous coverage, so there is no lapse in data continuity. The data 
are generalizable to the US commercially covered adult population, the majority of 
adults. 
Concerns specific to using administrative data for low back pain research have 
been raised by others. Our studies avoided many common flaws[138] and are transparent 
as to definitions and codes used (see appendices). 
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2. 7 Informed consent and confidentiality 
The data are de-identified prior to our accessing the source database. There is no personal 
health information in the data. The birth date was removed; the subject's age as of 
January 1, 2009, was included. 
2.8 Data management 
To protect against loss of data, the data extract was stored in two places: (1) where data 
analysis will be performed and (2) on a flash drive, locked, in a different location. To 
protect against loss of programs, they were saved after every analysis session to a flash 
drive. By agreement with the Ingenix Impact Database Research Committee, the data will 
be destroyed at the end ofthe project or on December 31,2014, whichever comes first, 
unless an extension is obtained. 
2.9 Study setting 
The analyses were performed in Boston, Massachusetts. 
3 STUDY ONE: COST EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY FOR 
EXISTING IDIOPATHIC LOW BACK PAIN 
3.1.1 Objectives 
Persistent, non-specific low back pain is no longer considered a purely biomechanical 
phenomenon. An increasing body of evidence points to the influence of psychological 
factors on whether a person develops persistent NSLBP as well as on a patient's response 
to treatments for persistent NSLBP. Social features such as education and relationships 
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with family and friends are associated with treatment response.[139, 140] As a result, 
persistent NSLBP now generally is considered to be a phenomenon in which biological, 
psychological and social factors interact.[141, 142] Treatment for a multi-faceted 
condition requires a multi-faceted approach. For NSLBP, treatment for structural 
conditions increasingly is supplemented by addressing patient-specific modifiable 
behaviors, such as insufficiently exercising, or risk factors, such as catastrophizing. 
Patients are encouraged to actively engage in self-management rather than just passively 
receiving health care services.[27] 
As described in section 1.1.1, Cognitive Behavioral Therapy (CBT) is of 
particular interest for treatment ofNSLBP.[72] Numerous European studies have found 
that CBT results in lower-cost care with better outcomes. Lamb (2010) found that CBT is 
cost-effective relative to "active management"- education and access to health care 
services- at £1786 per quality oflife year gained (QAL Y) for British patients seeking 
care from a general practitioner and randomized to treatment.[75] Johnson (2007) also 
addressed British patients, and found that a program with both exercise and CBT was 
most expensive per QAL Y, at £5000[sic].[116] Lambeek (2010) found that Dutch people 
out of work due to low back pain who were randomized to integrated care - a workplace 
intervention based on participatory ergonomics and graded activity based on cognitive 
behavioral principles -had lower costs and better outcomes than those who received 
services without a psychological component.[143] Hlobil (2007) found that graded 
activity was cost-beneficial related to "usual care" in enabling people on disability leave 
to return to work. [ 144] Schweikert (2006) studied Germans admitted to inpatient 
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rehabilitation for low back pain, and lower indirect costs but no significant differences in 
direct costs or QAL Y s. 
To our knowledge, no study has investigated whether CBT is cost effective for 
treatment of persistent NSLBP from the US commercial payer perspective. The goal of 
this study is to determine whether CBT would be cost effective for persons with NSLBP 
from the perspective of commercial payers. 
Hypothesis 1: A similar study, performed in the U.S., would demonstrate that Cognitive 
Behavioral Therapy, in addition to active management, is cost-effective relative to active 
management alone for low back pain, over the course of one year. 
Hypothesis 2: A similar study, performed in the U.S., would demonstrate that Cognitive 
Behavioral Therapy, in addition to active management, is cost-effective relative to active 
management alone for low back pain, over the course of ten years. 
3.1.2 Methods 
3.1.2.1 Model structure 
We constructed a Markov decision tree model in Microsoft Excel to estimate cost-
effectiveness of advice with CBT relative to advice without CBT at 1- and 1 0-years 
(Figure 3.1). Incremental costs were measured from the US commercial payer 
perspective. Incremental effectiveness was measured as quality-adjusted life years 
(QAL Ys) gained. The outcome was the incremental cost-effectiveness ratio (ICER). 
Costs and effects were discounted at 3%.[145] 
To estimate 1-year cost-effectiveness, we (a) applied likelihood of recovery and 
utilities from the Back Skills Training Trial (BeST), in which adults with NSLBP were 
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randomized to CBT plus active management or active management alone and followed 
for 12 months[75] , (b) applied the types and frequency oftreatment sought among 
subjects in both arms of that trial, (c) derived what US commercial payer costs would be 
for these services. Each step is detailed below. 
To estimate 10-year cost effectiveness, we applied an annual60% recurrence rate 
oflow back pain, the modal rate in the literature (range 27-85%).[146-148] We also 
apply annual mortality probability starting at age 54, the mean age of subjects in the 
BeST.[149] 
3.1.2.2 Likelihood ofRecovery 
The Back Skills Training Trial (BeST) reported that, at the end of the follow-up year, 
59% of subjects in the CBT group reported improvement in pain and function at 12 
months, compared to 31% in the standard care group.[75] We applied these recovery 
likelihoods to our study groups. 
3.1.2.3 Health Services Utilization 
The BeST is a valuable source for this study because subjects were randomized to 
treatment groups but not to subsequent services. They were free to seek care, and general 
practitioners to refer patients to care, for back pain as they deemed appropriate. [81] 
Therefore, the types of care they sought are legitimately applied to our theoretical 
population. 
The trial produced detailed information about the rates of health services received 
by patients in the treatment and control groups. Categories included (a) visits to general 
practitioners, nurses, osteopaths, physical or occupational therapists, psychologists, 
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counselors, acupuncturists, chiropractors, and emergency rooms, (b) diagnostics 
including radiologic scanning, computed tomography scanning, magnetic resonance 
imaging, and blood tests, (c) medications including Antidepressants, gels and creams, 
non-steroidal anti-inflammatories, painkillers, and sleeping pills, and (d) outpatient and 
inpatient procedures. 
3.1.2.4 Valuation of Health Services Cost 
For each type of service reported in the RCT, we derived the US cost from an 
administrative database by selecting claims for adults with NSLBP. We used only claims 
with service-specific combinations of provider types, procedure codes, and revenue 
codes. For each type of service, we calculated a weighted mean value from services 
received during 12 months. These steps are detailed below. 
Study Sample: We identified adults age 18-64 with existing NSLBP, as described 
in section 2. Figure 3.1 highlights in gray the subjects used in this study. Figure 3.2 
demonstrates how our sample identification fits with the BeST methods. During a three-
month period, subjects are identified as having low back pain. This correlated with the 
subject recruitment period in the BeST. We require that they received services during the 
six months prior to their index diagnosis, implying existing pain. The BeST reported 
summary health care services for low back pain over one year. We used claims paid 
during the 12 months after "randomization" to estimate costs of each type of service. 
Inclusion criteria: we selected people with two or more diagnoses ofNSLBP 
within a six-month period. Prior literature on NSLBP reflects a lack of consensus on the 
definition and, therefore, which diagnosis codes should be used to identify people with 
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Figure 3.1. Sample subjects used in cost-utility of CBT study 
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Cause: 
-
Figure 3.2. Sample selection relative to source RCT 
2008 2009 I 2010 
J I A I S I O I N I D J I F I M A I M I J I J I A ISIOI N I D I J I F I M 
Back Ski lls Training Tria 
This study 
I Existing LBP 
Existing LBP 
R&R· Patients sought care as needed/wanted 
Claim 10• Select claims to estimate costs 
'Recru~ment & Randomization 
NSLBP.[138, 150] Table 7.1lists the codes used by six research groups to identify "low 
back pain," "low back pain with and without leg pain" or "leg symptoms," "degenerative 
disease," or "mechanical low back problems." We included codes supported by the 
majority of the research groups. Where there was no consensus, we used Cherkin as a 
guide.[124] Table 7.1 also indicates whether we used each code. 
In addition to codes specific to the lumbar region, we included four codes 
identifying pain in the "thoracic or lumbar" regions. The vast majority of people 
identified with these four codes had additional claims specific to lumbar low back pain 
(59-100% for the four codes). 
Exclusion criteria: Low back pain may be due to a specific, identified spine 
condition such as fracture or dislocation or another medical cause such as neoplasm or 
pregnancy (see Table 7.2).[138] For spine conditions, pregnancy, and trauma, we 
excluded anyone with two claims indicating the condition within the six months prior to 
their index diagnosis. Diagnostics of low back pain may reveal other conditions, so we 
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looked for claims indicating neoplasm, infection or inflammation within 90 day after, as 
well as six months prior to, the index diagnosis, and excluded people with two claims for 
any of the conditions. As described in section 2.2.1, Overall exclusion criteria, our 
approach had clinical and statistical support. 
Using demographic variables available in the claims database, we found our 
subjects were somewhat younger than those in the RCT (46.3 compared to 53 or 54 in the 
two arms) and had approximately the same sex distribution (57% female compared to 
59% and 61 %). Both differences are statistically significant, in part due to the large 
sample (Table 3.1). 
Table 3.1. Demographic characteristics of source populations 
Back Skills Trainin~:; Trial In~:;enix Imeact Research Database 
Control Advice plus Adults with NSLBP P-
(n=233) CBT (n=79,144) value 
{n=468} 
Age (years) 54 (14.9) 53 (14.6) 46.3 (10.3) <0.01 
Sex (female l 142 (61%) 278 (59%) 45,112 (57%) <0.01 
Costing specific services: The BeST tracked the use of services by participants in 
each study arm: clinical visits to general practitioners, nurses, physical or occupational 
therapists, psychologists, counselors, osteopaths, acupuncturists, and chiropractors; visits 
to emergency rooms, outpatient clinics, and surgeries; diagnostic services (MRI, CT scan, 
X-ray, and blood tests); medications for pain, sleep, and depression management, non-
steroidal anti-inflammatories, and analgesics; and use of selected non-medical supplies. 
For each type of service, we produced a set of clinically appropriate procedure 
codes, both Current Procedural Terminology and ICD-9, and facility-based revenue 
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codes. We included evaluation and management services, therapeutic services, specialist 
services, imaging, anesthesia, corticosteroid treatment injections, muscle testing, and 
neurological testing. 
A single office visit often will be billed using multiple claims. For example, 
chiropractor visits can be billed as one evaluation and one therapeutic service. Total costs 
for LBP visits to professional providers were based on all claims associated with the 
service by summing cost of unique combination of patient, provider type, and day. 
Some services are provided by multiple providers, particularly if they are 
performed in a facility for which the space or technology must be reimbursed. For 
example, surgery will result in claims for the use of preparation, operation, and 
recuperation rooms, for materials such as bandages, and for medications such as 
anesthetics as well as for professional services. In order to ensure we captured all claims 
for imaging, outpatient services, emergency room visits, and surgeries, we followed a 
multiple-step process. First, we determined a set of providers and services which would 
be relevant for each type of care. For example, an emergency room visit could logically 
include an ambulance ride, but not treatment in a hospice. Corticosteroid treatment 
injection could logically involve a nurse, who may prepare the patient, but not a 
dermatologist. Second, we determined the service had been received by a given patient 
by identifying claims with service-specific codes. Third, we identified all claims for the 
member who got the service, from the relevant providers and services, on the day of the 
service. Finally, we calculated the cost ofthe service as the sum of costs from the set of 
claims. The result is a conservative estimate of costs. 
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Pharmaceutical claims do not have diagnoses, so to derive costs for medications 
we identified medications associated with an episode, not diagnosis, of LBP. We 
processed all claims for members with NSLBP through Symmetry Episode Treatment 
Grouper® software, which identifies and classifies episodes of care based on inpatient, 
ambulatory, pharmaceutical, and ancillary services. The clinically homogeneous and 
statistically stable episodes commonly are used in health services research.[129, 131] 
This process yielded multiple costs for each type of service. For example, surgery 
would have a range of costs based on the process described above. A relatively precise 
type of service, such as a visit to a general practitioner, could be represented by anything 
from one "Evaluation and Management" claim to Evaluation and Management with 
multiple diagnostic or treatment services. For each type of service, we calculated a 
weighted average cost. (Service costs reflect the total allowed amount, i.e., the total 
potential cost to the payer. Costs borne by patient in the form of a copayment or 
deductible were not included.) 
Intervention costs were measured as 2008 British pounds and, adjusting for US 
inflation rates for medical care services, costs were adjusted to U.S. 2009 dollars. 
3.1.2.5 Health-Related Quality of Life 
Utility estimates calculated from the five-item EuroQol in the BeST trial were used. The 
CBT arm had a post-treatment score of 0.640 (0.0 16), somewhat higher than the Control 
arm score of 0.592 (0.023). At the end of year 1, the CBT utility is applied to all subjects 
in the CBT arm and the Control utility to all subjects in the control arm. At the end of 
years 2 through 10, the CBT utility is applied to subjects who are in an improved state 
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and the Control utility to subjects in a not improved state. (Section 8.2 outlines 
approaches to attaining utilities before the BeST results were available.) 
3.1.2.6 Base Case Model 
The base case models - 1 and 10 year- reflects a common US health plan structure, 
covering pharmaceutical and medical services but not acupuncture or chiropractic 
services. Figure 3.3 models the course subjects in each arm would theoretically take. 
First, subjects are randomized to either the CBT arm or the Control arm. Per-subject 
intervention costs of$703.04 for CBT and $374.69 for control are applied in year 1. At 
the end ofthe first year, recovery rates are applied to each arm as reported by the BeST: 
59% of CBT subjects reported recovery and are moved into the "get better" health state 
in the beginning ofyear 2 (see Figure 3.3) while 31% of Control subjects report 
recovenng. 
A fundamental assumption is that the CBT subjects' higher recovery rate in 
Year 1 is due to the CBT training they received. The BeST defined compliance with the 
CBT intervention a priori as attendance at their initial assessment and at least three of the 
six therapy sessions. Subjects who did not meet this criterion were, in Years 2 through 
10, assigned the Control group's relapse rate. 
The time cycle for the model is one year. At the end of the first year, some 
subjects will have improved, and have the higher utility. During the second year, all 
subjects have a small probability of dying. Of those who do not, some will have a relapse 
oflow back pain (estimated rate: 60%). Those who relapse have a probability of 
transitioning into three mutually exclusive health states: "get better" at the rates seen in 
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the BeST, die, or remain "not better." 
Subjects who did not improve during the first year will enter the second year with 
a lower utility value. These subjects may improve (if they do not die), with a 59% 
likelihood if they are in the CBT arm and a 31% likelihood if they are controls. If they 
improve, they are assigned the higher utility at the end of the year. This process is 
repeated in years 3 through 10. 
We assume some skill degradation, at a rate of20% per year. This loss of 
program effectiveness is factored into every model. 
Figure 3.3. Model Estimating Cost-Effectiveness at 1 and 10 years 
Year 1 Years 2-10 
~------------------------A 
I 
I 
CBT 
Yes 59%; ~Relapse? 
-+ lmp<ovo? u 
0 .592 : Improve? I 
I 
-->' 
Control~ Improve? 
Yes 31 %; 
0 .640 
No 69% : 
0 .592 
3.1.2.7 Sensitivity Analyses 
Relapse? 
Improve? 
* Improvement rate will decline 
annually as skills degrade. 
We accommodated uncertainty in the model inputs in numerous ways. First, we assessed 
the effectiveness of the intervention by (a) assuming that each arm had equal success 
rates, and (b) applying an as-treated approach. The equal success rate was calculated as 
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the mid-point of the actual rates of 59% and 31% for the CBT and Control arms, 
respectively, or 45%. In the as-treated model, costs and utilities associated with members 
who did not complete the CBT training were applied to the Control arm rather than the 
CBTarm. 
Second, we performed numerous sensitivity analyses on the Base Case intention-
to-treat model, holding all other values constant. To assess uncertainty around service 
utilization, we increased and decreased reported health care utilization rates by two and 
three times the standard deviation for each type of service. To assess uncertainty annual 
recurrence ofLBP, we applied high and low values found in the literature. To assess 
uncertainty around utility estimates, we increased (decreased) each utility reported by 
BeST by 3 standard deviations. (See Table 3.2 for a summary of estimates used in each 
model.) 
We modeled a "worst case" scenario from the perspective of a commercial payer, 
the scenario expected to produce the highest raw cost results due to high use of medical 
services by CBT subjects: high annual recurrence rate (85%) and high service utilization 
estimate (plus three standard deviations). 
Second, we conducted simulations of 5000 trials for the both Base Cases (1 and 
10 year) and for every sensitivity analysis. We report three results for each analysis. In 
addition to the mean ICER, the standard result reported for cost-effectiveness studies, we 
also report the minimum and maximum ICER to demonstrate the range of results from 
the 5000 trials. 
Third, sensitivity analyses examine cost-effectiveness in different insurance plan 
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designs. We added chiropractic services, acupuncture, then both to the base case, and 
modeled a medical-only plan (without pharmaceutical costs). 
Table 3.2. Parameters varied across sensitivity analyses 
CBT Control Relapse 
Pr(Better) Pr(Better) 
Base Case 59%§ 31% 60% 
Low CBT effectiveness 59% § 31% 60% 
(skill degradation) 
Equal probability of 45%§ 45% 60% 
improvement 
Relapse Rate, Low 59%§ 31% 27% 
Relapse Rate, High 59%§ 31% 85% 
Utility, Improvement, 59%§ 31% 60% 
Low 
Utility, Improvement, 59%§ 31% 60% 
High 
Utility, No improvement, 59%§ 31% 60% 
Low 
Utility, No improvement, 59%§ 31% 60% 
High 
"Worst case" scenario¥ 59% § 31% 85% 
. . § ProportiOn nnprovmg m year 1, dechnmg by 20% each year . 
¥Additional parameter: service utilization inflated by 3SD. 
3.1.3 Results 
3.1.3.1 Base Case Analysis 
High Utility Low Utility 
0.640 0.592 
0.640 0.592 
0.640 0.592 
0.640 0.592 
0.640 0.592 
0.592 0.592 
0.688 0.592 
0.640 0.523 
0.640 0.661 
0.640 0.592 
The original base case demonstrated that CBT is cost-effective in the first year, at $7197 
per quality oflife year (QAL Y) gained (Table 3.2). The cost per QAL Y is lower at 10 
years, $5,833. Although the subjects' skill level degrades over time, the CBT arm accrues 
utilities more quickly than it accrues costs. 
3.1.3.2 Sensitivity Analyses 
Sensitivity analyses demonstrate overall very consistent results (Table 3.3 and Figure 
3.4). Applying the minimum (maximum) cost estimate of the 5000 iterations only slightly 
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changes the Base Case ICERs, to $7170 ($7234) and $5805 ($5870). 
Table 3.3.1-Year and 10-Year Cost Effectiveness ofCBT- Base Case and Sensitivity 
Analysis Results 
1 yeariCER 10yeariCER 
Model Mean Min Max Mean Min Max 
Base Case $7,197 $7,170 $7,234 $5,833 $5,805 $5,870 
No Skill Degradation* nla nla nla $5,676 $5,649 $5,712 
As Treated* nla nla nla $11,376 $10,638 $12,103 
Service Rate -3D $7,200 $7,174 $7,219 $5,679 $5,653 $5,697 
Service Rate -2D $7,206 $7,172 $7,207 $5,684 $5,651 $5,686 
Service Rate +2D $6,943 $6,917 $6,943 $5,423 $5,398 $5,423 
Service Rate +3D $6,830 $6,765 $6,839 $5,338 $5,273 $5,347 
"Worst Case" * * nla n/a n/a $5,338 $5,273 $5,347 
Utility, Improved-Low $7,582 $7,554 $7,621 $6,026 $5,997 $6,064 
Utility, Improved-High $6,849 $6,823 $6,884 $5,364 $5,339 $5,398 
Utility, Not Improved-Low $7,289 $7,261 $7,326 $5,726 $5,699 $5,763 
_ Utility, Not Im,eroved-High $7,108 $7,Q81 $7,144 $5,626 $5,600 $5,662 
Relapse rate-Low * nla nla nla $5,631 $5,604 $5,667 
Rela se rate-High* nla nla nla $5,704 $5,677 $5,741 
-~qu3:! Prob. Improvement $7,217 $7,190 $7,254 ~~,754 $5,727 $5,791 
Costs-Medical Only $5,238 $5,179 $5,274 $3,732 $3,673 $3,767 
Costs-Base+ Acupuncture $7,292 $7,258 $7,325 $5,770 $5,736 $5,803 
Costs-Base+ Chiropractic $7,333 $7,302 $7,366 $5,810 $5,780 $5,843 
Costs-Base+ Acu & Chiro $7,427 $7,390 $7,457 $5,904 $5,867 $5,934 
* 1 year results equal Base Case model by definition. 
** 1 year results equal model with service utilization increased by 3SD. 
Applying higher and lower utility estimates had a stronger effect on the 1-year 
results, particularly the low (high) estimate for improving ($7582, $6849). Increasing the 
rate of service utilization decreased the ICER to $6830. The model assuming no effect of 
intervention, so equal improvement in each arm, proved cost effective at only slightly 
higher cost per QAL Y ($7217). Even these values only deviated from the Base Case by 
5% or less. 
The as-treated analysis resulted in 1 0-year estimates almost double the 1 0-year 
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intention-to-treat ICER, $11,376 ($10,638, $12,103). (1-year estimates are the same, by 
definition.) All other sensitivity analyses designed to assess uncertainty resulted in ICERs 
within 8% of the Base Case. Increasing the estimate of service utilization by three 
standard deviations, with or without the additional "worst case" criterion of high 
recurrence rates, decreased the ICER to $5338. 
Plan design had varied effects on the results. We modeled adding acupuncture, 
chiropractic, or both types of services, with little effect on the ICER ($5770, $5810, and 
$5904, respectively). Removing pharmaceutical coverage decreased the ICER by a third 
($3732). 
Figure 3.4 plots the results of the base case and each sensitivity analysis with a 
short bar and a vertical hatch mark indicating the range of the 5000 iterations. The range 
is barely discernible except for the As Treated 1 0-year result. 
3.2 Discussion 
CBT is a cost-effective addition to active management of existing NSLBP from the US 
commercial payer perspective, at $7,197 per QAL Yin the first year, decreasing to $5827 
over 10 years. While consistent with prior findings, this study is the first to assess cost-
effectiveness of all services for LBP from the US commercial payer perspective. [7 5, 116, 
143, 144] 
Cost-effectiveness was achieved even in the first year. This finding has important 
implications in the US commercial context, in which risks are assessed annually. We 
found no US standard willingness to pay threshold, but ICER ratios, all but one set under 
$10,000, fall well below the standards used in developed health-care economies.[151] 
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Figure 3.4. Relative effect of each sensitivity analysis on the mean estimates. 
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Assessing the effect of uncertainty yielded extremely stable results overall. 
Uncertainty in utilization rates is accommodated by running the model5000 times and 
performing sensitivity analyses. Additional sensitivity analyses were performed to assess 
variation in treatment success, utility values, health care utilization rates, and annual 
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recurrence (relapse) rates. The vast majority of sensitivity analyses were within 8% of the 
Base Case cost. 
The as-treated sensitivity model had the greatest effect, with estimates about 
double those of the intention-to-treat Base Case. As costs and utilities shifted to the 
Control arm, the difference between the costs grew more quickly than the difference in 
utilities. 
Notably, the "worst case" sensitivity estimate assessing a very weak intervention 
effect, resulted in a 10-year ICER slightly lower ($5444) lower than the Base Case. This 
finding will be of interest to health plans. There is no reason for them to be concerned 
that cost effectiveness can only be achieved if it is implemented by the best practitioners, 
for the most responsive patients. On the contrary, even fairly weak Cognitive Behavioral 
Therapy is cost-effective relative to education alone. 
Sensitivity analyses assessed the effect of particular health plan benefits, which is 
of further specific interest to decision-makers. Adding acupuncture and chiropractic 
services had a negligible effect, resulting from low unit costs and low utilization rates in 
the BeST. Removing pharmaceutical coverage from the plan design, hence removing cost 
of medications from the model, decreased overall costs and therefore the 1 and 1 0 year 
ICERs ($5238 and $3688, respectively) because the Control arm reported higher use of 
pharmaceuticals, particularly NSAIDs (73% higher), Sleeping pills (71% higher) and 
Painkillers (27% higher). 
Self-insured employers, in particular, may be interested in our results. In addition 
to paying the cost of treatment for NSLBP as insurers, as employers they pay the costs of 
40 
lost productivity due to NSLBP.[150] Self-insured employers will doubly benefit from an 
intervention that reduces pain and disability in its employee members. 
3.2.1 Strengths and Limitations 
Strengths of the study include rigorous cost specification. Costs reflect the actual 
experience of a large set of adult NSLBP patients, accounting for variations in severity 
and complications. We identified subjects using a transparent, literature-based definition. 
For each category of care, we selected only directly relevant services from claims with a 
first diagnosis ofLBP, which suggests primacy. We derived weighted costs, applying 
pre-defined, service-specific algorithms. 
Costs were standardized across payers, eliminating effects of geographical or 
contractual variation. All members had continuous insurance coverage, eliminating 
missing data concerns. Using costs, rather than charges, enhances generalizability. 
The source study for recovery rates, utility rates, and health care utilization rates 
combines the benefits of randomization to treatment, generalizability, with observation of 
patient health care choices over time, as the study imposed no restrictions on the health 
care services the subjects could seek for their back pain. The study collected data on all 
relevant services, including professional, diagnostic, outpatient, inpatient, 
complementary, pharmaceutical, and ancillary. Similar studies are not as 
comprehensive.[! 52] BeST authors supplemented the published data with additional 
detail, allowing us to specify associated costs with accuracy. Studies are rarely so 
transparent about services included in costing.[! 50] 
We used the mean age of subjects, 54, in the source study to determine mortality 
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rates. At this age, mortality is still fairly uncommon. The result would be similar if we 
had used the mean age of subjects in the data used to supply costs, 46 (data not shown). 
Although it is common practice to apply the results ofRCTs in one health system 
to other populations, even when explicitly recognizing that treatment availability differs 
across countries,[95, 153] there is some risk in assuming that US patients would seek 
services at the same rate as patients in the United Kingdom. Provider availability, referral 
requirements, and financial considerations could theoretically affect treatment 
choices.[152] 
To assess the validity of using service rates from the BeST, we compared US 
rates from the dataset from which we derived costs to the BeST active management 
group. The US patients had similar mean treatment rates from general practitioner (+3%), 
nurses ( -1% ), and physical or occupational therapists ( + 1% ). The US population had 
somewhat lower rates of diagnostic services (-15.3%) and receiving medication (-17.9%) 
or mental health care (-28%), slightly higher rates of surgical admissions(+ 13%), and 
much higher rates of emergency room visits (+50%). The rate of emergency room visits 
was quite low (0.03 in the CBT group and (0.02 in the active management group), so 
would not have a large influence on the results. 
We thoroughly addressed potential concerns about the stability of our model. A 
broad set of sensitivity analyses assessed the effect of uncertainty in the data and 
variation in treatment effect, demonstrating stability. We also addressed questions that 
may arise from fmding cost-effectiveness in the Base Case model: would Cognitive 
Behavioral Therapy be cost-effective if other costs were included? We assessed different 
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health plan designs and found little effect of adding costs. We did find that a common 
plan, covering medical care only, was even more cost-effective. 
Service data are based on subject recall, not direct measurement, and could be 
biased in either direction. The combined effect of multiple runs and sensitivity analyses 
may not address the unknowns adequately. 
As described in Section 2.6, Limitations of using administrative data, there are 
inherent limitations to the data, which we used to estimate the cost of services. This study 
avoided many common flaws of using administrative data[138] and provides 
transparency as to which codes are used. 
4 STUDY TWO: PATTERNS OF SERVICE UTILIZATION FOR RECENT ONSET SPINE 
DISORDERS 
4.1 Background & Rationale 
4.1.1 Importance of classification 
No widely accepted method exists for classifying patients with low back pain into 
clinically meaningful subgroups.[9, 154, 155] As discussed in section 1.1.2, defining 
such subgroups is critical for three reasons. First, researchers must be able to specify 
patient selection criteria that will minimize heterogeneity in order to produce 
interpretable effects and avoid sub-groups nullifying each other's results. Second, 
clinicians need better means to predict which patients would benefit from which 
treatments. Third, patients' anticipation of the potential duration and intensity of 
symptoms contributes to their desire for treatment. Better classification could result in 
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better patient education and more realistic expectations. 
4.1.2 A brief history of classification 
Efforts at classifying low back pain began in earnest in the 1990's after the First 
International Forum for Primary Care Research on Low Back Pain listed finding 
subgroups the most important goal of research. [ 15 6] Delitto created a classification 
scheme for "low back syndrome" intended to go beyond the Quebec Study Guide, which 
was based on the number of days since diagnosis, by incorporating the severity of 
symptoms. His objective was to move beyond a pathology-based model and incorporate 
self-reported pain and disability, as well as examination results, to assign a patient to 
specific types of physical therapy.[157] An algorithmically driven, classification-based 
treatment approach could, he hoped, result in diagnosis or referral based on data, rather 
than experience which can include "excessive commitment to particular modes of 
therapy, or tendencies to discount competing therapies" (p706).[158] 
Inter-rater reliability was only moderate. [159] An updated version of the 
classification produced somewhat higher reliability. However, only 49% of patients had 
stable enough results between the two examinations to be included, itself an important 
finding for classification.[160] Additionally, the treatment-based classification system 
was only moderately effective. One study produced "preliminary evidence" of its efficacy 
using a univariate approach.[159] Attempting to buttress the findings, George & Delitto 
used discriminant function analysis (DF A), which limited them to discriminating two of 
the three groups of interest. They found moderate discrimination. [ 161] 
Petersen et al. identified 12 syndromes and three subcategories based on 
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pathoanatomic classification, which also yielded only acceptable inter-rater 
reliability.[162] The major problem with pathoanatomical classification is consistently 
low correlation between "abnormal" findings and pain or disability.[17, 28, 31, 32, 78, 
97, 163] 
Other efforts have focused on: symptoms (physical model); the effect of sustained 
end range spinal loading, lifting with flexion and rotation (mechanical loading model); 
ongoing mal-adaptive motor control behavior (motor control model); the potential for 
sustained peripheral nociceptive input to change cortical mapping and create "pain 
memory" (neuro-physiological model); integrating biomechanical and pathoanatomical 
models (signs and symptoms model); and recognizing the impact of psychological 
reactions such as coping, fear, and avoidant behavior (psychological models).[155] There 
are five major movement-based approaches alone: Mechanical Diagnosis and Treatment, 
Treatment Based Classification, Pathoanatomic Based Classification, Movement System 
Impairment Classification, and O'Sullivan Classification System.[83] 
As recently as 2011, the European Federation of International Association for the 
Study of Pain (IASP®), Chapters conference summary noted that "we need to design a 
new classification of unspecific back pain[ sic], breaking it down into appropriate 
subgroups to allow for the development of pinpointed treatments for each. "[82] 
In the absence of definitive models, numerous prospective cohort studies have 
attempted to delineate the clinical course ofLBP, using both duration and intensity.[146] 
Research efforts to define subgroups has used many approaches: including a broader 
spectrum of people with LBP, including those who do not seek treatment,[98] including 
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only those with no prior episodes,[164] measuring outcomes more frequently,[98] 
following patients for longer time periods,[146] or including different types of 
practitioners. [ 165] 
As discussed in section Psychological factors, particularly depression or anxiety, 
are known to have a complex relationship with low back pain.[52] At least one study 
explicitly exclude people with depression to minimize heterogeneity.[54] 
4.1.3 Objectives 
Our primary objective was to identify subgroups of people with low back pain, including 
NSLBP, intervertebral disc herniation, spinal stenosis and degenerative spondylolisthesis, 
using latent class analysis of administrative data. At a minimum, we sought to use the 
most direct evidence of pain, the use of painkillers. We also hoped to take advantage of 
data indicating diagnostic and treatment services received. 
Objective 1: Differentiate distinct clusters oflow back pain using administrative data. 
Hypothesis 1: Low back pain can be grouped into multiple, distinct, clusters of treatment 
intensity based on utilization rates, including cluster(s) that reflect persistent utilization, 
cluster(s) that reflect fluctuating utilization, and a cluster that reflects one-time 
utilization. 
Objective 2: Assess relationship of known risk factors for LBP with LBP clusters. 
Hypothesis 2: Age will be associated with low back pain cluster. 
Hypothesis 3: Sex will not be associated with low back pain cluster. 
Hypothesis 4: Baseline psychological status, defined as presence of diagnosed depression 
or anxiety, will be associated with low back pain cluster. 
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4.2 Methods 
4.2.1 Study Subjects 
All subjects with a primary diagnosis of low back pain, either NSLBP or a specific cause, 
and with no diagnosis indicating low back pain during the prior six months were selected 
from the main sample. The primary diagnosis is the first listed on the claim and is 
commonly interpreted as the most clinically meaningful diagnosis.[121, 166, 167] 
Arguably, one should select only subjects who have NSLBP. However, there are 
two reasons to include those with specified causes of disc herniation, stenosis, or 
spondylolisthesis. First, there is still no solid consensus on the definitions. Genevey, 
Atlas and Katz found great variation in eligibility criteria for radiculopathy due to 
intervertebral disc herniation and neurogenic claudication due to lumbar spinal stenosis in 
randomized clinical trials.[154] Not having widely accepted eligibility criteria, each 
group of authors devised their own. With such variation among researchers, one could 
not expect more diagnostic precision among clinicians. 
Second, it is not clear that these populations can be identified in administrative 
data. For example, diagnoses of sciatica (724.3) may be followed by imaging, which can 
provide detailed information on the extent of thecal sac compression, nerve root 
impingement, and Modic changes.[11 , 110, 163] It may be followed by surgery with a 
supporting diagnosis, but, as was demonstrated in Section 1.1.2, many patients who are 
eligible for surgery choose not to undergo it. Such subjects could not be identified for 
exclusion, resulting in unintentional heterogeneity. 
Therefore, we included all subjects identified using the criteria defined in 
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Section 1 with a six-month clean period. The objective is to assess the patterns of care 
received by patients who seek care and receive a diagnosis of spine disorders and who do 
not have causes such as trauma, neoplasms, pregnancy, or infection. By definition, the 
35% to 40% of people who experience pain but do not seek care will not be included.[57, 
168-170] 
People with serious mental illness, intellectual disabilities, or dementia are less 
likely to make their own health care decisions and their use of health care services is 
known to differ from non-impaired adults.[171 , 172] Therefore, we excluded subjects 
with those conditions (n=804, 519, and zero, respectively). Figure 4.1 highlights in gray 
the subjects used in this study. 
Figure 4.1. Sample subjects used in patterns of utilization study 
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This population is, by definition, healthier than a general adult population. All 
subjects were continuously enrolled in a commercial plan, implying that most maintained 
their employment during a time of massive job losses. (Some, particularly spouses, could 
be enrolled through an employed subscriber, and others could have maintained coverage 
through means such as COBRA after loss of employment.) This indicates some measure 
of physical and fmancial health. However, the objective of this study is not to be 
generalizable to the national population. Combined with similar studies using different 
cohorts, this study aims to create an understanding of what patterns across the population 
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are, as a Venn diagram demonstrates overlaps among, and unique aspects of, groups. 
Using administrative data, there is no means to adjust for personal preferences, 
such as whether a subject takes a minimalist or maximalist approach to health care, or 
whether they lean towards "natural" or technical approaches,[173] or for confounding by 
indication. The aim is that the size of the dataset will protect against small numbers of 
people skewing the results. Rather, the purpose of latent class analysis is to identify 
patterns that are shared by substantial proportions of a population. 
4.2.2 Data specification 
Medical claim lines include at least one diagnosis code and either a procedure code, 
indicating the professional service received, or a revenue code, specifying the service 
provided by a facility, such as use of an operating room or laboratory services. We 
included only claims with a primary diagnosis of low back pain. 
Providers often use multiple claims to report the various services provided during 
one encounter. [ 1 7 4] Some insurers, very similar to those represented in our data, advise 
chiropractors, for example, to use two claim lines for visits that include evaluation and 
management as well as manipulation.[175-177] In order not to double-count services, we 
defined a visit as one encounter with one provider in one day, as have other researchers, 
[138, 146, 174] and applied logic to identify the most clinically relevant service provided 
during the visit. Clinical relevance was determined from the patient's perspective. For 
example, a visit that resulted in a claim for a therapeutic service (e.g., chiropractic) and a 
claim for an evaluation & management service was counted as a therapeutic service; the 
patient's objective was to receive therapy. Similarly, claims submitted for surgical and 
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imaging services on the same day were counted as surgeries; the patient's objective was 
to receive surgery and the imaging is presumed supportive of that surgery. 
Pharmaceutical claim lines to not have a diagnosis code, so cannot be directly 
linked to low back pain. We used the Episode Treatment Grouper software described in 
Section 2.7 to identify pharmaceutical claims assigned to low back pain episodes. Every 
claim is assigned to just one episode. Therefore, low back pain had the strongest "claim," 
based on clinical likelihood and proximity in time, on the prescription. For example, a 
narcotic prescription would be assigned to a trauma episode if it existed, or an 
antidepressant to a diagnosis of depression if it existed. 
Prescriptions are often for more than a 30 days' supply, up to 90. If there were 
more than 30 days in a 30-day period, we carried the supply into the following 30-day 
periods. We capped the days' supply at 90 per quarter. Prescriptions filled on the same 
day as a surgery or corticosteroid injections were excluded. 
In addition to using baseline depression or anxiety as a comorbidity, we planned 
to use depression or anxiety that developed after diagnosis as a covariate. We needed to 
ensure that the timing of the psychological diagnosis was during the 27 months after LBP 
diagnosis. Therefore, we identified claims with the appropriate date and the following 
ICD-9 codes to identify developed depression or anxiety: 296.3, 296.30, 296.31, 296.32, 
296.33, 296.34, 300.09, 311, 311.0, and 311.00. If a subject was identified as having 
developed depression or anxiety, using ICD-9 codes, and as having baseline depression 
or anxiety, using chronic ETGs (see Section 7.2), the baseline variable was set to indicate 
no condition. 
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4.2.3 Analysis 
4.2.3.1 Data specification 
For each subject, data for the 810 days following their initial diagnosis for low back pain 
of any sort are used in the analysis. The data are split into 90-day time periods. While 
these time periods are referred to as "quarters," they are subject-specific 90-day periods, 
as demonstrated in Figure 4.2. A subject whose initial diagnosis is in early January would 
have a first quarter of January-March. A subject whose initial diagnosis is on March 30 
would have a first quarter of April-June. 
Figure 4.2. Subject-specific time periods. 
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4.2.3.2 Description of Latent cluster analysis 
Latent class analysis (LCA) is used to identify unique subgroups, or classes, of people 
who share underlying, or latent, characteristics. Rather than being directly measured, the 
latent characteristic is inferred from a set of categorical variables. LCA can be used to 
derive a multidimensional typology from a set of behavior patterns. For example, LCA 
has been used to identify atypical subtypes of depression, to identify unique weight -loss 
strategies, and to organize dimensions of sexual risk behavior. [ 178-180] 
LCA output parameters include class membership probabilities, the proportion of 
the population expected to be in each latent class and item-response probabilities, which 
represent the probability of each response to the variable, conditional on latent class 
membership. Variable response probabilities demonstrate the strength of the association 
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of the response to each estimated latent class. 
The matrix of class membership probabilities and variable response probabilities 
is used to interpret and label the latent classes. For example, if the categorical variable is 
"number of days' supply of pain medication in a 90-day period," and the categories are 
none, 1-30, and 31-90, people in each latent class have a probability of having had a zero, 
less than 30, or 31-90 days' supply of pain medication for that 90-day period. For each 
latent class, the response probabilities must, by definition, add to 1.0. 
The number of latent classes formed is pre-specified and a series of models is 
estimated with a different number of classes to be formed in each. As the number of 
classes increases, the results reflect more precise underlying patterns. The researcher the 
selects model with the number of classes that best fits the data based on three criteria. 
The most important criterion is that the patterns must be clinically or behaviorally 
meaningful. Second, the goodness-of-fit statistics should be lower than in the model with 
fewer classes. Latent class analysis produces a number of goodness-of-fit statistics. The 
proc LCA vl.3.0 Users' Guide doesn't differentiate between the statistics and cautions 
the user from relying on them, although "they may still be useful as heuristics.").[181] In 
papers by the developers of the procedure, they report the Akaike's Information Criterion 
(AIC) then Bayesian Information Criterion (BIC)[179] and note that a "smaller AIC and 
BIC for a particular model suggests that the trade-off between fit and parsimony is 
preferable"[ 182] 
Third, a model should not be over-specified to the sample. Class membership 
probabilities that are very low may be the result of an over-specified model. 
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LCA is convenient for the SAS user due to the recent development of a 
downloadable PROC LCA program for use with SAS software.[181] 
4.2.3.3 Effect of varying the number of classes in the model 
This section will demonstrate the results of a series of models in which the number of 
classes specified increases from two to six. A chart for each model (a) shows the response 
probabilities for having filled a prescription for painkillers during each quarter and 
(b) demonstrates the change from the prior model. All charts are set to the same y-axis to 
facilitate comparisons. 
The example examines the use of painkillers following an incident low back pain 
diagnosis. Each subject contributes data for nine quarters (90-day periods) following his 
or her diagnosis. "Using painkillers" is defined as having filled at least one day's supply 
of prescribed narcotic or non-narcotic medication that is not associated with having 
surgery or getting a corticosteroid treatment injection. The two response options for each 
quarter are (1) having filled a 1 to 90 day supply of painkillers and (2) having filled no 
prescription for painkillers. 
Figure 4.3 demonstrates the results of a 2-class model. The x-axis includes a point 
for each quarter in the 27-month follow-up period. They-axis displays the probability of 
receiving a type of service (zero to 1.0). For each class, the data point indicates the 
likelihood of receiving health care services- specifically, in this example, a prescription 
for painkillers- during the quarter. The vast majority of subjects, 86%, were somewhat 
likely to have a prescription in the first quarter (17%) and very unlikely to have a 
prescription in subsequent quarters ( <8% ). 
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The second latent class, which 14% of subjects were expected to be in, 
experienced a different pattern as well as a different probable amount of painkillers. Their 
probability of having painkillers was highest in the first quarter at 69%, stayed level at 
63-65% from Q2 through Q6, then declined steadily through Q9, ending at 58%. 
Figure 4.3. Results of 2-Class Model 
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Figure 4.4 superimposes the results ofthe 3-class model on the results of the 2-
class model, to demonstrate the shift in exposed latent classes. The 2-class results are 
displayed, as in the previous chart, with black lines and filled markers. The 3-class model 
results are displayed with gray lines and unfilled markers. 
The differences between the 3-class model and 2-class model clearly demonstrate 
how adding classes allows the data to more accurately identifY the underlying 
(unobserved) mutually exclusive and exhaustive subgroups. The 3-class model clearly 
splits the level/decreasing class into two classes with distinct shapes. One new class had a 
fairly level curve with higher overall values (83-92% versus 58-69%); the other had a 
distinct descending pattern with lower values (37% dropping to 27%). Additionally, the 
3-class model assigned 12% of subjects to the new descending class rather than to the 
class with the lowest probabilities. The 3-class model fits the data substantially better 
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than the 2-class model, as demonstrated by AIC and BIC statistics less than half as large 
(10422 v. 23793 and 10688 v. 23968, respectively). The two new classes more accurately 
represent the actual experience of subjects than the combined level/decreasing class. 
Figure 4.4. Comparison of Results of 3- and 2-Ciass Models 
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Figure 4.5 superimposes the results of the 4-class model on the results of the 3-
class model. The 3-class results are displayed, as in the previous chart, with gray lines 
and unfilled markers. The 4-class model results are displayed with black lines and filled 
markers. 
Two of the three classes remained in the 4-class model: (1) the class with 
relatively high probability in Q 1 followed by level probabilities from Q3 through Q9 and 
(2) the class with quite high probabilities that remained fairly level across all the entire 
time period. Notably, both models identified the same two underly ing subgroups, 
assigning the same proportion of subjects and almost precisely the same probabilities to 
the two groups. The level class was slightly more tightly defined, with the lowest 
probability only 7 points, compared to a 9-point range, below the highest probability. 
Just as the 3-class model identified two new underlying subgroups, the 4-class 
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model distributed the remaining 20% of subjects in two dramatically different subgroups 
than seen in the 3-class model. One class, with 11% of subjects, retained the consistently 
decreasing shape, although it has a sharper decline, from 63% to 9% in Q8, and ends with 
a slight uptick to 13%. 
The fourth class, with 9% of subjects, displayed a new pattern. In this subgroup, 
subjects' probability of receiving painkillers declined after the first quarter, from 33% to 
14% in Q3, then steadily increased to 55% in Q8, and declined again to end at 47%. The 
4-class model fits the data substantially better than the 3-class model, as demonstrated by 
AIC and BIC statistics decreasing by over a third (from 10422 to 5987 and 10688 to 
6345, respectively). The shape of the new class is an important addition. 
Figure 4.5. Comparison of Results of 4- and 3-Ciass Models 
1.00 
0 .75 
0 .50 
0 .25 
0 .00 
Ql Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
{',. 74% 
0 20% 
- 6% 
~74% 
-x-9% 
-6% 
...... 11% 
Figure 4.6 superimposes the results ofthe 5-class model on the results of the 4-
class model. The 4-class results are displayed, as in the previous chart, with black lines 
and filled markers. The 5-class model results are displayed with gray lines and unfilled 
markers. For clarity, the classes that remain essentially unchanged are shown without 
markers. 
Again, the model identified the same classes seen in the model with one fewer 
class, with extremely similar proportions of subjects and probabilities over time. The 
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model essentially split the subgroup with decreasing probabilities into two similar 
classes. (1) One, with 7% of subjects, was at 64-66% in Q1 and Q2, dropped 
precipitously to just 5% in Q5-Q8, then rose to 9%. A few subjects, 1%, were assigned to 
this class rather than the one with extremely low probabilities. (2) The other, with 6% of 
subjects, remained over 50% through Q5 then dropped to under 20% in Q7-Q9. 
The 5-class model fit the data better than the 4-class model, with AIC and BIC 
statistics of 4441 and 4891, respectively. However, the improvement from the prior model 
is not as strong and patterns seem to be repeating. The smallest class now had just 5% of 
the sample. 
Figure 4.6. Comparison of Results of 5- and 4-Class Models 
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Figure 4.7 superimposes the results of the 6-class model on the results of the 5-
class model. The 5-class results are displayed, as in the previous chart, with gray lines 
and unfilled markers. The 6-class model results are displayed with black lines and filled 
markers. For clarity, the classes that remain essentially unchanged are shown without 
markers. 
The 6-class model honed the class newly identified in the prior model. For 7% of 
subjects, the probability of having painkillers rose and declined repeatedly over the nine 
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quarters. It declined sharply from 24% in Ql to 8% in Q2, steadily increased through Q5 
(38.6%), then decreased to merely 3% in Q8 only to rebound to 10% in Q9. Another new 
class of subjects had a high, level probability (75-80%) for four quarters, followed by a 
steady decline to 29.3-30.0% in the last two quarters. 
Figure 4.7. Comparison of Results of 6- and 5-Class Models 
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The improvement from the prior model is minimal (AIC 3323 and BIC 3864) and 
new patterns do not add more information. Many classes had variable probabilities over 
the time period, reflecting more intense service utilization in some quarters than others. 
In this demonstration, the 4-class model is strongest, identifying four 
distinguishable sets of subjects, which can be assigned meaningful labels: Level, 
Descending, Repeated Highs, and Ql Highest then Level. One of the key factors in 
choosing a model is being able to label each class clearly and informatively, indicating 
how each differs substantially from the other classes.[182] In the five-class model, the 
class with an overall descending pattern is split into two. One is level for two quarters, 
and the other for four, before the probabilities of getting painkillers declines. 
Over the last decade, the concept of "chronic" low back pain has been replaced 
by "persistent" and "recurrent" low back pain, indicating the importance of distinguishing 
between pain that continues and symptoms that abate and flare up, repeatedly. The 4-
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class model demonstrates classes with high-utilization, decreasing utilization, and 
decreasing then increasing utilization. The 5 and 6-class models may ultimately prove 
interesting, but we felt that the 4 classes hold the most promise for being informative as a 
first assessment. The four classes were very distinct from each other. In contrast, the 5 
class model split the Descending class into two classes with descending curves; one 
began its decline after the second quarter and the other began its decline after the fourth 
quarter. The latter was split, in the 6-class model, into classes with Descending and 
Repeated High curves. It was difficult to specify meaningful labels that differentiated the 
new classes identified in the 5- and 6-class models. 
4.2.3.4 Analyses Performed 
The essential analysis to compare our data to the prior studies would include Painkillers 
alone. However, we hoped to include additional variables to take full advantage of the 
dataset. Therefore, we built a model iteratively. First, we performed univariate analysis of 
each of 16 individual types of service, including separate analyses of narcotic and non-
narcotic painkillers (Table 4.1 ). The subject either received that type of service during the 
quarter, or did not. 
As the univariate results supported combining variables (see Results, below), we 
combined variables into four main categories, as shown in Table 4.1, and performed 
analyses with combinations of two and three variable categories (e.g., Painkillers and 
Therapy, or Painkillers, Therapy, and Office Visits). (Note that minor services, such as 
blood tests, were not included in the combined analyses. They would likely have 
involved an office or ER visit, so are implicitly included in the Visits category.) Section 
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9.2 provides detail on the structure of these analyses. 
Latent Class Analysis performs poorly if data are sparse. We did not know 
whether the data would support multivariate analysis. Iteratively building more complex 
models allowed us to create a final model with confidence. The main analysis compared 
all four combinations of major services, creating a coherent picture of the overall pattern 
of service utilization. 
The final analysis addressed the use of painkillers in three levels: the subject 
received a high level of painkillers during the quarter, defined as above the median level 
received by all subjects; the subject received a low level of painkillers; or the subject 
received no painkillers during the quarter. The objective of this analysis was to produce a 
single model of low back pain services that is comparable to prior research. 
Table 4.1. Services included in each set of Latent Class Analyses 
Univariate Analyses 
Surgery 
Injection 
Imaging, Lumbar 
Imaging, Other regions 
Painkillers, narcotic* 
Painkillers, non-narcotic 
Visits- New patient** 
Visits- Established patient** 
Visits -ER* 
Therapy 
Psychological 
Blood tests 
Diagnostics, Other 
Antidepressants 
Sleep aids 
Material support*** 
Bi & Trivariate Analyses 
Surgery & Injection 
Imaging 
Painkillers, all 
Visits, all 
Therapy 
* not associated with surgery or injection 
* * with no surgery, injection, imaging or therapy received in the visit 
***e.g., crutches, braces 
Quadrivariate Analysis 
Surgery, Injection, 
or Imaging 
Painkillers, all 
Visits, all 
Therapy 
PainkiUer Analysis 
Painkillers, all 
We selected painkillers for two reasons. First, pain is the salient feature of low 
back pain and painkillers are the service most directly applicable to pain. Other services, 
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particularly therapeutic, could address function rather than, or in addition to, pain. 
Second, one objective of the study was to compare our results with those of two prior 
latent class analyses of low back pain, both of which had a tripartite outcome of pain. 
Finally, we validated the results. Latent class analysis distributes subjects to non-
overlapping classes, each of which probabilistically has similar characteristics- in this 
case, similar health care service utilization for low back pain. We randomly sampled two 
sets of five members from each of the four classes produced. We then compared the 
actual services these subjects received to the services they were likely to receive, per their 
assigned class. 
4.3 Results 
4.3.1 Characteristics of the study population 
Subjects were overwhelmingly likely to have NSLBP. Only 1.5% had 
intervertebral disc herniation, 0.4% had spinal stenosis, and 0.2% had spondylolisthesis, 
for a total 2.0%. A slight majority of the subjects were female (53.4%), as is expected of 
patients with low back pain. Female subjects were slightly older than male (45 .5 
compared to 44.7, p<0.0001). 
This continuously commercially insured population is fairly healthy. Just 17.1% 
of the subject had at least one comorbidity (82.9% had none), with 2.3% having more 
than one. (Appendix 1 details how comorbidities were identified.) 
More subjects were identified as developing depression or anxiety (6435, 9.0%) 
than having it at baseline (444, 0.62%, 23 subjects had both). 
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Table 4.2. Comorbidities in Latent Class Analysis sample 
Comorbidity # 0/o 
Diabetes 2800 3.92% 
Chronic pulmonary disease 2787 3.90% 
Alcohe>.l or Drug dependenc):: 1,886 2.64% 
Rheumatologic disease 1,689 2.36% 
Myocardial infarction 1,361 1.90% 
Migt:_~jne 1,275 1.78% 
Osteoporosis 617 0.86% 
Cerebrovascular disease 364 0.51 % 
Liver disease 364 0.51% 
Renal disease 311 0.43% 
Depression 277 0.39% 
Peripheral vascular disease 217 0.30% 
Anxiety 190 0.27% 
Congestive heart failure 165 0.23% 
Ulcer 123 0.17% 
Acquired immunodeficiency syndrome 66 0.09% 
4.3.2 Choice of Model (Results of Set 1, Univariate Analyses) 
As seen in Section 4.2.3 .3, a series of analyses with different nunibers of classes 
determines the appropriate number of classes to include in the final model. We modeled 
each of the 16 services, specifying 2 through 5 classes. Each analysis produced similar 
results . The 4-class model consistently and strongly improves upon the 2-class and 3-
class models, judging by the patterns that emerge and the smaller AIC values. The 5-class 
model rarely adds information, tending to produce a pattern similar to one in the 4-class 
model and often resulting in very small classes. For example, some services (e.g., 
Injection, Therapy) produce a fifth pattern that also has repeated highs, but in different 
quarters. The data for other services are not sufficiently robust to define a set of five 
classes given the specifications ofthe model (e.g., Imaging-Lumbar, Estabiished Patient 
Visits) . (See detailed results in Table 9.3 .) 
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A 4-class model consistently produces the most classes each of which contributes 
additional data. The four dominant patterns are, in order of number of subjects: 
1. Level very low probabilities, preceded by a higher probability in quarter 1 
("Ql Highest Then Level"). This pattern is apparent in every model run 
except sleep medications. 
2. Overall declining probabilities over the nine quarters, with variations 
including: continuous decline, level prior to decline, and level following 
decline ("Decreasing"). The decline often ends with a slight increase from 
quarter 8 to quarter 9. This pattern is typically apparent in the 2-class model 
and almost always emerges by the 3-class model. 
3. A wave pattern, with a decline after quarter 1 followed by an increase across 
many quarters, reaching a level above the initial probability, and possibly a 
second decrease and increase ("Repeated Highs"). This pattern typically 
emerges in the 3-class or 4-class model. 
4. Probabilities that remain within a fairly narrow range across all nine quarters 
("Level"). This pattern typically emerges in the 3-class or 4-class model. 
The following charts in Figure 4.8 demonstrate the four patterns across the 16 
types of service. Series labels are not included as the objective is to demonstrate the 
commonality across types of service, not to distinguish particular services. With one 
exception, y-axes are set at zero to one. Results for models with 2 through 5 classes for 
each type of service can be found in Table 9.3 . 
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Figure 4.8. Patterns across all services 
Pattern "Ql Hi best then Level" 
Twelve of the 16 services have this pattern, 
with a first quarter probability under 25%. 
Therefore, they-axis ofthis chart is truncated 
at 0.25 for optimal display. 
Some services appear to have level patterns. 
However, the subgroup fits this pattern 
relative to the other patterns for this service. 
For example, the probability of having an ER 
visit is just 1.2% in the first quarter, but is 
less than 0.5% in the remaining quarters. 
Pattern "Ql Hi best then Level", continued. 
Three services (Blood Tests, Material 
Supports, and Diagnostics-Other), followed 
the same pattern, but had quarter 1 
probabilities over 0.9995. 
Pattern "Decreasin " 
Twelve services, including all the major 
services, have the Decreasing pattern. The 
probabilities may start to decline after quarter 
2, or even quarter 3, but the overall pattern is 
a quarterly decrease through quarter 6 or 7. 
All services settled below 0.1 0, regardless of 
whether they began near 0.75, near 0.25, or 
between. The majority of services also 
display a small uptick from quarter 8 to 
quarter 9. 
Eleven services, including all the major 
services, have the Repeated Highs pattern, 
with probability of receiving the service 
· dropped after the first quarter but increasing 
to peak, often at double the Q1 level, in 
quarter 7 or 8. 
Probability ofER visits seem relatively level, 
with two slight peaks, at Q6 and Q9. Relative 
to the other classes for the service, this class 
had repeated highs. 
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Pattern "Level" 
All services except two, Psychiatric and Office 
Visits with a New Provider, have the fourth 
common class, Level. The minimum probability 
is within 25 point of the maximum probability, 
with the exception of lumbar imaging (31 pts ). 
Some Level classes are "level" in relation to the 
service's other classes. had more approximately 
the other class' patterns. For example, Imaging-
Lumbar (squares) and Surgery (circles) had a 
form close to Repeated Highs. Therapy 
(triangles) shows a fairly consistent decrease 
over time. This is the most level class for the 
service. 
4.3.3 Main Latent Class Analysis results 
,--· 
1.00 
Ql Q2 Q3 Q4 QS Q6 Q7 Q8 Q9 
The main model includes all major services in four categories (Table 4.1 ): 
1. Surgery/Injection/Imaging ("S/III"), combining surgery, injection, and any 
imaging with a diagnosis of low back pain; 
2. Painkillers, with narcotics and non-narcotics from a prescription not 
associated with a surgery or injection; 
3. Visits, combining office visits with a new patient, office visits with an 
established patient, and Emergency Room visits, all with no surgery, 
injection, or imaging services; and 
4. Therapeutic services, including physical, occupational, 
The analysis produced four distinct classes, three with moderate to high utilization 
patterns and one class with almost no utilization (Figure 4.9). 
The largest class was Ql Highest Then Level, with 52% of subjects. After their 
initial diagnosis, subjects had less than half a percent probability of getting any kind of 
service in every quarter (note they-axis is truncated at 0.05). Ifthey received any service 
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after Q1, it was typically Therapy Only. This class is now called "Minimal/No 
Utilization." 
The next largest class, Decreasing, contained a third of the subjects. They had a 
very high likelihood (92.7%) of getting any services in the 90 days following their initial 
diagnosis. The probability dropped rapidly- by at least 10% of the prior quarter's value-
through the fourth quarter, when it reached 44%. Over the next five quarters, the 
probabilities display a distinct valley pattern, although they remained within a five point 
range. This class is also known as "Moderate Utilization." 
Almost a quarter, 23.3%, of subjects was likely to receive three or more types of 
service in the first quarter. In subsequent quarters, they were only 0.4% to 2.5% likely to 
get such a variety of services. Similarly, the likelihood of receiving any two types of 
services, but no others, declined over time, with one exception. After dropping from 4.9% 
in Q 1, the likelihood of having an office visit and receiving painkillers - but having no 
other services -remained fairly stable at 2.1% to 2. 7% in quarters 3 through 9. 
When interpreting these charts, it is important to understand that, in a given 
class, each subject would be in one category in each quarter, but not the same category 
in every quarter. This means the subjects in this class could, for example, be in the 
Therapy only category in Ql, Therapy and Painkillers in Q2, No Services in Q3, etc. The 
actual experience of subjects is that they were likely to use services in about half of 
quarters 2 through 9. Subjects with actual improvement, reflected in a lack of services in 
quarters 2 through 9 would more likely have been included in the Q 1 Highest Then Level 
class. (See Section 4.3.4 for confirmation of these results.) 
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The remaining two classes had small but substantial populations with quite high 
probabilities of receiving services across the 27 months. The Level class, with 8% of 
subjects, had a 98% likelihood of receiving services in the first quarter and probabilities 
at least 85% across the entire time period. The largest individual service was 
prescriptions for Painkillers Only. The use of painkillers overall was higher, as subjects 
often received other services in the same quarter, such as Therapy as well as Painkillers. 
The total probability of using Painkillers was 42% in the first quarter and ranged from 70 
to 82% after the first quarter. (These are slight underestimates, since painkiller use cannot 
be disaggregated in the 3-variable and 4-variable combinations.) This class is also known 
as "Painkillers." 
Figure 4.9. Results of 4-Class Model for All Services 
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The fourth class, Repeated Highs, had 7% of subjects. Starting at 89%, the 
likelihood of getting services dropped to 74% in the third quarter before rising, reaching 
81% in quarters five and six. This class was most likely to receive therapeutic services. 
As is apparent in the chart, the likelihood of Therapy Only increased rapidly, from 21% 
to 50% in quarter six, before declining. Overall, subjects in this class were 4 7% likely to 
get therapeutic services in the first quarter, rising to 71% in the sixth quarter, before 
falling to 53%. This class is now known as the "Therapy" class. 
Notably, every class had a substantial likelihood of receiving three or more major 
types of service in the first quarter (Level/Painkillers, 39%, Decreasing and Repeated 
Highs/Therapy, 23%, Q1 Highest Then None/Minimal/No Utilization, 7%). 
The Level/Painkillers and Repeated Highs/Therapy classes also shared continuing 
use of Therapy and Painkillers together. The rate stayed fairly even across quarters for 
both classes, at 13% and 9%, respectively. There were no other shared patterns of 
individual services or sets of services. 
The slight Q8 to Q9 increase seen in the Decreasing class for many variables in 
the univariate and bivariate analyses is only hinted at in 4-variable model. The overall 
rate of utilization was at the lowest, 39.5%, in the sixth quarter, after which it rose to 
39.6%, 40.1 %, and 41.4%. While these increments are very small, the consistency 
implies that relapses may be occurring with more frequency. 
Figure 4.10 depicts the dramatically different levels of health services utilization 
in the four classes of subjects we have identified. Half the subjects used essentially no 
services for low back pain after the first quarter ("Minimal/No Utilization" class). A third 
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had a moderate level of risk, slightly decreasing over time, with an average 50% 
likelihood of some service(s) during each quarter ("Decreasing" class). Subjects in this 
class were slightly older than the Minimal/No Utilization class (45.5 versus 44.9, 
p<O.OOl). 
A sixth of subjects, the LeveVPainkillers and Repeated Highs/Therapy classes 
combined, had very high utilization rates, averaging 90% and 77%, respectively. Both 
classes, on average, were slightly older than the class with essentially no services (45.8 
and 45.6, respectively, versus 44.9, p<O.OOl). 
Figure 4.10. Average probability of receiving any major health services, by class, Q2-Q9 
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Multivariate analysis shows no significant differences among classes in sex 
(range: 46.2-47.7, p=0.214), the number of comorbidities at baseline (range 19.3-20.0, 
p=0.814), having depression or anxiety at baseline (range 0.55-0.68, p=0.474) or the 
likelihood of developing depression or anxiety over 27 months after diagnosis (range 8.8-
9.5, p=0.368). 
We had hypothesized that baseline depression or anxiety would be associated 
with services received for low back pain. Therefore, we supplemented the ANOV A with 
chi-square bivariate analyses comparing each high utilization group to the group with 
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essentially no services. The results confirm no statistically significant difference between 
groups (p=0.156-0.774). 
4.3.4 Association of group assignments with co morbidities or types of low back 
pain 
Subjects in the utilization groups had generally similar patterns of comorbidities as the 
subjects in the Minimal/No Utilization group. Table 4.3 demonstrates the few differences. 
The second column displays the percentage of subjects in the reference group. Each set of 
columns to its right displays, for significantly results, the percentage of subjects in the 
comparison groups and p-value. No differences were found for baseline depression or 
anxiety, migraine, ulcer, rheumatoid arthritis, combined musculoskeletal condition 
(osteoporosis and rheumatoid arthritis), CHF, CVD, alcohol or drug abuse, liver disease, 
perivascular disease, pulmonary disease, or renal disease. 
The Painkiller group was slightly more likely to have osteoporosis (1.13%) than 
the reference group (0.83, p=0.0275). Individual utilization groups differ slightly from 
the reference group for diabetes, AIDS/HIV, and myocardial infarction. 
Table 4.3. Comorbidities by assigned subgroup 
Subgroup Minimal/No Repeated Highs/ Painkillers/ Moderate 
compared to Utilization Therapy Level Utilization/ 
minimal/no (Reference) Decreasing 
utilization: 
% % p % p % p 
Osteoporosis 0.83 n.s. 1.13 0.0275 n.s. 
AIDS/HN 0.11 n.s. n.s. 0.05 0.0233 
Diabetes 3.96 n.s. 3.36 0.0332 n.s. 
Myocardial 1.88 2.34 0.0274 n.s. n.s. 
infarction 
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Table 4.4 demonstrates the distribution of the three specific types of low back 
pain- IDH, spinal stenosis, and degenerative spondylolisthesis- across the assigned 
subgroups. The three specific types are defined as requiring a confirmatory MRI with a 
primary diagnosis for the specific type within either 30 or 90 days. Subjects with a 
diagnosis, even primary, but no confirmatory MRI are not identified as having the 
specific type of low back pain. 
Relative to the Minimal/No Utilization group, the Therapy and Moderate 
Utilization subgroups both have a higher proportion of subjects with IDH and of any 
specific cause. The Moderate Utilization group also has a higher proportion of subjects 
with Spinal Stenosis. The results are somewhat stronger for specific causes confirmed 
within 90, rather than 30, days. The percentage differences are not large. 
Table 4.4. Distribution of specific causes of low back pain across assigned subgroups 
Min/ No Therapy Painkiller group Moderate utilization 
utili- group group 
zation 
% % p % p 
Specific cause confirmed by MRI within 30 days of index LBP diagnosis 
IDH 3.75 4.60 0.0034 4.11 0.1992 
Spinal Stenosis 0.59 0.51 0.4956 0.48 0.3427 
Degenerative 0.17 0.14 0.6394 0.13 0.4833 
Spondylolisthesis 
Any specific 4.45 5.18 0.0224 4.68 0.4446 
Specific cause confirmed by MRI within 90 days of index LBP diagnosis 
IDH 4.93 5.79 0.0095 5.43 0.1141 
Spinal Stenosis 0.75 0.77 0.8307 0.74 0.9825 
Degenerative 
Spondylolisthesis 
Any specific 
0.23 
5.82 
0.29 0.4861 0.17 0.3379 
6.72 0.0114 6.30 0.1582 
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% p 
4.05 0.0577 
0.71 0.0560 
0.20 0.3572 
4.93 0.0067 
5.36 0.0172 
0.97 0.0032 
0.28 0.2662 
6.52 0.0004 
4.3.5 Assessment of class assignment 
Each member was assigned to a class based on the probability of being in each class. 
Proc LCA produces posterior probabilities, the likelihood of subjects being assigned to 
each class. Table 4.5 demonstrates that subjects' empirical data indicate that at least 
89.6% ofthem were assigned to the class to which they should have been assigned. 
Column headings are the assigned classes. Rows show the likelihood of subjects having 
been assigned to each class. For example, the subjects who were assigned to the Repeated 
Highs class had an 89.6% chance ofbeing in that class, compared to only 2.8% chance of 
being in Decreasing, a 0.9% chance ofbeing in Level, and 0.02% chance of being in Ql 
Highest Then Level. (The percentages are not expected to totallOO%.) The mean 
probability for members being in their assigned class ranged from 90-99%, with 
probabilities increasing with the size of the class. 
Table 4.5. Likelihood of subjects being in a given class in the 4-variable, 4-class model 
Q1 Highest 
Decreasing 
Level 
Repeated Highs 
Q 1 Highest Decreasing Level Repeated Highs 
0.9930 (0.0429) 0.0275 (0.0769) n/a 0.0002 (0.0020) 
0.0067 (0.04120 0.9500 (0.1073) 0.0439 (0.0969) 0.0956 (0.1423) 
n/a 0.0142 (0.0579) 0.9471 (0.1101) 0.0082 (0.0431) 
0.0002 (0.0030) 0.0276 (0.0769) 0.0091 (0.0461) 0.8960 (0.1495) 
These probabilities compare well to published probabilities for latent class (or 
cluster) analysis of low back pain. In one study, probabilities were as low as 50%, with a 
probability of 90% or greater for 80% of subjects. [9] In another, "subjects fell easily into 
one cluster (data not shown)."[98] 
We performed a quick analysis of empirical data for the two sets of five subjects 
each indicates subjects were assigned to the appropriate class. 
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• All 10 subjects assigned to Q 1 Highest then Level had services in the fust 
quarter only (including initial diagnosis); they are clearly in the correct group. 
• Most of the 10 subjects assigned to Level had services in most quarters. Two 
had services in all but one quarter and one had services in all but two quarters. 
They are clearly in the right group. 
• Individual subjects in the other two groups, Decreasing and Repeated Highs, 
aren't as obvious. By definition, these subjects are expected to have services in 
some quarters and not others. Only one subject in Decreasing had services 
consistently (in quarters 1-5), then no services consistently (in Q6-Q9). The 
rest had services in at least one quarter after "stopping" getting services for at 
least one quarter. Based on limited analysis, it appears that subjects in 
Repeated Highs both (1) are less likely to get services in early quarters (2, 3) 
and, when they do get services again, get them for consecutive, not single, 
quarters. 
We graphed the two sets of five members Decreasing and Repeated Highs groups 
to supplement the analysis. If all the subjects in a group had a service in a quarter, the 
quarter value will be 5; if three subjects in the group had a service, the quarter value will 
be 3, etc. Figure 4.11 demonstrates the results. 
4.3.6 Results of bivariate analyses 
As described in section 4.2.3.4 Analyses Performed, the analyses of two and three 
variables served to build the final model. The bivariate analyses combine similar services 
into five categories, surgery/injection, imaging, painkillers, therapeutic services, and 
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Figure 4.11. Empirical data for sets of 5 subsets assigned to each category 
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visits to providers. The key finding is that each combination mirrors the univariate 
results, producing the four patterns: Q 1 Highest then Level, Descending, Level, and 
Repeated Highs (Table 9.5). 
Table 9.8 describes two sets ofresults in detail: (1) patterns of service types for 
each combination of services resulting from 2-class models, and (2) patterns over time 
results from 3-class models for each combination of services. 
The most significant result from these analyses is that a small set of subjects 
emerged very high probabilities of getting each combination of services in every quarter. 
For example, 7% of subjects were 80% to 89% likely to receive both Surgery/Injection 
and Painkillers in each quarter. Additionally: 
• 8% of subjects were 79-94% likely to receive Therapy & Painkillers; 
• 8% of subjects were 80-89% likely to receive Imaging & Painkillers; 
• 8% of subjects were 70-94% likely to receive Therapy & Imaging; 
• 7% of subjects were 60-82% likely to receive Surgery/Injection & Therapy; 
and 
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• 4% of subjects were 63-75% likely to receive Surgery/Injection & Imaging. 
The bivariate analyses could not determine whether these subjects were the same 
people. The final model demonstrates there is a single class of subjects with very high 
utilization (Level class). 
4.3. 7 Results of trivariate analyses 
The trivariate models added one significant piece of information. The univariate and 
bivariate models had implied that one class of subjects (Ql Highest Then Level) would 
receive the most services in the first quarter, and few services in subsequent quarters. 
The trivariate models produced one class with extremely low probabilities in all 
quarters, as see in Table 4.6. Values for the second and ninth quarter values are presented 
apart from the middle quarters to highlight (a) how low the probabilities were once they 
have dropped from initial treatment, and (b) the small increase in the last quarter in some 
models. These subjects are unlikely to receive any services after their initial diagnosis. 
Table 4.6 Every quarter with a probability over zero for subjects in the Ql Highest Then 
Level class, from all models. 
Variables in Response Categories Q1 Q2 Q3-Q8 Q9 values 
model with Non-zero results values values values 
Surgery/Injection/ Thera~~ onl~ 2.99% 0.21% <0.23 0.30% 
Imaging, Therapy Thera~~ & Painkillers 2.14% 0.03% <0.03% 0.04% 
& Painkillers S/I/1, Therapy & 0.57% 0.00% 0.00% 0.00% 
Painkillers 
Surgery/Injection/ Thera~~ & Visits 0.14% 0.08% <0.03% 0.05% 
Imaging, Therapy S/I/1, Therapy & 0.45% 0.01% 0.00% 0.00% 
& Visits Visits 
Surgery /Injection/ Painkillers & Visits 1.47% 0.07% <0.04% 0.05% 
Imaging & S/I/1 & Painkillers & 0.36% 0.00% 0.00% 0.00% 
Painkillers & Visits 
Visits 
Therapy & Thera~~ only 3.38% 0.36% <0.30% 0.36% 
Painkillers & Therapy & Painkillers 1.05% 0.00% 0.00% 0.00% 
Visits & Visits 
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4.4 Three-Level Model Compared to Other LCA studies 
We analyzed three levels of painkiller (both narcotics and non-narcotics, and not 
associated with surgery or injection) use. The levels are: 
• No painkillers used 
• Low Volume, defmed as at or below median quarterly prescription level. 
• High Volume, defined as above median quarterly prescription level. 
We specified two through five class models. As with the analysis with two levels 
of painkillers (found in table 9.3), the 4-class model proved most appropriate, as 
demonstrated in Table 4.7. The 2-class model produced the Q1 Highest Then Level and 
Decreasing patterns. The 3-class model added a Level/Hump class, with a much stronger 
AIC (28243 versus 46995). The 4-class model ' s fit was still better, with AIC 23091; it 
divided the Decreasing class into two more clearly defined classes by adding a Repeated 
Highs class. 
Table 4. 7. Results of 2-, 3- and 4-class models of painkiller use with tripartite structure. 
Q 1 Highest Then Decreases Level or Hump Repeated Highs 
# AIC Amt. 
Level 
%, values in Q 1, %, high/ low %, range %, values in Q 1, low 
then Q2-9 & 2nd hish 
2 46995 Low 87.0% 19 then 13 .0% 12 to 8 
<3 
High 87.0% 9 then <2 13.0% 59 to 52 
3 28243 Low 76.0% 8 then <2 18.3% 18 to 12 5.8% 3-6 
High 76.0% 6 then <1 18.3% 34 to 17 5.8% 76-88-80 
4 23091 Low 76.8% 8 then <2 9.1% 16 to 6 5.6% 4-6 8.6% 19-12-17 
High 76.8% 6 then <1 9.1% 50 to 3-7 5.6% 79-87-79 8.6% 19-8-31 
The utilization patterns in each of the four classes are displayed in Figure 4.12. 
Each chart represents one class of subjects. Each subject in that set received either none, 
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a low amount, or a high amount of painkillers during each quarter, according to the 
probabilities demonstrated for the set. For example, a subject in the Repeated Highs class 
has a 15% chance of receiving a high level of painkillers in the first quarter but less than 
a 10% chance in Q2 through Q4. It is likely that some subjects who actually got high 
levels of painkillers in Q 1 had a low level of, or no, painkillers in Q2 through Q4. 
The vast majority (77%) of subjects had a very low likelihood of taking 
painkillers after the first quarter. Their initial probability of 13.1% dropped to 4.3% in the 
second quarter, leveled out at under 30%, then increased slightly in the ninth quarter, to 
3.5%. Most subjects who take any painkillers take a lower amount. 
Figure 4.12. Latent classes identified in the 4-class trivariate model of painkiller use 
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The second largest class (9%) had a pattern of Decreasing use over time. Initially, 
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subjects in this class had a 65.8% overall probability oftaking painkillers. The 
probability oftaking a high or low amount decreased over time until the eighth quarter. 
The probability of taking painkillers increased to the last quarter, more steeply for taking 
a high amount (3.0% from 0.7%) than for taking a small amount (9.5% from 8.2%). 
The class with Repeated Highs had nearly as many subjects (9%) as the 
Decreasing class. The likelihood of painkiller user declined from the first to second 
quarters ( 41.5% to 26.6% ), then increased to a point higher than the initial level, and 
finally declined slightly. However, the probability of taking a high amount was 
proportionately higher, relative to the probability in the first quarter, than the probability 
of taking low amount (66% higher, compared to 37% higher). Therefore, while the 
number of subjects using a low amount averaged 2.2 times the number oftaking a high 
amount, it was only 30% greater in the last quarter. The overall likelihood of a subject in 
this class taking painkillers at the end ofthe time period was 24% higher (51.3%) than it 
was at the beginning ( 41.5), despite the decline in the latest quarters. 
A substantial class (5%) had extremely high use, with total probabilities of taking 
painkillers ranging from 85.5% to 92.7% (Q5) and probability of high use ranging from 
71.2% to 80.0%. Probabilities of both use levels were highest in the middle of the time 
period, remaining nearly level from the third through sixth quarter before beginning a 
very slight decline. As with the Repeated Highs class, probability of high use ended at a 
point higher than it began (73.5% versus 71.2%). 
4.5 Results of Analyses with Covariates 
Latent class analysis with covariates determines whether distribution across classes 
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differs across covariate classes. 1 One class is the reference class. An odds ratio for each 
non-reference class describes the likelihood that the covariate class is in the non-
reference class, relative to the reference class. Therefore, there is a p-value for each non-
reference class in the model. 
Analyses for 2-, 3-, and 4-class models were run to determine whether the 
addition of a covariate affected the overall results. It did not, so results for the 4-class 
models for use of painkillers are presented here. The reference class, in every model, is 
the Q 1 Highest Then Level class. 
Sex was not related to the distribution across classes (p=0.7227). 
Having baseline depression or anxiety was related to the distribution across 
classes overall (p=0.0067) but the differences are very small and the significance driven 
by sample size. Subjects were more likely to be in the Repeated Highs class (odds ratio 
1.16), less likely to be in the (lowest utilization) Decreasing class (0.56), and equally 
likely to be in the Level class (0.01). No individual odds ratios were significant (p-values 
of0.258, 0.223, and 0.153, respectively). 
Relatively few subjects had baseline depression or anxiety (n=444), so we 
performed an analysis of painkiller us in just those subjects. Figure 4.13 presents the 
results alongside the results for all subjects. The class that showed the most improvement 
over time, Q1 Highest Then Level, had fewer subjects than in the model with all subjects 
(66% versus 75%). In contrast, the Decreasing class had many more (24% versus 11 %). 
1 The analysis of covariates presented with the set 4 results was performed differently. In 
that case, the subjects assigned probabilistically to each class were directly compared. 
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Subjects with baseline depression or anxiety were likely to maintain an almost 50% 
likelihood of using painkillers through the first year after diagnosis before beginning to 
decrease use. Both the Level and Repeated Highs groups, while small (6% and 5%, 
respectively), had a distinct trend of increasing use of painkillers over time. 
Age was strongly associated with distribution across classes. Subjects in each 
older quartile were 3.3% to 6.5% more likely to be in classes other than Ql Highest Then 
Level (p=O.OOOO). 
Figure 4.13. Results of 4-Ciass model of painkiller use by subjects with baseline depression 
or anxiety and for all subjects 
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The odds ratio from the second to third quartile was the greatest, which was odd. 
In order to determine whether the likelihood of changes in pattern of low back pain 
changed as people age, we performed a series of analyses, comparing subjects over a 
certain age to those under, dividing subjects at ages 25, 30, 35, 40, 45, 50, 55 and 60. 
Table 4.8 demonstrates that likelihood of being in a certain class varied by age. 
The odds of being in one of the two classes that experienced the highest probabilities of 
receiving care over the time period (Hump and Repeated Highs) increased through age 35 
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or 40 then decreased, relative to being in the Q1 Highest Then Level class. The 
probabilities were greatest for comparisons in which one age group is not substantially 
smaller than the other. The difference in odds for being in Decreasing class was greatest 
(12% more) for subjects 40+ compared to those under 40, for being in the Repeated 
Highs class (11% more) for people 45+ compared to those under 45; and for being in the 
Hump class (22% more) for subjects 50+ compared to those under 50. 
Table 4.8. Odds ratios for being in moderate or high utilization classes, relative to no 
utilization class, by age, in the 4-variable, 4-class model 
Coml!arison Classes Re(!eated Highs Level Decreasing (!-value 
18 to under 25 v 25-64 1.0053 1.0526 0.9585 0.8545 
18 to under 30 v 30-64 1.0822 1.0643 1.0961 0.1029 
18 to under 35 v 35-64 1.0752 0.1637 1.1059 0.0002 
18 to under 40 v 40-64 1.0996 0.1354 0.1173 0.0000 
18 to under 45 v 45-64 1.1113 1.1249 1.0620 0.0000 
18 to under 50 v 50-64 1.0622 1.2222 1.0732 0.0005 
18 to under 55 v 55-64 1.0765 1.1074 0.9925 0.0235 
18 to <60 v. 60-64 1.0815 1.0635 0.9214 0.2320 
4.6 Seasonality 
The nine-quarter time period for each subject begins with his or her initial low back pain 
diagnosis, which occurred between January 1 and March 30, 2009. Quarter 1 therefore 
represents a 90-day period ranging from January-March (for subjects with a diagnosis in 
early January) through April-June (for ,subjects with a diagnosis in late March). 
The only chart with any commonality between quarters one, five, and nine is the 
6-class model for painkillers (Figure 4.7) seen in Section 4.2.3.3. A class with 7% of the 
subjects started with a 25.4% probability of having a prescription for painkillers, dropped 
in the second quarter, increased to the fifth quarter, dropped again, and increased from 
the eighth to ninth quarters. The peaks were not close (25.4%, 38.6%, and 10.3%, 
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respectively). More importantly, the 6-class model does not improve much statistically on 
the 5-class model. It is unlikely that health services utilization for low back pain was 
affected by season. 
4. 7 Discussion 
The language used by researchers and clinicians to describe low back pain that does not 
quickly resolve - for the short term, at any rate - has changed from "chronic" to 
"persistent" or "recurrent."[4, 20, 23, 49, 98, 165, 183, 184] Researchers have sought to 
differentiate patients further, using cluster analysis to identify subgroups such as 
"fluctuating" or "persistent" at mild, moderate, or severe levels.[9, 98] Using different 
cohorts, studies produce overlapping but not entirely congruent subgroups. 
Ax en (20 11 i identified 244 patients seeking care for low back pain from a 
convenience sample of chiropractors, the usual provider in Sweden.[4] The subjects had 
not sought care during the prior three months, but were recruited after the second 
treatment to exclude those subjects referred to other providers for treatment of specific 
causes of pain; by definition, subjects "continued" to seek care. Axen identified stable, 
fast improvers, slow improvers, and a "typical patient" group, with medium 
bothersomeness at baseline and an average improvement over the first 4-5 weeks. Using 
text messaging, Axen achieved a high response rate, with 72% of subjects responding for 
80% of data points. Axen includes charts of the trajectory of pain over six months, noting 
that "change in the clinical course might simply indicate a slower speed of recovery, but 
2 This study was published after we had begun our analysis. 
82 
it might also indicate the start of a relapse." 
Our study adds to this literature in the following ways. (1) Our cohort is very 
large, allowing nuanced discrimination between groups of people with different 
experiences oflow back pain. (2) We include 27 months of data, tracking patient 
experience far longer than the six or twelve months in other studies. (3) The subjects have 
continuous medical and pharmaceutical data; there are no missing data in any time 
periods. (4) We require a six-month clean period, increasing the likelihood (albeit not 
proving) that we identify incident low back pain. (5) The cohort is generalizable to an 
adult, non-disabled population. 
We confirm our primary hypothesis, that low back pain can be classified into 
distinct clusters of treatment intensity. We identify two major classes of experience with 
low back pain: approximately half the subjects (the Minimal/No Utilization class) did not 
receive additional services after their initial diagnosis; the other half received a moderate 
to high volume of services in every subsequent 90-day period. 
Among those who received services, we identify three distinct groups. They not 
only had different patterns of care timing, which implies different patterns of continuity 
or relapse, but also received different types of health care services. 
The Decreasing/Moderate Utilization subgroup, with a third of all subjects, had an 
extremely high likelihood (93%) of getting additional services in the first quarter. The 
rate decreased substantially in the second and third quarters, but was still fairly high. For 
the remaining 214 years, these subjects maintained a moderate level of utilization, 
averaging 42% each quarter. Subjects in this class tended to receive individual types of 
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service, e.g., therapy or painkillers, rather than multiple types of service in a quarter. 
These subjects may have had mild persistent pain that occasionally prompted them to 
seek care or may have had occasional recurrence of low back pain. 
The other two classes also had a small proportion of subjects ( 1 0% and 19%) who 
did not receive additional services in the first quarter, appearing to recover immediately. 
However, they did receive services during later quarters. The rate and type of services 
implies their pain may have been more severe, more likely to recur, or more frequently 
recurring. The group had a slightly higher percentage of subjects with any specific cause 
confirmed by imaging within 30 or 90 days. 
Subjects in the Therapy subgroup were very likely (70% to 81 %) to get services 
each quarter after the first six months, including moderate (20% to 26%) likelihood of 
receiving more than one type of service in each quarter. These subjects had particularly 
high utilization of therapeutic services such as physical therapy or chiropractic care. The 
use of therapeutic care may indicate that disability, rather than pain, is salient for this 
class. A recent meta-analysis by Costa et al. found that disability persisted longer than 
pain among people who did not improve quickly.[20] The group had a slightly higher 
percentage of subjects with either IDH or any specific cause confirmed by imaging 
within 30 or 90 days. 
Subjects in the Painkiller group had very high (at least 85%) probability of 
receiving services in each quarter, including moderate (27% to 34%) chance of receiving 
multiple types of service after the first six months. Subjects in this class were likely to 
receive painkillers, if any service. This class may include "drug-seekers" who used 
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reports of pain as a means to acquire narcotics as well as those who truly experience pain. 
Drug-seeking is believed not to be uncommon among people reporting low back pain.[63, 
185, 186] However, these subjects tended to receive Therapy as well as Painkillers rather 
than office Visits as well as Painkiller prescriptions, which argues for perceived need 
rather than drug-seeking. Also, there was no difference in diagnosed drug or alcohol 
problems between this group and the Minimal/No Utilization group. Regardless, even if 
beneficial for immediate pain management, the effect of long-term use of opioids for low 
back pain is unknown and may not be optimal.[6, 185, 187] 
In addition to high levels of therapy and pain medication, subjects in the Therapy 
and Painkiller groups have some likelihood of surgery, corticosteroid injections, or 
imaging in every quarter, suggesting that they have no long-term effect. The literature 
agrees that long-term outcomes are elusory. A systematic review of injections for treating 
lumbar spinal stenosis found weak evidence suggesting that injections are effective for 
select short-term outcomes in some patients.[33] A meta-analysis oflumbar fusion versus 
conservative treatment not only found no difference, but stated that further research 
would be unlikely to change the conclusion.[37] Imaging, including MRI, may help 
identify or confirm causes of low back pain, but quarterly imaging is not likely to 
produce additional information. 
This study was based on patterns of utilization. The objective was to differentiate 
sets of subjects based on health care services received. Although we did not analyze 
costs, the continued high volume of treatment clearly would incur significant costs, 
particularly when compared to costs (not) accrued by subjects who had negligible 
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likelihood of receiving services after their index diagnosis. 
We used the limited set of variables available in the data to identify characteristics 
of the different classes. As hypothesized, females and males had similar utilization 
patterns. As hypothesized, age was associated with low back pain cluster. The moderate 
utilization class was slightly older than the class with no services, but the statistical 
significance is driven by the large sample size rather than overall difference, which was 
less than one year. 
The relationship of age to classification group reflects the complexity of 
managing and predicting the course of low back pain. Age had less effect on 
classification among subjects whose incident diagnosis occurred when they were younger 
(under 40) or older (50+). The likelihood for being in the moderate utilization group, 
relative to being in the no utilization group, peaks near age 40. The likelihood of being in 
one of the high utilization groups, relative to being in the no utilization group, peaks at 
45-50. There is no apparent biomechanical or physiological reason for this interaction. 
Given the well-documented effect of psychosocial and demographic characteristics on 
low back pain, the association of subgroup with age suggests a possible interaction with 
psychosocial or demographic characteristics (other than age). 
We did not demonstrate the hypothesized relationship between depression or 
anxiety and health services utilization for low back pain. These conditions are rare overall 
in this continuously commercially insured population. It is interesting that 14 times as 
many subjects were diagnosed with depression after their diagnosis of low back pain as 
before. This could reflect unmet psychological need prior to LBP diagnosis, a possibility 
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that has recently resulted in calls for screening for depressive symptoms.[52, 53, 60] 
Alternately, it could be the result of provider bias, as depression, like low back pain, is a 
highly subjective condition. 
In sum, our fmdings refine the concept of a "general pattern of improvement over 
time (rapid initial improvement followed by a plateau),"[188] found in numerous 
randomized clinical trials as well as a meta-analysis of cohort studies,[20] with the 
clarification that the plateau is at a moderate to high level of service utilization. Those 
subjects whose low back pain will repeat at all will likely use a high volume of services 
over time. Some researchers call for a "chronic care model"[27] of low back pain as it is 
rarely cured, results in high and increasing costs over time, particularly for persistent 
pain.[34, 57] We agree that the focus of low back pain should shift from treatment to 
management, with an emphasis on self-management.[76, 78, 79] 
4.8 Strengths 
The large sample of71498 nationally representative subjects with continuous 
medical and pharmaceutical data enabled us to find very consistent patterns of health 
services utilization. The patterns hold across multiple types of service (e.g., 
physical/occupational therapy, prescriptions for painkillers, or surgery) as well as 
combinations of services (e.g., PT/OT and surgery or PT/OT and prescriptions for 
painkillers). There are four major patterns of service utilization over time. Based on the 
assumption that service utilization reflects underlying need (i.e. , pain or decreased 
function), as presented in the conceptual framework (see Figure 1.1), the patterns suggest 
that there are four different patterns of experience with low back pain after an index 
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diagnosis. 
The long time period, 27 months, had three benefits. First, the total probability of 
receiving a health care service for low back pain over time- about 20% probability in 
quarters three through nine - supports the length of the clean period. Six months is 
sufficient to identify incident, not repeat, cases. 
Second, we demonstrate no influence of seasons. The national sample of subjects 
would not be exposed to the same seasonal environmental risks, such as having to shovel 
snow, but all subjects have continuous insurance coverage with annual contracts that 
would start in January. While contracts vary, they are often structured such that there is 
an incentive to get health services at a particular point, such as after the annual out-of-
pocket maximum had already been spent, which would vary by member. There is no 
indication that the level of services was affected consistently by annualized insurance 
contracts. 
Third, we demonstrate the continuing probability of services for more than two 
years. If subjects get any service for low back pain after their index diagnosis, they are 
likely to get services in most subsequent quarters. Some patients are decreasingly likely 
to receive services during the first year, and others may not receive services in the two or 
three quarters immediately following their index diagnosis, but they all are likely to 
receive services over the full 27 months. Some patients are continuously very likely to 
receive services for the entire time period. 
We required a single diagnosis of low back pain for inclusion because the key 
objective of the study was to demonstrate for providers the sets of clinical experiences 
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that can be expected for a given patient seeking treatment for incident low back pain. 
Other studies of utilization, particularly of musculoskeletal conditions, have also used 
just one claim.[120-123] 
4.9 Limitations 
As described in Section 2.6, Limitations of using administrative data, all studies using 
administrative data are subject to a familiar set of limitations. One criticism of 
administrative data is that researchers may not be clear about the codes used for inclusion 
and exclusion criteria, such as the region of the spine addressed.[138] We were 
transparent about our methods and have included great detail in the appendices. 
By definition, we are only able to assess pain as manifested in services for low 
back pain. A subject must (a) feel pain or experience decreased function, (b) choose to 
seek care, (c) get an appointment, and (d) have the service approved for payment by the 
insurer in order for the data to be included. Therefore, our estimates of service utilization 
could be underestimates of actual pain or disability. 
Continuous enrollment in commercial insurance implies that many subjects were 
employed during the entire time period and are likely to be healthier than the US 
population. Employment has been associated with improvement in functional status due 
to low back pain. [189] This also strengthens our fmding of continued use of health 
services among almost half the subjects. 
Although we had a clean period double that in much prior research, an even 
longer one may be necessary to identify truly incident cases. Our data suggest that some 
subjects have pain-free periods longer than six months between bouts of low back pain. 
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Vasseljen's study of"incident" pain found that 84% of their subjects reported having had 
prior low back pain, usually more than one year prior to recruitment. [25] 
4.10 Recommendations for Future Research 
The health services utilization patterns we identify may reflect unmeasured 
characteristics ofthe pain, such as its cause or intensity, or of the subjects, such as their 
self-management techniques, care- or drug-seeking behaviors, or clinical and psycho-
social characteristics. Data for these patients from medical records and other sources, 
such as self-reports, could be used to identify these latent characteristics. For example, 
improvement has been associated with pain severity, psychological distress, and socio-
economic factors,[190] patients' perception about whether their back pain will 
persist,[191] fear-avoidance,[67, 68] and poor self-efficacy for physical activity.[192] 
Our somewhat counter-intuitive finding that subjects whose initial low back pain 
diagnosis is in mid-middle age ( 40-50) are likely to use health services more than those 
who are diagnoses when either younger or older is not actionable without a deeper 
understanding of what other factors may be involved. 
Utilization of services may be influenced by provider characteristics. Payment 
structure and self-referral have been associated with service volume and total costs for 
Medicare low back pain patients. [ 129, 131] Linking specific members back to providers 
could be used to investigate variation across providers that contribute to the different 
types of services used by different groups. 
Disease Management programs could randomize patients into types of service to 
determine which types, or combinations, of service have the greatest improvement in 
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outcomes. Randomized trials of treatment rely on subjects following through, and patient 
preference may interfere with actual treatments received. For example, in the SPORT 
trial, many subjects assigned to surgery chose not to receive it, and many who were 
assigned not to have surgery elected it, requiring an as-treated analysis.[193] 
Randomization to more similar types of service may better support intention to treat 
analysis.[75, 194] 
A substantial proportion of subjects with baseline depression or anxiety, 24%, 
have an almost even chance of taking painkillers for the entire first year after their 
incident low back pain diagnosis. An addition 1 0% have an increasing likelihood of using 
painkillers over the fully 27 months. Future research could seek to identify treatment and 
self-management approaches specific to new patients with depression or anxiety. 
Latent class analysis can be used to find new ways to approach problems. For 
example, LCA was recently used to determine whether clusters of MRI findings were 
more accurately associated with low back pain than individual fmdings.[195] The clusters 
were grouped into biologically plausible degenerative pathways, presenting the 
opportunity for targeted research. 
LCA can also be applied to conditions or behaviors related to low back pain. For 
example, a similar type of analysis was used to classify and predict long-term medication 
compliance.[196] 
Our results imply that randomized clinical trials should have follow-up period 
longer than one year to accurately capture outcomes. Many recent studies have longer 
follow-up period, up to five-years, which is promising.[103 , 191 , 197-202] Perhaps more 
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importantly, studies with multiple end-points may have different results at the various 
points. Conflicting results are typically interpreted to mean that the intervention's 
effectiveness waned or grew.[193, 203] As seen in Figure 4.10, subjects in the two sub-
groups with high relapse rates almost arbitrarily have low back pain at a given point in 
time. If one group has a 60% likelihood of receiving services at that point in time, and the 
other group has a 40% likelihood, then different results can be due to chance, regardless 
of whether the groups are evenly distributed across study arms. Our results also implies 
that continuous tracking of subjects, using techniques such as automated weekly text-
message reports- which have been implemented successfully in LBP studies[3, 4]-
could more accurately assess change in status over time. 
Finally, translational research can inform how to encourage recognition of the 
"slow paradigm shift toward viewing back pain as a chronic recurring condition"[188] 
among clinicians. Treating all incident cases of low back pain in the same manner is 
analogous to treating repeated migraines in the same manner as discrete headaches. 
Increasing evidence points to changes in brain structure in patient with persistent or 
recurring low back pain[204, 205] which may pre-exist the pain.[206] There may be 
greater differences between people with persistent effects of low back pain and those 
with a discrete episode than between subtypes of those with persistent effects. 
Key points: 
• Individual people experience low back pain in identifiable clusters which may 
reflect underlying clinical or psychosocial characteristics. These latent 
characteristics may be identified using other data sources. 
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• This study demonstrates that half the people with recent onset low back pain 
either relapse repeatedly or experience persistent pain or disability for a full27 
months, over which they receive health care at a moderate to high rate. 
• Clean periods of six months may not be adequate to identify incident episodes of 
low back pain. 
• Randomized clinical trials require follow-up periods of greater than 12 months to 
fully identify outcomes. 
• Continuous monitoring, rather than measurement at finite endpoints, could 
produce more accurate assessment of change in status. 
5 STUDY THREE: COST OF TREATMENT FOR INCIDENT INTERVERTEBRAL DISC 
HERNIATION 
5.1 Background & Rationale 
The effect of rMRI confirmation of a diagnosis of intervertebral disc herniation (IDH) on 
the cost or outcomes of patient care is not clearly understood. On the one hand, it may 
result in a better understanding of the patient's condition, resulting in better treatment 
outcomes. For example, it could identify a spinal stenosis, which is also a good candidate 
for surgical intervention. On the other hand, the rMRI may uncover perceived mechanical 
abnormalities that are not proven to respond to surgical procedures. Specialist visits and 
intervention on those perceived abnormalities has associated costs and risks.[113] The 
rate ofrMRI for low back pain in general,[32, 207] and IDH specifically,[113] is 
increasing rapidly. It is important to determine whether rMRI is cost-effective. 
Prior assessments ofthe cost-effectiveness ofrMRI for IDH were stymied by 
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small sample size.[l 04, 114]. They were unable to ascertain which distribution most 
accurately described the data, and were therefore unable to determine the mean costs with 
confidence. 
Our study determines the distribution of costs associated with low back pain 
services following an incident diagnosis ofiDH3 using a large sample. We will determine 
the distribution of costs dependent on whether the subject has a confirmatory MRI within 
90 days. 
Objective: determine the shape of the cost curve of episodes of low back pain. 
5.2 Methods 
5.2.1 Sample 
Study subjects were people who sought health care services for an incident case of low 
back pain (LBP) during a 3-month period and received a primary diagnosis of lumbar 
Intervertebral Disc Herniation (IDH) (Figure 5.1 grey highlight). They had no evidence 
of existing low back pain, and had no other plausible causes of their pain. 
Figure 5.1. Sample subjects used in cost-utility study 
Existing: 
I 
Incident: 
I 
L IDH J I 55 11 OS 
Cause: Non-specific !mechanical, including Spon dylosis 
IDH =Intervertebral disk herniation 
The specific ICD-9 codes used to identify IDH include: 
• 722.1 0 Displacement of lumbar intervertebral disc without myelopathy 
3 As noted in study two, a six-month clean period may not be adequate to demonstrate 
incidence. It was, however, the a priori defmition. 
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• 722.2 Displacement of intervertebral disc, site unspecified, without 
myelopathy 
• 722.6 Degeneration of intervertebral disc, site unspecified (analysis ofthese 
subjects showed they tend to have subsequent claims with more 
definitive IDH) 
• 722.73 Intervertebral lumbar disc disorder with myelopathy, lumbar region 
We did not use two codes that did not clearly indicate intervertebral disc 
herniation: 
• 722.1, Displacement of thoracic or lumbar intervertebral disc without 
myelopathy 
• 722.70, Intervertebral disc disorder with myelopathy, site unspecified 
People with severe mental illnesses such as bipolar disorder and schizophrenia or 
cognitive disorders such as dementia or Alzheimer's Disease interact with the health care 
system in fundamentally different ways than people without severe mental illnesses.[171, 
172]. In addition to the exclusion criteria described in Section 2.2.1, we removed subjects 
with severe mental illnesses (n=93) and dementia (n=2) to achieve a sample generalizable 
to the non-mentally ill adult population. (No potential subjects had intellectual 
disabilities.) Finally, potential subjects with a Lumbar MRI prior to the diagnosis of 
Intervertebral Disc Herniation were excluded. 
Of the 6664 members in the fmal dataset, 3851 (57.8%) had an MRI with 
diagnosis of LBP within 90 days after diagnosis. 
There is no evidence of selection bias. Table 5.1 demonstrates that the two groups 
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do not differ by sex or age. While the proportion of females seems low, given the well-
documented higher prevalence of spine disorders among females, the proportion of 
females among adults with IDH ( 41.4%) is reportedly lower than among adults with 
Spinal Stenosis (63.9%) or Degenerative Spondylolisthesis (66.2%)(135]. Subjects who 
did not get an MRI were far more likely to have localized joint degeneration in a region 
other than the back (18.1% v. 12.2%, p<0.001). This is expected, as physicians may be 
less likely to believe that MRI could contribute useful clinical information. 
Table 5.1. Baseline Characteristics of People with IDH 
MRIArm NoMRIArm P-value 
Age 46.3 (1 0.4) 46.0 (10.3) 0.1941 
Sex (male) 2056 53.4% 1538 54.7% 0.2982 
Comorbidities 
H~Qertension 840 21.8% 549 19.5% 0.0227 
Infectious disease 787 20.4% 579 20.6% 0.8835 
Joint degeneration, local, non-back 469 12.2% 508 18.1% <0.001 
Heart disease 370 9.6% 255 9.1% 0.4528 
De2ression or Anxiety disorder 357 9.3% 277 9.9% 0.4280 
Rheumatologic disease 99 2.6% 56 2.0% 0.1208 
Osteo2orosis 43 1.1% 27 1.0% 0.5353 
Obesity* 181 4.7% 113 4.0% 0.1799 
Diabetes 264 6.9% 161 5.7% 0.0618 
Gastrointestinal disorders 214 5.6% 139 4.9% 0.2678 
Asthma/CO PO 182 4.7% 135 4.8% 0.8899 
Alcohol or drug deQendence 143 3.7% 94 3.3% 0.4184 
Migraine 93 2.4% 67 2.4% 0.9304 
Arterial disease 68 1.8% 54 1.9% 0.6435 
Liver disease 17 0.4% 14 0.5% 0.7389 
Kidne~ disease 21 0.5% 12 0.4% 0.4953 
MultiQle sclerosis 23 0.6% 5 0.2% 0.0089 
Ulcer 13 0.3% 6 0.2% 0.3473 
PeriEheral vascular disease 8 0.2% 4 0.1% 0.5331 
* Obesity is infrequently specified in claims data. 
As expected, this population of commercially insured people has fairly low rates 
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of most comorbidity. Given the large sample size, the general lack of statistical 
significance implies that the study groups truly have similar clinical profiles. One 
exception is hypertension, which 21.8% of people who received an MRl are diagnosed 
with, compared with 19.5% of those who did not get an MRI (p-0.0227). We can think of 
no clinical rationale for people with hypertension being more likely to be referred to get 
an MRI. The groups also had different rates of Multiple Sclerosis, but the numbers are 
extremely low (23 and 5). 
5.2.2 Specification of Costs 
5.2.2.1 Cost of medical services 
Costs for medical services include the total allowed amount (includes patient' s 
contribution and withheld amount). To be included in the base case and all but one 
sensitivity analysis, claims must have (a) diagnosis oflumbar intervertebral disc 
herniation and (b) combinations of providers and procedures, for human providers, or 
revenue billing codes, for facility providers, that indicate that the claim is a service for 
the disc herniation. 
Human practitioners include: 
• MDs: General Practitioners, Orthopedists, Surgeons, Anesthesiologists, Sports 
Medicine specialists, Neurologists, Radiologists, MRl specialists, 
Rehabilitation specialists, Pain Medication specialists, Psychiatrists, 
Emergency, Urgent Care, Multi-Specialty Groups. 
• Other practitioners: Physical Therapists, Occupational Therapists, Mental 
Health Professionals, Nurses, Physician Assistants, and Chiropractors. 
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Procedures include: 
• Evaluation and management services 
• Lumbar surgery, anesthesia 
• Injection, including guidance for injection 
• Imaging, including interpretation 
• Physical, occupational, and osteopathic therapy 
• Chiropractic and acupuncture services 
• Diagnostics such as neural function, needle electromyography 
• Supports such as lumbar braces and lumbo-sacral or thoracic-lumbar-
sacral orthotics 
• Health and behavior assessments 
• Facilities services included anesthesia, CT scan (except for head), laboratory, 
medications, MRI (except for head/neck or lower extremities), pharmacy, 
professional services such as anesthetist or diagnostic radiologist, therapy, or 
surgery. The services are similar to those used in other cost of low back pain 
research. [ 15 0] 
5.2.2.2 Cost of pharmaceutical services 
Costs for pharmaceuticals are determined by selecting medication (a) commonly 
used to treat low back pain and (b) associated with an episode of low back pain. 
Pharmaceutical claim lines have no diagnosis. Therefore, we used the ETG software 
described in Section 2.7 to determine whether each claims was an episode of"Joint 
degeneration, localized- back," which includes the four ICD-9 codes we used to identify 
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disc herniation. The software assigns each claim to the one most likely condition, based 
on the claim' s clinical and temporal relationship with potential ETG-defined conditions. 
Therefore, the prescription would not be for trauma, non-back surgery, or other 
conditions. Medications include: 
• Skeletal muscle relaxants 
• Non-steroidal anti-inflammatory (NSAID) agents & analgesics 
• Acetaminophen 
• Narcotics 
• Non-narcotic analgesic combinations 
• Glucocorticoids 
5.2.3 Base Case Analysis 
The base case includes the medical and pharmaceutical claims described in Section 5.2.1. 
5.2.4 Sensitivity Analyses 
Four sensitivity analyses address the assumptions built into the base case and uncertainty 
in the data. 
1. Include chiropractic costs as well as those in the base case. Chiropractic care 
is very common; when included, chiropractic claims constitute more than a 
quarter (26.7%) of all claims. (We considered including acupuncture services 
as a sensitivity analysis. However, they are less than 1% of claims so would 
have negligible effect on total costs.) 
2. Require stronger evidence that the claims are for low back pain. Include just 
medical claims that have a primary diagnosis code, not any of four diagnoses, 
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of low back pain. All other requirements of the base case apply. 
3. Allow weaker evidence that the claims are for low back pain; include costs for 
all claims with a diagnosis of low back pain, with no requirement based on 
provider, procedure, or billing type. 
4. Include just medical, not pharmaceutical claims, using claims from the base 
case. 
Table 5.2 provides the number of subjects in each analysis. The datasets differ in 
size as expected. The largest set is that which includes costs from all medical claims with 
diagnoses of low back pain (n=6462). The "Base plus Chiropractic" set has nearly as 
many subjects, only 20 fewer. Those 20 subjects would only have received services that 
did not meet the Base Case criteria. The Base Case, in turn, has 436 (6.6%) fewer 
subjects; they only received low back pain services from Chiropractors. The "strongest 
evidence" set is smallest, with 5899 subjects. Numerically, the differences are 
inconsequential. 
Table 5.2. Number of subjects in each analysis 
MRI NoMRI Total 
Base Case 3628 2389 6017 
Base plus Chiropractic 3665 2777 6442 
Medical, only if primary diagnosis of LBP, and Pharmacy 3554 2345 5899 
Medical, all LBP claims, and Pharmacy 3682 2780 6462 
Medical Onl~ 3595 2161 5756 
To assess the implications of using such a large dataset, we created ten random 
subsets of each base set, with 10% of subjects each. 
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5.2.5 Outliers 
The tail of the MRI group generally attenuated slowly, as seen in Figure 5.2. The 101h to 
2nd highest cost members' costs increases fairly consistently then had a very large 
increase, approximately doubling, to the highest cost member. The four sensitivity 
analysis datasets have the same pattern. In all five sets, the highest cost member's value 
was set to the group's second highest cost member' s value. 
In contrast, costs at the tail ofthe No MRI group increased steeply but not 
smoothly, with no clear outlier in any of the five datasets. We did not truncate any 
members' values in these datasets. 
Figure 5.2. 10 Highest cost subjects, by group. 
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Table 5.3 shows the distribution of costs in each analysis dataset, and the 
difference between the sensitivity analysis data and base case data. The medians are 
consistently far lower - less than half- the mean costs, reflecting the extreme skewness 
of the data. Skewness is also demonstrated by the standard deviations, which are greater 
than the means. 
Costs in all sensitivity analysis datasets are generally very similar to the base case, 
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and differ in the expected direction. Adding chiropractic services to the base case 
increased subjects' mean total costs by 3.1% and 5.4% in the MRI and No MRI Groups, 
respectively. In contrast, removing pharmaceutical costs decreased subjects' mean total 
costs by 4.5% and 2.0%. Requiring stronger evidence that the care was for low back pain, 
so removing some claims, decreased mean costs by 6.7% and 11.6%. 
Table 5.3. Cost Distribution in Analysis Datasets 
MRI 
No 
MRI 
Run N Mean SD 
Bas~g<lS.~-- --------- ·········----------} 628 .. ~~,358 --~~,762 
Base pl_!!s Chiropractic 3665 $4,493 $6,798 
Max Median 
$91 ,083 $1 ,935 
$91 ,083 $2,123 
Medical, only if primary diagnosis of 3554 $4 068 $6 571 $90,379 $1 ,729 -~BP~an~~h~<t~>-: ----······· · ------------------·-······ ·- ~----- : __________ _ 
~edica~ any claim with an LBP 3682 $5 936 $8 602 $97,649 $2,923 
dmgnosts, and Ph<tfffiacy __ ' ___ ' ________ _ 
Medical Only 3595 $4,162 $6,568 $88,159 $1,807 
Base Case 2389 $2,481 $5,614 $112,277 $736 
Base plus Chiroprac~ic 2777 $2,615 $5,397 $113,381 $976 
Medical, only if primary diagnosis of 2345 $2,1 94 $4,918 $83,448 $661 LBP, and Pharmacy 
Medical, any claim with an LBP 
-~!<tgt!<;>S.~S. , and Ph~<t~Y. ___ _ 
Medical Only 
2780 $3 ,242 $6,724 $134,179 
2161 $2,430 $5 ,282 $110,385 
$1 ,174 
$775 
% Difference from Base Case Mean Max Median 
0.0% 9.7% Base plus Chiropractic + 3.1% 
---- ------------
-0.8% -10.6% Medical, only if primary diagnosis of _6.7% 
MRI LBP, and Pharm<t~>'-------- -·------·-··-······---- ---- ··--·-··-·· ---------·-·-··- _ 
Medical, any claim with an LBP 
No 
MRI 
diagnosis, and ~h_arm_a_c~y ___ _ +32.2% +7.2% +51.1% 
Medical Only -4.5% -3.2% -6.6% 
Base plus Chiropractic +5.4% +1.0% 32.6% 
-25.7% -10.2% Medical, only if primary diagnosis of 
_b:BP, and Ph~ac)': ___ _ -11.6% 
+19.5% +59.5% Medical, any claim with an LBP +30.7% diagnosis, and Pharm_a_cy.,__ _______________________ _ 
Medical Only -2.0% -1.7% +5.3% 
Allowing costs from all claims with a low back pain diagnosis, regardless of the 
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type of provider or service received, had the greatest effect. In both groups, it increased 
mean costs by a third and total costs by over 50%. 
The ten random subsets of the two base case datasets, as expected, these smaller 
datasets were far more likely to have outliers, as the highest-cost subjects were 
distributed among them. Two of the 1 0 MRI group subsets had percent differences of 
> 100%, one with such increases from the 3rd to 2nd highest as well as 2nd to highest. 
Four of the No MRI subsets had percent differences of> 1 00%, on~ from the 3 rd to 2nd 
highest, with a substantial increase (43%) to the highest. 
5.2.6 Analysis 
We performed univariate analyses to estimate the precise cost curve of the empirical data, 
uninfluenced by covariates. We used the SAS capability procedure, which generates: 
• descriptive statistics 
• cumulative distribution function and probability-probability plots, with 
explicit comparison to theoretical distributions 
• goodness-of-fit statistics. [208] 
To generate distribution functions, we sorted the subjects in each analysis dataset 
into percentiles by members' total costs for low back pain care then calculated the total 
costs accrued by each percentile. 
Procedure-procedure plots fix the theoretical distribution at a 45° angle and 
displaying the empirical distribution relative to the fixed line. Figure 5.3 compares the 
empirical distribution (dots) with the exponential distribution (line). The dots symbols 
are over the line until the 83rd percentile of subjects, demonstrating that actual costs are 
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accrued more quickly than they would be if the true distribution were exponential. If the 
true distribution were exponential, the dots symbols would follow the same trajectory as 
the blue line. 
Figure 5.3. Structure of probability-probability plot 
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Therefore, PP plots from different datasets can be compared visually as well as 
statistically. We produced a PP plot for each dataset comparing the actual distribution to 
four theoretical distributions: exponential, lognormal, Weibull, and Gamma. Output 
includes goodness-of-fit tests and expected values at each quantile. 
5.3 Results 
5.3.1 MRI Group 
Both visual inspection of the procedure-procedure plots and statistical comparisons 
demonstrate that the data, overall, are more similar to the Lognormal distribution than the 
Weibull or Gamma. The Exponential distribution fits the data poorly. The distribution for 
subjects without MRI the Base Case and strongest evidence datasets, were most similar to 
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both the Lognormal and Weibull distributions, fitting neither very well. 
In the Base Case analysis of the MRI Group, all three goodness-of-fit tests, 
Kolmogorov-Smimov, Cramer-von Mises, and Anderson-Darling, do not reject the 
Lognormal (p>0.150, >0.500, and >0.500, respectively, Table 5.4). The data also fit the 
Weibull model quite well, with neither the Cramer-von Mises nor Anderson-Darling tests 
Table 5.4. Goodness-of-fit test results for MRI Group 
Distribution: Lognormal Weibull Exl!onential 
MRIGroul! Test I! Value I! Value I! Value 
Base Case Kolmogorov-Smimov >0.150 n/a 0.001 
Cramer-von Mises >0.500 >0.250 <0.001 
Anderson-Darling >0.500 0.215 <0.001 
Base plus Kolmogorov-Smirnov >0.150 n/a 0.004 
Chiropractic Cramer-von Mises >0.500 >0.250 <0.001 
Anderson-Darling >0.500 0.208 <0.001 
Medical with primary Kolmogorov-Smimov >0.150 n/a <0.001 
diagnosis and Cramer-von Mises >0.500 >0.250 <0.001 
Pharmacy Anderson-Darling >0.500 >0.250 <0.001 
Medical, all LBP 
Kolmogorov-Smirnov >0.150 ' n/a 0.012 
Cramer-von Mises >0.500 >0.250 <0.001 
claims, and Pharmacy 
Anderson-Darling >0.500 >0.250 <0.001 
Medical Only Kolmogorov-Smirnov >0.150 n/a <0.001 Cramer-von Mises >0.500 0.195 <0.001 
Anderson-Darling >0.500 0.126 <0.001 
rejecting it, although not as convincingly (p>0.250 and =0.215, respectively). All three 
tests reject the Exponential model (p.::;0.001). (Goodness-of-fit tests are not available in 
SAS through v9.3; see below for alternative analysis.) 
The probability-probability charts demonstrate that the MRI Group distribution is 
well fit to the Lognormal, and slightly less precisely fit for the Weibull (Figure 5.4 Set 1). 
Set 2 displays a moderately fit to the Gamma and poor fit for Exponential. 
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Figure 5.4. Probability-probability plots of Base Case, subjects with MRI 
Set 1: Lognormal and Weibull Distributions 
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Medical services only (no pharmaceutical) 
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5.3.2 No MRI Group 
The results are less definitive for subjects with No MRI Base Case. Statistical tests 
produce different results, with Kolmogorov-Smimov "selecting" Lognormal (it not only 
doesn't reject Lognormal; it has the highest p-value across the goodness-of-fit tests, 
p>O.l50) while Cramer-von Mises and Anderson-Darling both select Weibull (p>0.250). 
All three tests reject the Exponential distribution (p<O.OOl, Table GOF). 
The actual distributions of the Medical with Primary Diagnosis plus Pharmacy 
group also appear similarly close to both theoretical distributions (Table 5.5). The 
goodness-of-fit tests do not agree which distribution is closest to the first, with 
Kolmogorov-Smimov selecting Lognormal (p>0.150) while Cramer-von Mises and 
Anderson-Darling select Weibull (p>0.250). The other three datasets yield results similar 
to those in the MRI Group, with strong support for the Lognormal in both tests and plots. 
Figure 5.5 demonstrates that for the Base Case and Primary Diagnosis cases, the 
plots for the Base Case follow visibly different trajectories, but neither Lognormal nor 
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Table 5.5. Goodness-of-fit test results for the No MRI Group 
No MRI Grou~ ~Value I! Value ~Value 
Base Case Kolmogorov-Smimov >0.150 n/a <0.001 
Cramer-von Mises 0.114 >0.250 <0.001 
Anderson-Darling 0.043 >0.250 <0.001 
Base plus Kolmogorov-Smimov >0.150 n/a <0.001 
Chiropractic Cramer-von Mises >0.500 0.01 <0.001 
Anderson-Darling >0.500 <0.010 <0.001 
Medical with primary Kolmogorov-Smirnov >0.150 n/a <0.001 
diagnosis and Cramer-von Mises 0.145 >0.250 <0.001 
Pharmacy Anderson-Darling 0.061 >0.250 <0.001 
Medical, all LBP Kolmogorov-Smirnov >0.150 n/a <0.001 
claims, and Cramer-von Mises >0.500 <0.010 <0.001 
Pharmacy* Anderson-Darling >0.500 <0.010 <0.001 
Kolmogorov-Smirnov >0.150 n/a <0.001 
Medical only Cramer-von Mises >0.500 <0.010 <0.001 
Anderson-Darling >0.500 <0.010 <0.001 
* This dataset has strongest evidence for the Weibull distribution. 
Wei bull is clearly a better fit (Set 1 ). As with the MRI group, the distribution only weakly 
follows the Gamma distribution and clearly does not follow the Exponential (Set 2). 
Figure 5.5. Probability-probability plots of Base Case, subjects with No MRI 
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Medical services only (no pharmaceutical) 
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Medical services only if primary diagnosis is LBP, and Pharmaceutical 
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5.3.3 Observed:Expected Ratios 
Statistical testing of the Gamma distribution is not available in SAS through v9 .3. 
Therefore, we compared the observed and expected ratios across quantiles.4 A ratio close 
to one indicates that the actual distribution is close to the theoretical distribution at that 
quantile. For example, if the ratio of actual costs accrued by the 5th (25th, 90th) percentile 
of subjects to the costs the theoretical distribution projects would be spent by the 5th (25th, 
90th) percentile of subjects is close to one, the theoretical distribution accurately predicts 
costs for the 5th (25th, 90th) percentile of subjects. 
In Table 5.6, the ratio for each of the four theoretical distributions is presented, 
along with the rank, with rank "1" being closest to 1.0 and rank "4" furthest from 1.0. 
The ratios are almost uniformly the closest (rank= 1) for the Lognormal distribution in the 
MRI group Base Case, and second-closest for the Weibull. For the No MRI Base Case, 
the ratios do not clearly distinguish whether its distribution is closest to the Lognormal or 
Weibull. The results are consistent across sensitivity analyses (Table 10.1). 
The observed to expected ratios could not indicate a closest distribution for the 
one sensitivity analysis for which neither visual inspection nor the goodness-of-fit tests 
could identify a best distribution, Medical with Primary Diagnosis plus Pharmacy No 
MRI group. 
Across the sensitivity analyses, the ratio is most frequently closest to one with a 
4 A quantile is a points taken at regular intervals from the cumulative distribution 
function (CDF). Quantiles typically used to assess distributions are: 1, 5, 10, 25, 50, 75, 90, 95, 
99, and 100%, providing symmetrical information about the distribution with the most 
information for the tails. 
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Table 5.6. Observed and expected ratios for Base Case, MRI and No MRI Groups 
Lognormal Weibull Gamma Ex~onential 
%ile OlE Rank OlE Rank OlE Rank OlE Rank 
1% 0.182 2 4.873 3 6.674 4 0.152 1 
5% 0.072 1 1.101 3 1.211 4 0.312 2 
10% 0.043 0.425 4 0.386 2 0.415 3 
Base 25% 0.004 1 0.046 2 0.137 3 0.463 4 
Case 50% 0.085 1 0.131 2 0.221 3 0.355 4 
with 75% 0.071 1 0.083 2 0.145 3 0.154 4 MRI 
90% 0.007 1 0.067 3 0.053 2 0.154 4 
95% 0.137 3 0.095 1 0.124 2 0.287 4 
99% 0.301 1 0.354 2 0.497 3 0.822 4 
1% 0.739 1 1.357 3 7.075 4 0.933 2 
5% 0.541 2 0.038 1 0.709 3 0.912 4 
Base 10% 0.537 1 1.129 3 1.627 4 0.707 2 
Case 25% 0.248 3 0.064 2 0.039 0.712 4 
with 50% 0.191 2 0.120 1 0.297 3 0.568 4 
No 75% 0.015 1 0.138 2 0.284 3 0.326 4 
MRI 90% 0.170 4 0.027 1 0.051 2 0.131 3 
95% 0.310 3 0.125 1 0.125 2 0.480 4 
99% 0.505 1 0.505 2 0.766 3 1.647 4 
Lognormal distribution than with the other distributions. Across all quantiles, for the base 
and all sensitivity analyses, there are 72 observed to expected comparisons. Lognormal 
has the ratio closest to one 54 times. Wei bull is closest 10 times, with the second closest 
value in 36 cases. 
The Exponential distribution's observed to expected ratios are often closest to one 
at the lowest quantiles, 1%, 5%, and 10%. However, as visual inspection makes clear, it 
is by far the least well-fitted distribution in most quintiles, with the largest observed to 
expected ratio in 50 of the 72 comparisons. Neither Exponential nor Gamma is an 
appropriate distribution for the costs in these datasets. 
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5.4 Discussion 
Researchers would like to know the distribution of health care costs among patients with 
IDH to use in leveraging RCTs to perform cost-effectiveness analyses. Efforts to date 
have been stymied by fairly small sample sizes. In smaller datasets, a single outlier has 
more influence - whether retained as is or truncated - than in larger datasets. 
We found that Lognormal clearly fits our data better than Weibull or Gamma. 
Exponential did not fit. The results were less definitive for the No MRI group than the 
MRI group, with Weibull results stronger than for the MRI group. Our findings were 
consistent across sensitivity analyses that tested the results in opposite directions. We 
expanded the cost set (a) to include chiropractic costs and (b) to allow weaker evidence 
that the claims were for low back pain. We also limited the cost sets (a) to remove 
pharmaceutical data, and (b) to require stronger evidence that the medical claims were for 
low back pain. 
As expected, the cost data was very skewed. We rigorously assessed potential 
outliers and found just one patient whose total costs were misaligned with the others 
(0.03%). We truncated that patient's costs at the next highest value in the MRI group's 
base case and sensitivity analysis datasets. We did not identify any outliers in the No 
MRI group. 
As noted above, Thompson and Nixon found that models were very sensitive to 
the truncation point and argued that more robust data were needed: To demonstrate the 
effect of using a large dataset, we subdivided both groups into random 1 0% subsets. Of 
the 20 subsets, 30%-2 MRI and 4 No MRI subsets- had apparent outliers with values 
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more than double those of the adjacent subject. All but one of the apparent outliers fit 
into an evident tail in our data. With over 6000 subjects, we were far less likely to 
misspecify and incorrectly topcode a data point than we would have with a subset. 
The fact we use 27 months of data could be strength or a weakness. As strength, 
we may have captured costs that would be arbitrarily neglected using a shorter time 
frame. On the other hand, it is possible that costs for low back pain distal to the index 
IDH diagnosis were due to another clinical cause. 
We performed univariate analysis, which also may be strength or a weakness. 
Univariate analysis has the benefit of being easy to interpret, but lacks statistical 
sophistication. On the other hand, they are not influenced by independent variables, as 
regressions are. While much work has been done on which statistical approaches are most 
appropriate for different data circumstances,(209, 210] the influence of covariates is 
typically, if not universally, addressed as a statistical issue rather than a conceptual issue. 
Just as greater transparency regarding inclusion and exclusion criteria will benefit low 
back pain research,(138], it would be useful for researchers to describe which 
independent variables were included in their models, their distribution with study arms, 
particularly the tails, and their effect on the regressions. 
6 CONCLUSIONS 
As insurance policies move towards "consumer engagement," people are being asked to 
consider quality and demonstrate price sensitivity as they make health care decisions. 
Entrenched beliefs about low back pain may stand in the way. Lay patients retain the 
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belief that low back pain definitively has a structural, mechanical cause.[211] Therefore, 
they often have "unrealistically high expectations" of surgery, anticipating greater 
improvement in pain and function than is clinically expected.[212] 
Concerns about cost may encourage patients to seek alternatives to surgery, 
including self-management of low back pain. Results could be self-perpetuating, as 
patients who participate in their care tend to be more satisfied and experience better 
outcomes.[65] Private insurers increasingly promote self-management by subsidizing 
premiums for members who actively address their health problems.[213] Cognitive 
Behavioral Therapy (CBT), which we found to be cost-effective for management of 
persistent low back pain, helps patients learn self-management skills. CBT may be 
particularly beneficial for Americans, as they may have more dysfunction, psychosocial, 
emotional and behavioral impairments than the populations of eight comparator 
countries. [214] 
We demonstrated that CBT is cost-effective within just one year, saving more in 
health care costs than was spent on CBT training. This result is relevant in the private 
insurance context of one-year contracts. We also demonstrated that CBT maintains cost-
effectiveness over ten years. This result is relevant for the long-term insured, in programs 
such as Medicare or the Department of Veterans' Administration. 
The result is also potentially relevant for the commercially insured. The Patient 
Protection and Mfordable Care Act (ACA) may reduce churn -people frequently 
changing insurance plans - once people are accepted into a plan. Insurers are planning on 
spending more than twice on recruiting new members in 2014, compared to 2012 ($500m 
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compared to $210m),[215] in order to attract younger or healthier members whose 
premiums will pay for the care needed by older or sicker members. The insurers are 
economically motivated to help members not become sick or, if they do experience a 
condition such as low back pain, to manage it inexpensively and proactively. 
Patient centered medical homes and bundled payment structures aim to increase 
integrated care. A recent meta-analysis of 33 inception cohort studies essentially found 
that low back pain outcomes are "likely unrelated to the effects of specific 
interventions."[20, 188] The results of our Latent Class Analysis agree. Subjects in the 
three classes with moderate or high utilization had 93-98% likelihood of receiving 
services in the three months after the index diagnosis. The rates and combinations of 
services differed across the three groups, two of which had high probabilities of receiving 
multiple services. The results suggest that receiving a high volume of services for low 
back pain, regardless of the types and combinations of service, does not result in 
measurable benefit. If there were a discernible benefit, we would expect subjects who 
received extensive services soon after their index diagnosis to have lower probabilities of 
receiving services in subsequent quarters. 
Latent Class Analysis also can be used to leverage those large databases to 
introduce a new approach to classification. Subgrouping efforts to date have been 
prospective. An analysis such as ours can identify which patients were probabilistically 
assigned to the various classes retrospectively, then link the data to supplemental data 
sources to identify variation among the patients. Lines of investigation could include 
types of providers and types of services initially received as well as psychosocial and 
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clinical baseline status and, if available, the results of predictive tools. 
Finally, a small proportion of patients with specific types oflow back pain may 
benefit from surgery. For these patients, accurate cost-effectiveness analyses can be 
performed by applying the appropriate distribution. The distribution is likely Lognormal, 
and possibly Weibull, but clearly not Gamma, Exponential. 
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APPENDICES 
7 APPENDIX 1: BACKGROUND INFORMATION 
7.1 Codes used as inclusion and exclusion criteria 
Table 7.1 lists the specific codes used by existing studies. Each set of researchers used a 
slightly different definition, as demonstrated in this list. (The identification letters 
correlate to the column heading in Table PRIORICD.) 
A: Martinet al. (2007) -"degenerative disease"[96] 
B: Vogt et al. (2005)- "low back pain"[216] 
C: Kominski (2005)- "low back pain with or without leg symptoms"[217] 
D: Hoogedoom (2002) - "low back pain"[218] 
E: Skouen (2002) - "low back pain with and without leg pain"[219] 
F: Cherkin (1992)- "mechanical low back problems"[124] 
Table 7.1. ICD-9-CM Codes used in prior research to identify patients with spine disorders, 
and in this study 
ICD-9 Definition i AI Bl Ci Di Er F i 
307.89 Pain diso~ders related to psychological factors I other 
353.1 Lumbosacral plexus lesL<?~ ---------.. --·---
- 353.4*¥ Lumbosacral root lesions, not elsewhere classified 
·-·- ·_ ; 
_115.0 _ _ Q_~!-~.Q~~ritis, g~ner~!i_zed ----- ------ - ----- - -+--
715.5 [Possible typographic error in manuscript; diagnosis 
·····-···--·-·-·-----do~~l!ot _t'l~!_s.!J _____ _ _ _________ _ 
715.90 Osteoarthrosis, unspec. whether generalized or ! X 
Incl. 
No 
No __ j 
Yes 
No 
No 
No 
localized, uns_pec si~------------i--'---' i 
719.4 Pain injoint I xl No 
-~-+~~--~+-~~--
720.0 Ankylosing~ondy'-l_it_is _ _ __________ -+--:-L X!_ ,_ ,_ , _ _ N_o _ _, 
720.2 Sacroiliitis, not elsewhere classified [........ I XI No 
721 ~ondylosis and allied disorders f f i X No 
721.3 Lumbosacr~!_~E.<?_ndy_!_?_sis wi!_g~:t!_t_~~lgpat~y,__ __ ---!' xtl _)~~&_--+-X.....;, __ Y_e_s ____, 
721.4* Thoracic or lumbar s ondylosis with myelo athy I XI Yes 
_7__21.42 ___ ~p_ondylosis with myelopath~, lu!!J:par r~J<?!! ______ ! X ! ~ xr x' ! X I Yes ' 
721.5 Kissing spine ---! I xf"""""' ' X i ---y-~ 
----·-·------··----:----:-· ----+--+-+--+--+-----•--+---- ! 
721.6 Ankylosing vertebral hyperostosis - --·'--·! X,_l_ -+---+--+-::xc::e: __ -=-Ycc-e_s___, 
721.7 Traumatic s and lop._a_th-:'y'--:_ _______ !_X_! __ ._,_ ,_X-;· _ _ Y_e_s___, 
721.8 ___ Qtht'l~allied disg~~-t'l!.S ofsp_in_e__ ·- ----+-- +-~1~-' _ .. _:_~! Yes ___ j 
721.9 Spondylosis ofunspecified site 1 XI X X Yes 
721.90 Spondylosis ofunspecified site without mention of ; xt f x! Yes 
myelopathy ; I 
721.2..!_ __ _ Spondylosis of uns ecified site with myelopa_t~hy"-- --' xi xi I X I Yes 
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ICD-9 Definition i A B i C f Dl E i F l Incl. 
722 Intervertebral disc disorders 
- ----·········· -----,------
i_._ i_._ Xi No -~""---t----i---=-:+--+-=-::+-:::-::+-----,---:­
. Xi i XI Xi Yes 722.1 * Displacement of thoracic or lumbar intervertebral disc 
without m>-:elo ath ,_,_l_l_,_j ___ ---i 
722.1 0 Displacement of lumbar intervertebral disc without i X X Xi Xi I XI Yes 
1 
_ _________ _!!l:yelopat!Iy__ _____ . ... _ ----~·-·-'---'---;--+---;---' .............. ·-- -" 
722.2 Displacement of intervertebral disc, site unspecified, ' Xi ! XI ' Xi Yes 
without myelo athy 
722.3 Schmorl's nodes I Xi Yes 
722.30 Schm()El's no~~-s. , unspecified region i X' I X, Yes __ , 
722.32 --- -~~orl's no~~s. .. _lu.!!!~~-~~g!~Q ____ ......... ________ ___ .__L_l(t-1 -+---+-t-i _x..._i _ _y~_s. ____ , 
722.5_* _ Degeneration of thoracic or lumbar intervertebral disc 1-:-. -+-+-
722.51 Degeneration of thoracic or thoracolumbar 
Yes 
No 
intervertebral disc ~~~~-~-~ 
Degeneration of lumbar or lumbosacral intervertebral 
disc 
-----------·- ···--·····--
722.52 Yes 
I~--·~ 
722.6* _ Degeneration of intervertebral disc, site uns ecified Yes 
722.7 . Intervertebral ~jsc disorder with myel()~_-=th~'------+--+-+-
722.70 Intervertebral disc disorder with myelopathy, 
No 
No 
-·-·------· unspe~JE.~_d reg,-=-io=:-n ___ _ 
722.73 Intervertebral lumbar disc disorder with myelopathy, Xi Yes 
lumbar region 
722.8 Postlaminectomy syndrome I X ; . No 
722.80 --~ostlaminect()IDY syndrome, unspeci~~_<! _r_e_...g'-io_n ___ _,_-+-::::X-::+'-::-f--+--+' -'X-=-·r---'N::_;_::_o __ 
_2~~-:_83 ______ Postlaminectot!!:Y_~ync~Eome, lumbar region_____ ' X' Xi ·-'·-' -~-_B_o __ .
722.9 __ _9ther and Ul!S.pecified disc disorder +-I_X+I_X-+i_ ;____,+-; _N~ _ __, 
722.90 Other and unspecified disc disorder of unspecified I Xi i Xi 
__________ r_e~gi_·o_n __________________ __ -+--+-~ 
_7_2_2_.9_3___ Other and ll!l:S.Pecified disc disorder of l_l.ll!l~ar re ion ! XI 
_7_24 ___ Other and uns ecified disorders of back I Xi 
724.00 ~inal stenosis, unspecified region other than cervical Xi Xi i XI 
724.02 Spinal stenosis of lumbar region, without neurogenic X Xi ' XI 
---.,--~--:-'c_la_u_d_ic-,ca-'-t __ io-=-n:---:-----:--:-:- -·--:----+--+--! !- 1 
724.03* Spinal stenosis oflumbar region, with neurogenic 
claudication 
724.09 SJ?.inal stel!osis, other region other than cervical J i Xi i X, 
724.2 Lumbago I Xi Xi XI ! Xi 
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Yes 
Yes 
No 
Yes.__ 
Yes · 
Yes 
ICD-9 Defmition : A I B i C ! D ! E ! F ! Incl. 
_7_37.0 -- ---~~!~~cent post~~~l_9_p_!l_9~~~---------- _ i X i No I 
73 7.1 Kyphosis (acquired) _____ -=_-=_-=_-=_-=_+-_-+ -X-+L--·+-·---·'· ·-+----+---· No ___ , 
737.10 Ky hosis (acquired) (postural) : X No 
737.20 Lordosis (acquired) (postural) Xi i XI No 
737.3 Ky hoscoliosis and scoliosis Xi No 
737.30 S~?liosis [and kyphyscoliosi~]1 __ ~-~!o_._pat_h_ic _____ -+---+--+! -=-X=+i-f_,_l X---+1--=--N:._::o_--i 
737.39 Other X i No 
- ~;:.4 _____ ~~~:i;:;:;:d~~~~:~~~i~_ _ ___ i__~LXI , X Xi ~:s __ j 
738__.i_ __ _ Othe_!_~!?_q~kedQ~form_i1:y_<?__f_~c~~--~P!!l_e ____________ i L _j_ I X . No 
_ 732__.3_ No~~llopathic lesion of lumbar_~~gi()~, ~~-- ! Xi X: ' X Yes 
739.4 Nonallopathic lesion of sacral region, NEC Xi Xi --: : X 1 Ye-s~· 
739.5-9 Nonallo athic lesion of[other] region, NEC ! Xi No 
756 Congenital anomalies of spine ! ! No 
756.10 Anamoly of spine, unspecified i X! I X! No 
756.11 S ondylolysis, lumbosacral re ion ! ! i I X Yes ~~+-~--~~-: 
756.12 Spon~lolisthesis i Xi X! ! X! Yes 
756.13 A~sel_!~e of~ertebr~_~ongenital ! Xi !_X_! __ N_o _ ____, 
_]~~ ~14_ Hel!l:~~~!!~b_!~-------- -·· ··· ·· - __ --···-···----------- -l-----l-~L-+--+-· i X ---~() __ . 
_ 7_~U_L_ __ F:usion ()f_sp~(;!!_ congenitaj_____ -+-I X----+-1 --+-t-- __ !_Xl_ __ N_o __ . 
756.16 Kliepel-Feil syndrome I XI . X No 
756.17 Spina bifida occulta _X---j!-;------;------;--. _x-+' __ N_o_----i 
756.19 Other ! X! I I X ' No 
805 Fracture of vertebral column without mention of spinal I X No 
cord injury 
805.4 _ Lumbar, closed ! X 1 i X I No 
805_.6_ _ Lum_!?_~~! open I X+-: --+------'------+-. _x_:-: ___ __::;_N=o~--
--~Q_?~---- Uns_p~~if~d, '?!<?_~~_c!_________ ___ ~- ~_!_ __ _,____ ' Xi No ____ _] 
-- ~~2 .2_ _ Thora<;_i~~nd }~!_!l_l:?_ar ~~t!~~a, closed _ ....... L J_2n ___ __ ,_+--~_N_o ___ j 
839.20 Lumbar vertebra ! X No 
839.3 Thoracic and lumbar vertebra, open i Xi No 
839.30 Lumbar vertebra i Xi No 
839.41 Other vertebra, closed I coccyx l X No 
839.42 Other vertebra, closed I sacrum i Xi No 
846 Sprain and strain of sacroiliac re ion I I I : : Yes 
846.0 _ ____§prain and S1!:ain of lumbosacral Uointl__(!i_gamen!) : i x i,_x____,i_ -!--!~! __ Y_e_s _ 
__!~~) S~in and straJ!1__9fsacroiliac W:gament) l!x ! X i X _ _yes __ j 
846__._~ S pr~J!l- ~11~~tra!ll_<?_f~~~~ina_!!!~_i!!g!!I!I:~_11-_!) ____________ L_ ..... i. ~L~L---+--+-1 X=+! __ Y=-:c'-e-=--s _____, 
846.3 S rain and strain of sacrotub~()US (!i_gament) : __ ,i, XX: ___ ..i XXI __ ..! ' X ,_i _Y~es=-----.._ 
846.8 Other specified sites of sacroiliac region sprain and : X' Yes 
strain 
- -------'-----------·------------;-------i--+--+---+-,-----;------------i 
_8_4_6_.9 ___ U_n__,sp'-:-e_c~fied site of sacroiliac region sprain and strain I Xi X I i X i Yes 
84 7.2 Lumbar sprain and strain i Xi I X i Yes 
84 7.3 S rain and strain of sacrum I Xi ! X ' Yes 
84 7 .4 ___ S_,.p_ra_in_an_d_s_tr_a_in_o_f_c_o_c_cyx~_ ! Xi Yes 
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ICD-9 Definition A! BCDEF , Incl. 
_ 84 7 .9_ _ Spt:a_in and_ strain of~_l1specified site of back_~~-
996.4 Mechanical complication of internal orthopedic device, 
implant and graft 
--+---+--+ X 
X X' Yes 
x ·--No --! 
* The majority of subjects with a claim using this diagnosis code also had a claim with a 
diagnosis ofiDH: 353.4, 89.7%; 721.4, 58.8%; 722.1, 100.0%; 722.5, 90.1 %; 722.6, 80.1 %; 
and 724.03 , 91.2%. 
¥ Very few people with a claim using this diagnosis were not excluded. 
Table 7.2 lists the specific ICD-9 diagnosis or procedure codes used to exclude 
potential subjects. 
Table 7.2. ICD-9-CM codes identifying plausible cause of low back pain or existing low 
back pain (exclusion criteria)£ 
Back-specific causes 
Fracture of vertebral column 806.0 - 806.9 
Open vertebral fractures w/o spinal cord 
·~ury~--~--------~~~~-----
Closed vertebral fractures w/o spinal cord 805.0, 805.2, 805.4, 805.6, 805 .8 
805 .1, 805.3, 805.5, 805.7, 805.9 
Pathological fractures 
Vertebral dislocations 
--·------:---,--------,-~-----,,--: -
Inflammatory spondyloarthropathies 
Intraspinal abscess 
Cervical and thoracic disorders (only if 
primary diagnosis) 
733.1 
839- 839.59 
720.0 - 720.9 
353.2, 353.3, 721.0, 721.1 , 721.2, 721.41, 722.0, 
722.11 , 722.4, 722.71 , 722.72, 722.81 , 
722.82, 722.91 , 722.92, 723.0, 723.4, 
724.01 
Procedures indicating prior treatment for back pain 
_ Chordotomy ___ _________ ____ Q?.-2_~_93 .2_2 ________ ~~~~~ 
Cervical and dorsal fusions 81.01 - 81.03 
Back surgery 03.0- 03.1, 03.4- 03.8, 03.93, 03,94, 03.97, 
03.98, 80.5- 80.59, 81.00, 81.04- 81.09 
Possible back surgery·~---------~~7_8_.5_9--"-,_7_8_.6_9 
Other causes 
Neoplasms 140- 239.9 
Pregnancy 630- 676 
Osteomyelitis ----------~~~7_30- 730.99 _______ .... _ .. ___________ _ 
Vehicular accidents E800- E849.9 
·-~-----·------
Existing back pain ___ --~~~~~---~~-
All other codes used to identify people for 
inclusion in sample. 
Table 7.1 
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7.2 Identification of comorbidities 
Table 7.3 presents the comorbidities deemed important for two major researchers, Deyo 
and the SPORT research team, and the Episode Treatment Groups (ETGs) used to 
identify them. 
Table 7.3. ETGs used to identify selected comorbidities. 
Deyo lndex[124] Cummins/SPORT [135] ETG 
Mild liver disease (mild Liver disease Infectious hepatitis 
and moderate to severe) Non-infectious hepatitis 
Liver transplant 
___________ Other hepatobiliary disease* 
Diabetes with and Diabetes Diabetes 
without chronic 
complic __ a_ti_o_n_s __ _ 
Metastatic solid tumour Cancer 
Any malignancy Cancer 
including leukaemia and 
lymphoma 
Renal disease Kidney disease 
Peptic ulcer disease Stomach problem 
Bowel or intestinal 
----
Peripheral vascular 
disease 
Cerebrovascular disease Blood vessel disease 
Chronic pulmonary Lung disease 
disease 
Malignant metastases of the bone, 
central nervous system, liver or lung. 
Leukemia 
Lymphoma 
______ Mal_i~~!!!e~plasl!_l ___________ _ 
Chronic renal failure 
Chronic renal inflammation 
Other renal conditions* 
Ulcer 
Acid ~tic ulcer disease treatment 
Atherosclerosis 
Vascular diseases of the intestines or 
abdomen 
Aortic aneurysm* 
Arterial aneurysm exce t aorta* 
Cerebral vascular disease 
Asthma 
COPD 
Cystic fibrosis 
Occupational & environmental 
pulmonary disease 
Myocardial infarction Stroke Ischemic heart disease 
... fonge~tive _heru:!.f~il~~~---- HYR~.!!~!l:~!~--------------- ~ongestive heart fail~~-------·-
Dementia Nervous system disease Dementia 
Rheumatologic disease 
Hemiplegia or 
Joint disease 
Alzheimer's disease 
Adult rheumatoid arthritis 
Juvenile rheumatoid arthritis 
Lupus 
Major joint inflammation* 
---------------~~· ----------------
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Deyo Index[124] Cummins/SPORT [135] ETG 
parapleg~~- -----­
Acquired 
.. --·--··-··----·····-·· ····-- --- --- -·---·-·· 
AIDS 
immunodeficiency HN sero-positive w/o AIDS 
_syndro!ll~-- ------.. -............... -.---····-····---·-· 
--- ---··---······· 
Dru de endency 
Alcoholism 
__ C-=--hronic fatig_!le S):'ndrome None 
Post traumatic stress None 
disorder --------~ --------- - ----- --- --- -
------ ----····----·- _!':ibromyalg~ia ______ None ---------······- - --- -
Migraine Migraine headache 
--·-···---- - -- __ _ Osteoporosis Osteopor~sis _ _ _____ _ 
.. Depression 
Anxie 
* broad definition 
Depression __ --------·---·····-·····----
Anxie disorder 
Depression or Anxiety disorder 
8 APPENDIX 2: ADDITIONAL DATA FOR CBT STUDY 
This appendix provides additional information relevant to the cost-utility analysis of 
cognitive behavioral therapy, compared to advice without cognitive behavioral therapy, 
for people with existing low back pain that is not attributable to specific causes. 
8.1 Background 
8.1.1 Related, unpublished studies 
The literature includes descriptions of study protocols for two RCTs of the clinical 
effectiveness of CBT in Norwegian populations. Cost-effectiveness is a secondary 
objective of each study. The results have not been published. Regardless, their study 
populations, perspectives, or methods would result in different contributions to the 
literature than this study. 
1. A multicenter RCT is comparing the effectiveness of 4 different interventions; 
Brief Intervention (BI) and BI combined with CBT, nutritional supplements of 
seal oil, or nutritional supplements of soy oil.[220] Cost-effectiveness will be 
measured from the social perspective, specifically the social value of a 
reduction in the number of days on sick leave. The participants will be drawn 
from the Norwegian National Insurance Administration's patient population. 
2. In an RCT in two regions ofNorway, General Practitioners and Physical 
Therapists will be assigned to an CBT or control arm and will provide 
services to all patients according to the randomization.[221] Cost-
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effectiveness will be measured using three metrics: return-to work, utility 
based on EuroQoL 5D, and by estimating the total cost of all the four groups 
of doctors and physiotherapists in the trial. While the third metric is similar to 
ours, we include all LBP costs incurred by the patients. 
8.2 Selecting Utility Values 
In economic evaluations, preference weights should reflect societal values, derived from 
a population with the health state.[222] Therefore, we initially generated a utility for 
subjects whose pain does not improve by calculating a population-based utility from the 
nationally representative, public access Medical Expenditure Panel Survey (MEPS) data. 
The MEPS process maps medical conditions reported by respondent to summary-level 
ICD-9 codes. Based on the EQ-5D, people with NSLBP in two consecutive interviews, 
approximately three months apart, reported an average utility of0.74 (0.01). Our result 
was similar to the values for Back Disorders (0.786 (0.0001)) and for Spondylosis et al. 
(0.702 (0.002)) found by Sullivan and Gushchyan using MEPS data.[223] 
The utility values are high because MEPS measures whether people have had 
back pain in the recent past; they may not be experiencing pain when they are 
interviewed. People who are not necessarily seeking care for their low back pain have 
higher utilities, ranging from 0.68 to 0.88, than those who seek care.[223-226] The utility 
value from MEPS was unrealistically high to use for our study. Therefore, we searched 
the literature for studies with populations similar to ours, and which used the EQ-5D. We 
used utilities from the following studies. 
• Rivero-Arias et al. randomized 349 patients from 15 hospitals in the United 
Kingdom to surgery (n=l76) or to an intensive rehabilitation program 
(n=l73).[103] Patients were candidates for spinal fusion between 18 and 55 
years old (no mean is provided, but distributions imply a mean of 40-45) and 
had experienced low back pain for a minimum of 12 months.[227] 
• Solberg et al. test the effectiveness ofthe generic EQ-5D to measure low back 
utilities compared with a disease-specific tool. They assess 326 Norwegian 
surgical patients with an average age of 44.7. The patients had experienced 
back pain for 129 (256) weeks and leg pain for 58(83) weeks. 
• Brazier et al. report on a study of265 adults age 20 to 65 (mean 43) who had 
had been experiencing back pain for an average of 17 weeks prior to 
recruitment, with most people experiencing pain every day.[228] The follow-
up period was only three months, so we apply baseline data only. 
As noted above, the pre-treatment utilities had a wide range: 0.23 to 0.66 (on a 0-
1.0 scale, with 1.0 representing no pain). This is explained by the clinical differences 
among the populations. Solberg reported the lowest pre-treatment utility, 0.23. The 
patients had a mix of specific and NSLBP and "failed meaningful conservative 
treatment" (which was unlikely, at the time, to have included CBT); their clinical severity 
was relatively high. 
While Rivero-Arias' study participants were eligible for surgery, they had not 
explicitly failed conservative treatment. The two arms had higher utilities than Solberg's 
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population, 0.35 for surgery, and 0.41 for rehabilitation. The population Brazier studied 
had a much shorter duration of pain than the other two studies. Accordingly, their utility 
was much higher, at 0.64. 
We did not use studies with subjects with specific causes ofLBP or who were not 
seeking care, had adjusted utilities, or did not use EQ-5D. 
A British study published after we performed our analysis presents a similar wide 
range of baseline utilities using the EQ-5D.[194] The study stratified the subjects, who 
were age 18 and over (no mean provided) seeking care for low back pain of any duration, 
to one of three risk levels using a prognostic screening tool. The "high-risk" set of 
subjects report utility values of 0.325 and 0.252 in the intervention group and control 
group, respectively. The "medium-risk" set reported 0.540 and 0.573 and the "low-risk" 
set reported 0.725 and 0.733. 
The 12-month post-treatment utilities display a more narrow range. Rivero-Arias' 
population supplies the lower values, approximately 0.48 for rehabilitation and 0.51 for 
surgery (the raw values are presented graphically but not textually) and Solberg's the 
higher value, 0.70. The difference could be the clinical success of the treatments, 
particularly as a substantial proportion of Solberg's subjects had intervertebral disc 
herniation or spinal stenosis, which are known to respond to surgery.[112, 199, 229, 230] 
High and low estimates for people whose symptoms did improve, based on post-
treatment data from the same studies, varied by 0.22 points on a 0-1 scale, which is 
consistent with other research. [20] Two systematic reviews published after this analysis 
was done also reported wide variation due to patient heterogeneity, with weighted 
average improvement on a 100 point scale of"about 20" and 36.8 points (SD 14.8)[20, 
48] 
Pre-treatment utilities in the literature varied more, by 0.43 points. 
8.3 Costing Detail 
This section provides additional detail for how costs of specific services were calculated 
for the study of the cost utility of cognitive behavioral therapy. Costs are based on the 
health care utilization in the CBT and Control arms reported in the BeST results (see 
Table 8.1). 
Table 8.1 Health Care Resource Utilization by BeST Subjects 
Item Control mean (SE) CBT mean (SE) 
NHS general practitioner 1.86 (0.0 17) 2.06 (0.011) 
NHS practice nurse 0.11 (0.003) 0.16 (0.003) 
NHS physiotherapist 0.90 (0.016) 0.91 (0.008) 
NHS ER visit 0.02 (0.001) 0.03 (0.001) 
NHS outpatient visit 0.21 (0.004) 0.29 (0.003) 
NHS psychologist visit 0.09 (0.004) 0.10 (0.002) 
NHS admission 0.03 (0.000) 0.02 (0.000) 
NHS X-ray 0.28 (0.005) 0.17 (0.002) 
NHS CT scan 0.01 (0.001) 0.03 (0.001) 
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Item Control mean (SE) CBT mean (SE) 
NHSMRI 0.04 (0.001) 0.10 (0.001) 
NHS blood tests 0.50 (0.007) 0.63 (0.007) 
NHS prescription painkiller 2.22 (0.028) 2.01 (0.010) 
NHS prescription NSAID 2.02 (0.079) 1.09 (0.007) 
NHS prescription gels and creams 0.24 (0.006) 0.20 (0.003) 
NHS prescription sleeping pills 0.48 (0.018) 0.28 (0.004) 
NHS prescription anti-depressants 0.37 (0.007) 0.40 (0.004) 
Private physiotherapy 0.32 (0.009) 0.40 (0.007) 
Private osteopathy 0.53 (0.014) 0.28 (0.006) 
Private chiropractor 0.45 (0.017) 0.83 (0.020) 
Private counseling --- 0.01 (0.001) 
Private psychologist --- 0.03 (0.002) 
Private massage* 0.40 (0.013) 0.47 0.007) 
Private aromatherapy* --- 0.09 (0.003) 
Private acupuncture 0.09 (0.005) 0.22 (0.004) 
Private outpatient visit 0.06 (0.002) 0.08 (0.002) 
Private admission 0.01 (0.000) 0.01 (0.000) 
Private X-ray 0.01 (0.001) 0.04 (0.001) 
Private CT scan --- 0.01 (0.000) 
Private MRI 0.01 (0.001) 0.02 (0.000) 
Private blood tests 0.01 (0.00 1) 0.09 (0.002) 
OTC and private prescription painkillers 4.99 (0.65) 3.65 (0.024) 
OTC and private prescription NSAIDs 2.94 (0.049) 1.77 (0.012) 
OTC and private prescription gels and 0.88 (0.012) 0.72 (0.006) 
creams 
OTC and private prescription other 0.27 (0.005) 0.28 (0.004) 
drugs 
OTC exercise equipment* 0.24 (0.004) 0.20 (0.002) 
OTC back supports 0.16 (0.003) 0.13 (0.001) 
OTC mattresses & beds 0.22 (0.003) 0.24 (0.002) 
OTC aids and appliances 0.03 (0.001) 0.02 (0.001) 
OTH other* 0.07 (0.002) 0.07 (0.001) 
*Not likely to be included in a US commerctal plan, so not included. 
8.3.1 Professional services 
To identify claims to be used to cost professional services, we first selected claims 
indicating clinically appropriate services, as indicated by (a) a primary diagnosis ofLBP 
and (b) a procedure (billing) code indicating evaluation and management (E&M), 
therapeutic services, specialist services, muscle testing, and neurological testing. We did 
not include claims for services costed separately - anesthesia, imaging, outpatient 
procedures, surgeries, and emergency room visits. We did not include services provided 
in nursing homes as our population was community-based. We then subsetted services 
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provided by each provider type, e.g., General Practitioner or Acupuncturist. 
We identified procedure codes using the Berenson-Eggers Type of Service 
(BETOS) code sets, which were developed for the Centers for Medicare and Medicaid 
Services for clinical analysis, where possible. [231] In some cases, we selected procedure 
codes that were not included in a BETOS code set. For example, we include all E&M 
procedure codes. The BETOS code sets include "G codes," which are used for Medicare 
services, not commercially reimbursed services; they are not listed. 
Procedure code sets use the following CPT codes: 
• Acupuncture:97810,97811,97813,97814 
• Chiropractic (BETOS 01B): 98940, 98941, 98942, 98943 
• E&M Consultations (BETOS M6): 99241, 99242, 99243, 99244,99245, 
99251,99252,99253,99254,99255,99460,99461,99462,99463,99464, 
99465,99478,99479 
• E&M Hospital visit- initial (BETOS M2A): 99223, 99431, 99435 
• E&M Hospital visit- subsequent (BETOS M2B): 94003, 99217, 99224, 
99225,99226,99231,99232,99233,99234,99235,99236,99238,99239, 
99356,99357,99433 
• E&M Hospital visit- critical care (BETOS M2C): 94002, 94660, 94662, 
99291,99292,99466,99467,99468,99469,99471,99472,99475,99476, 
99480,99293,99294,99295,99296,99298,99299,99440 
• E&M Office visits- established patient (BETOS M1B): 0502F, 0503F, 
1000F,2000F,95115,95117,99058,99211,99212,99213,99214,99215, 
99354,99355,99366,99367,99391,99392,99393,99394,99395,99396, 
99397,99401,99402,99403,99404,99411,99412,99420,99429(Excluding 
99397 as it is specific for people age 65 and over.) 
• E&M Office visits- new patient (BETOS M1A): 0500F, 99201, 99202, 
99203,99204,99205,99381,99382,99383,99384,99385,99386,99387, 
99432 
• E&M- Prolonged: 99358, 99359 
• E&M Specialist- psychiatry (BETOS M5B): 90801, 90802, 90804, 90805, 
90806,90807,90808,90809,90810,90811,90812,90813,90814,90815, 
90816,90817,90818,90819,90821,90822,90823,90824,90826,90827, 
90828,90829,90845,90846,90847,90849,90853,90857,90862,90865, 
90875,90876,90880,90882,90885,90887,90889,90899,M0064 
• E&M- Telephone/Online: 99360-99365, 99441-99444 
• E&M - Unlisted: 99499 
• E&M- Work- or Disability- Related Exam: 99450-99456 
• Health & behavioral assessment: 96150,96151, 96152 
• Neurological testing: 95900-95929 
• Muscle testing: 95831,95832 
• Occupational Therapy Evaluation: 97003, 97004 
• Osteopathic manipulation: 98925-98929 
• Physical Therapy Evaluation: 97001, 97002 
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• Therapeutic procedures: 97010-97028, 97032-97039, 97100, 97110-97546, 
97750-97799,99218,99219,99220,99221,99222 
To validate the coding, we reviewed the procedure code sets for each service 
category. Each provider type had clinically expected procedure code sets. 
A single office visit will often produce multiple claims. For example, chiropractor 
visits are typically billed as one evaluation and one therapeutic service. Total costs for 
LBP visits to professional providers were based on all claims associated with the service 
by summing cost of unique combination of patient, provider type, and day. 
8.3.2 Imaging 
To identify claims to be used to cost imaging and radiologic examinations, we selected 
procedure codes indicating services specific to the lumbar region. They included: 
• ~scan:72148, 72149,72158 
• CT scan: 72131,72132,72133 
• X-ray: 72100, 72110, 72114, 72120 
Imaging services include multiple distinct procedures such as anesthesia, injection, and 
guidance. We included all claims on the day imaging was received that had both a 
primary diagnosis ofLBP and the same provider. 
8.3.3 Outpatient procedures 
To identify claims to be used to cost outpatient services, we first identified members who 
had eligible services by selecting claims indicating a primary diagnosis of LBP provided 
in an Ambulatory Surgical Center or General Acute Care Hospital and: 
• revenue codes indicating either Ambulatory Surgical Care ( 490-499) or 
Outpatient Visit (500-529) 
• and procedure codes indicating one of: 
• E&M Office visits- established patient (M1B) (codes listed above) 
• E&M Office visits- new (MlA) (codes listed above) 
• Major procedure- explor/decompr/excis disc (BETOS PlF): 0202T, 
32503,63001-63200,C9729 
• Anesthesia, lumbar spine: 00630-00670 
• Mod.sedation by diagnosing/treating MD: 99143, 99144, 99145, 99148, 
99149 
• Guidance for injection: 77003, 77012 
To validate the coding, we reviewed the resulting outpatient procedures. The vast 
majority of outpatient LBP services were injections (90.1 %), followed by exploration, 
decompression, or excision of a disc (6.8%). 
For members with these services, we then collected all LBP services on the same 
day, from both professional and facility providers. 
The BeST trial included psychiatric visits in the outpatient visit category 
(psychologist and counseling services are included as professional services, above). We 
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identified services provided by psychiatrists indicating a primary diagnosis of LBP and a 
procedure code indicating either: 
• E&M Office visits- established patient (M1B) (codes listed above) 
• E&M Office visits- new patient (M1A) (codes listed above) 
• E&M Consultations (M6) (codes listed above) 
• E&M Specialist- psychiatry (BETOS M5B): 90801, 90802, 90804, 90805, 
90806,90807,90808,90809,90810,90811,90812,90813,90814,90815, 
90816,90817,90818,90819,90821,90822,90823,90824,90826,90827, 
90828,90829,90845,90846,90847,90849,90853,90857,90862,90865, 
90875,90876,90880,90882,90885,90887,90889,90899,M0064 
There were few psychiatric services (n=254) relative to the number of outpatient 
procedures (n=5534). Average cost was driven by the outpatient procedures. 
8.3.4 Surgeries 
To identify claims to be used to cost surgeries, we first identified members who had 
eligible services. To differentiate between outpatient and inpatient surgeries, we first 
selected claims indicating a primary diagnosis of LBP and a revenue (facility billing) 
code indicating any surgery-related service. 
• Anesthesia: 370-379, 963, 964 
• Durable Medical Equipment (other than Renal): 290-299 
• Laboratory: 300-309 
• Observation/Treatment Room: 760-769 
• Operating Room Services: 360-369 
• Pathology: 310-319 
• Pharmacy:250-259,260 
• Professional fees: 900, 911, 960, 975 
• Recovery Room: 710 
• Supplies and Devices, Medical/Surgical: 270-279, 621-624 
• Therapeutic Services: 940, 942, 947 
For members with these services, we then collected all LBP services on the same 
day, from both professional and facility providers. To validate the coding, we reviewed 
the results. Ofthe combined services, the majority was provided by facilities (General 
Acute Care Hospital, 49.6%, Ambulatory Surgical Center, 15.7%, and Facility, Other, 
14.1 %) followed by physicians, each type with no more than 4.3% of services. Facility 
services were lead by prescriptions (36.7%), operating room services (17.6%) and 
laboratory services (8.2%). 
8.3.5 Emergency Room Visits 
To identify claims to be used to cost emergency room (ER) visits, we identified members 
who had an emergency room visit, using the BETOS code set M3. We then pulled all 
claims, professional and facility-based, with a primary diagnosis of LBP for those 
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members, on the same day as the ER visit. Procedure code sets comprising more than one 
percent of ER professional services include: 
• Emergency room visit (M3) (77.0%) 
• Spine Rad. lumbo-sacral exam (11.4%) 
• Spine MRI, lumbar (3 .6%) 
• Office visits- est. (M1B) (1.7%) 
• Hospital visit- initial (M2A) (1.4%) 
• Radiology (1.2%) 
Revenue code sets comprising more than one percent ofER facility-based 
services include: 
• Spine radiologic exam (76.7%) 
• Spine CT Scan (12.8%) 
• Spinal Cord/Spine MRI (10.5%) 
8.3.6 Pharmaceutical services 
Administrative claims for pharmaceutical do not report diagnoses. Therefore, to identify 
claims to be used to cost pharmaceutical use, determined which claims were associated 
with episodes of LBP. We processed all medical and pharmaceutical claims through the 
Episode Treatment Grouper® (ETG), which identifies an anchor claim, which must be an 
Evaluation & Management or Surgical service, to initiate a clinical episode. The grouper 
then identifies all medical, pharmaceutical, and ancillary claims that have a strong 
clinical association with the anchor claim. Finally, the grouper applies a hierarchy such 
that any one claim will only be associated with one episode, or clinical condition. For 
example, an antidepressant may be taken by a patient during overlapping time frames for 
episodes of low back pain and depression. The Antidepressant would be associated with 
the episode of depression. However, if an Antidepressant is taken during the time frame 
of a low back pain episode, in the absence of alternative conditions, it will be associated 
with the low back pain. 
We selected ETGs, which based on sets of diagnosis codes closest to those we 
used to identify people with LBP. The ETGs and the primary ICD-9 codes use to build 
them are as follows. 
• ETG "Joint degeneration, localized- back": 
• Other and unspecified disc disorder of lumbar region: 722.93 
• Spinal stenosis: 724.0, 724.00, 724.02, 724.03 , 724.09 
• Sciatica: 724.3 
• Thoracic or lumbosacral neuritis or radiculitis, unspecified: 724.4 
• Acquired Spondylolisthesis: 738.4 
• ETG "Minor orthopedic trauma- back" : 
• Sprains and strains: 846, 846.0, 846.1, 846.2, 846.3, 846.8, 846.9, 847, 
847.2, 847.3, 847.4, 847.9 
• ETG "Other minor orthopedic disorders- back" : 
• Schmorl's nodes: 722.3 , 722.30, 722.32, 722.39 
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• Other and unspecified disorders of back: 724, 724.2, 724.5, 724.6, 724.7, 
724.70, 724.71, 724.79, 724.8, 724.9 
• Nonallopathic lesion: 739.3, 739.4. 
Each pharmaceutical has a National Drug Code (NDC) that indicates 
characteristics of the medication including its strength, dosage form, packaging, and 
manufacturer. The Ingenix Impact Research Database includes the NDC and a drug code 
classification (DCC). We used DCC codes to identify the medications used by study 
participants. 
The BTT trial was held in the United Kingdom. Study participants could get 
services from either the National Health Service (NHS), which would pay the full cost of 
the medication, or a private source. The BeST supplied the rate at which subjects in both 
arms got medications of both types. To adapt this to the US commercial context, we 
applied the allowed cost of brand name medications (which are higher cost to the health 
plan) to the ''NHS" medications and the cost of generic medications (which are lower 
cost to the health plan) to "private" medications. 
8.3. 7 Blood tests 
To identify claims to be used to cost blood tests, we selected claims with the following 
CPT procedure codes: 
• Basic metabolic panel (including creatinine): 80048 
• General health panel: 80050 
• Electrolyte panel: 80051 
• Comprehensive metabolic panel (including creatinine): 80053 
• Hepatic function panel: 80076 
8.3.8 Non Medical Supplies 
We costed the reimbursed use of lumbar support, orthotics, walking as sisters, and 
extenders, devices used by patients with LBP when their ability to reach is impaired. We 
did not cost non-medical devices unlikely to be reimbursed by commercial providers, 
such as exercise equipment or beds. We used the following CPT procedure codes: 
• Back Brace, lumbar: K0630, K0631, K0632, K0633, K0634, K0635, K0636, 
K0637, K0638, K0639, K0640, K0641, K0642, K0643, K0644, K0645, 
K0646, K0647, K0648, K0649, L0300, L0310, L0315, L0317, L0320, L0321 , 
L0330,L0331,L0340,L0350, L0360,L0370,L0380,L0390, L0391,L0400, 
L0410,L0420,L0430,L0466,L0468,L0470,L0472,L0474,L0476,L0478, 
L0480,L0482,L0484,L0486,L0488,L0490,L0500,L0510,L0515,L0520, 
L0530,L0540,L0550,L0560,L0561,L0565,L0600,L0610,L0620,L0970, 
L0972,L0974,L0976 
• Orthotics, lumbar: L0625-L0710 
• Canes, crutches, walkers: E0100-E0159 
• Reaching or grabbing device: A9281 
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8.4 Excel Model Structure 
The purpose of this section is to demonstrate the structure of the model. Discussion of the 
v alues applied, such as the cost and utility estimates, are in the body of the dissertation. 
The model consists of w orksheets w ith the following elements: 
• Rate of utilization of specific services in the intervention arm, with 5000 
estimates (rows) randomly generated from the mean and standard deviation 
reported in the source RCT ( " CBT Nums" ). Figure 8.1. The rate is for the 
population; on average each person saw a general practitioner approx imately 
twice (2.06) while approx imately one in six people saw a nurse (0.16) during 
the year. 
Figure 8.1. Markov model- estimating service utilization 
Place-
holder 
col 
Meds 
Pc 
GP PT Out pt . X-ra CT Scan kill 
2.06 0.16 0.91 0.03 0.29 0.11 0.03 2 
(0.011) (0.003) (0.008) (0.001) (0.003) (0.002) (0.001) (0.0 
2.056095 0.159099 0.922122 0.031106 0.2.92233 0.166788 0.030179 2 . 017~ 
2.069861 0.156167 0.905513 0.031166 0.290589 0.16931 0 0.028549 2.015E 
2.063883 0.160733 0.920041 0.031279 0.288951 0.170854 0.030406 2 032~ 
2.054176 0.163829 0.904179 0.030318 0.290714 0.175126 0.029965 2.007E 
2.056815 0.163595 0.915819 0.030471 0.284881 0.166166 0.029105 1.996( 
2.041558 0.165199 0.921604 0.030028 0.285234 0.168510 0.029314 2 . 014~ 
2 057242 0.153449 0.909262 0.029835 0.285536 0.167851 0.031641 2.008i 
2.060069 0.159297 0.908372 0.030519 0.296347 0.167678 0.030238 2.000i 
' 01>~,,~ o 1~>"l?A~ o Q10n.t< 0 O?QQAO o ?Q07n o 101?4? o 11111>1 o n"ln.t?"l n nqq11>1 n l>?"lAI>7 'nnn~etc . 
• Rate of utilization of specific services in the control arm, with 5000 estimates 
(rows) randomly generated from the mean and standard deviation reported in 
the source RCT ("AM Nums"). The structure is the same as in Figure 8.1 . 
Figure 8.2. Markov model- applying costs to types of service 
;1.Cell name "CBTAvg" 
Min $4,031 .78 [tllnical Care Diagnostics Meds 
Avg $4,086.15 Psycho- Blood Pair GP Nurse PT ER Out pat logist X-ray CT Scan MRI test killer 
Max $4,144.33 $107.74 $115.63 $110.59 $246.10 $2,519.50 $290.79 $222.70 $265.90 $579.61 $23.39 $30.9 
$4,077.70 $221.52 $18.40 $101.98 57.66 $736.28 $29.31 $37.14 $8.02 $57.50 S14.76 562.4 
$4,080.38 $223.01 S18.06 5100.14 57.67 5732.14 $28.96 $37.71 $7.59 S57.50 S14.94 562.4 
$4,093.51 $222.36 518.59 $101.75 $7.70 $728.01 529.18 S38.05 $8.09 $58.50 S14.75 $62.9 
$4,095.03 $221.32 518.94 $99.99 $7.46 $732.45 528.32 $39.00 $7.97 $57.90 S14.60 $62.1 
$4,074.44 $221.60 $18.92 $101.28 57.50 $717.76 S28.78 $37.01 $7.74 558.42 $14.79 561 .8 
$4,094.88 5219.96 $19.10 $101 .92 $7.39 $718.65 S29.39 $37.53 S7.79 558.27 $15.00 562.3 
$4,076.39 5221.65 517.74 5100.56 57.34 $719.41 529.32 537.38 58.41 558.77 515.03 562.1 
$4,085.37 5221.95 518.42 51 00.46 $7.51 $746.65 528.35 $37.34 S8.04 $58.36 514.67 $61 .9 
$4,079.11 5222.52 518.88 5100.64 S7.38 5732.45 S30.02 $38.12 58.09 557.48 514.59 561 .9 
$4,107.09 5221 .08 S18.12 5102.10 57.58 5732.03 S28.11 $38.08 S7.70 $57.75 51 4.64 562.5 
$4,069.87 5220.56 518.26 5100.33 56.91 $72004 530.09 $38.27 58.77 $58.41 514.94 562.4 
$4,099.03 5223.51 517.91 5101.39 57.66 5720.97 529.53 $38.18 $8.29 557.43 $14.80 S62.5etc. 
• Cost of specific services in the intervention arm, with 5000 estimates (rows) 
calculated by multiplying the base cost by the rate in CBT Nums ("CBT 
Costs" ). Figure 8.2. The per-person cos ts are the s um of the row. The a v erage, 
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minimum, and maximum of the 5000 rows are also calculated. The cells are 
assigned names (e.g., "CBTA vg") for reference elsewhere in the workbook. 
• Cost of specific services in the intervention arm, base and 5000 estimates 
(rows) calculated by multiplying the base cost by the rate in AM Nums ("AM 
Costs"). The structure is the same as in Figure 8.2. 
• Some cells with unique values that will be referenced in the model are 
assigned names. They include intervention costs for each subject in the 
treatment group ("CBTintCost"), intervention costs for each subject in the 
control group, which got a base level of care ("AMintCost"), the estimated 
proportion of the population who had an annual relapse ("Relapsed"), and the 
remainder ("No_ Relapse"). 
Figure 8.3 demonstrates the model itself. 
Figure 8.3. Markov model- Structure . 
.. 
Parameters 
Relapse 0.60 
CBTPr(Btr) 0.59 
Ctl Pr(Btr) 
Discount n $ Util n Util 
CBTTx $ CBT <Tx $18,434,406 2710 $10,514,125 1352 
Ctl Tx $ $375 Utlt 294 174 $2,236,553 ~7 2U $1,186,206 141 
CBTAvg$ 0.640 173 54 $1,085,375 145.0 72 $367,724 46.2 
CtiAvg $ $4,716 0.592 121 119 $1.151,178 142.3 161 $818,482 95.2 
Pr(Died) Yr 2 0.0060 294 174 $1,852,677 m 2U $1,066,896 131 
CBTMin$ $4,032 0.616 1.76 1.04 $11,086 1.7 1.39 $6,370.44 0.8 
CtiMin$ $4,584 0.640 68.8 21.3 $357,482 56.0 28.7 $131,505.19 17.8 
CBTMax$ 0.640 50.7 9.9 $240,591 37.7 13.4 $61,149.92 8.3 
CBTMax$ 0.592 52.4 22.1 $295,632 42.8 29.7 $136,107.88 17.1 
SkiiiDeg 0.640 59.1 36.8 $380,529 59.6 49.5 $226,846.46 30.8 
0.592 61.1 81.9 $567,359 82.2 110.3 $504,916.31 63.4 
292 172 $1,841,591 271 2J2 $1,060,526 138 
0.616 1.88 1.10 $11,829 1.8 1.49 $6,811.76 0.9 
0.640 71.0 27.0 $388,926 60.9 36.4 $166,722.84 22.6 
0.640 43.6 12.6 $222,985 34.9 16.9 $77,526.12 10.5 
0.592 62.9 28.0 $360,404 52.2 37.7 $172,558.14 21.7 
0.640 46.2 32.0 $310.458 48.6 43.1 $197,441.14 26.8 
0.592 66.6 71.3 $546,989 79.2 96.0 $439,465.75 55.2 
Pr(Died) Yr 4 0.00693 290 171 $1,829,763 275 2JO $1,05J,714 137 
SkiiiDeg 0.616 2.01 1.18 $12,671 1.9 1.59 $7,296.97 1.0 
Start w/o pain, No Rips 0.640 63 .9 28.5 $366,393 57.4 38.3 $175,452.56 23.8 
Start w/o pain, Rips, Bt r 0.640 32.7 13.2 $182,327 28.6 17.8 $81,585.44 11.1 
Start w/o pain, Rips, No· 0.592 63.1 29.4 $367,262 53.2 39.7 $181,593.40 22.8 
Start w/pain, Btr. 0.640 43.9 30.6 $295,380 46.3 41 .1 $188,413.55 25.6 
Start w/pain, Not 0.592 84.7 68.0 $605,730 87.8 91.6 $419,372.09 52.6 
Pr(Died) Yr 5 0.0075 YrS 
-
170 $1,817,092 272 229 $1,046,417 136 
e tc. 
-
etc. for years 6 though 10. 
The right-hand section displays the parameters, including relapse rate, probability 
of each arm improving, probability of dying each year, skill degradation, and the discount 
rate. 
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Ofthose randomized to the CBT arm, 54 attended less than half the CBT sessions. 
They were determined, a priori, not to have had enough of the intervention to be 
considered to have learned the therapeutic techniques. Therefore, they have the Control 
arm's probability of improving. In the intention-to-treat Base Case model and sensitivity 
analyses, their costs and utilities are assigned to the CBT arm. 
All subjects who enter the second year may die during that year. Subjects who got 
better during the first year may relapse during the second year. If they relapse, they may 
improve and may not. Subjects who did not get better during the first year enter the 
second year with a lower utility value. They may become better, and they may not. These 
patterns are replicated through year 10. Every year, the probability of dying increases 
slightly and subjects' skill in applying Cognitive Behavioral Therapy techniques degrades 
by20%. 
The 1-year ICER is based on the total costs and utilities accrued during the first 
year, as demonstrated in Figure 8.4. The 10-year ICER is derived from the total costs and 
utilities across all 10 years. 
Figure 8.4. Markov model - calculating ICERs. 
$5,833 
CBT <rx 1352 
uti I 294 174 lJJ7 141 
0.640 173 54 $1,0&5,375 145.0 72 $367,724 46.2 
0.592 121 119 $1,151,178 142.3 161 $818,482 95.2 
9 APPENDIX3: ADDITIONAL DATA FOR LCASTUDY 
9.1 Additional data specification 
Table 9.1lists the following codes were used for Lumbar Imaging. All claims had a 
primary diagnosis of low back pain. 
Table 9.1. Imaging codes 
Lumbar 
MRI 
CT 
X-Ray 
Other 
MRI 
Procedure code 
72148,72149,72158 
72131-72133 
72100,72110,72114,72120 
72146, 72147, 72157 =Thoracic 
74181, 74182, 74183 =Abdomen 
72195, 72196, 72197 =Pelvis 
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Revenue code 
612 =Spinal Cord/Spine 
350 =General 
352 =Bod 
320, 972 = Spine 
610 = General 
614, 618, 619 =Other (not brain, 
head/neck, or lower extremities) 
CT 72128-72130 =Thoracic 350 =General 
74176,74177,74178=Abdomen & Pelvis 359 =Other (not Head/Neck/Brain) 
74150,71260,74170=Abdomen 
X-Ray 71010,71020,71100,71120,71130= n/a 
Ribs/sternum 
72170,72190 =pelvis 
Table 9.2. Specific medications included as narcotic and non-narcotic painkillers 
Narcotic agonist analgesics 
Hydrocodone bitartrate 
Levorphanol tartrate 
Morphine sulfate 
Hydromorphone hydrochloride 
Methadone hydrochloride 
Meperidine hydrochloride 
Codeine, sulfate or phosphate 
Oxycodone, immediate-release 
Propoxyphene hydrochloride 
Propoxyphene napsylate 
Oxymorphone hydrochloride 
Sufentanil citrate 
Fentanyl citrate 
Alfentanil hydrochloride 
Levomethadyl acetate 
Remifentanil hydrochloride 
Dihydrocodeine bitartrate 
Morphine sulfate, extended-release 
Oxycodone, extended-release 
Fentanyl, transdermal system 
Fentanyl citrate, oral transmucosal, buccal 
Coditrate pethidine 
Morphine sulfate liposome, extended-release injectable 
Hydromorphone hydrochloride, extended-release 
Fentanyl & ropivacaine (or other local anesthetic injectable) 
Oxymorphone hydrochloride, extended-release 
Narcotic & analgesic combinations 
Codeine phosphate & acetaminophen 
Codeine phosphate & aspirin 
Hydrocodone bitartrate & acetaminophen 
Hydrocodone bitartrate & aspirin 
Hydrocodone bitartrate & ibuprofen 
Oxycodone & acetaminophen 
Oxycodone & aspirin 
Meperidine & promethazine 
Propoxyphene & acetaminophen 
Propoxyphene hydrochloride & aspirin & caffeine 
Opium with or w/o belladonna 
Dihydrocodeine bitartrate & aspirin & caffeine 
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Meperidine & acetaminophen 
Meperidine & atropine 
Codeine phosphate & aspirin & antacid 
Oxycodone & ibuprofen 
Narcotic analgesic combinations, miscellaneous 
Narcotic agonist-antagonist, alone or in combinations 
Buprenorphine hydrochloride 
Butorphanol tartrate 
Dezocine 
Nalbuphine hydrochloride 
Pentazocine 
Pentazocine & naloxone 
Pentazocine & aspirin 
Pentazocine & acetaminophen 
Narc otic agonist -antagonist combinations, miscellaneous 
Non-narcotics: Centrally-acting analgesics 
Methotrimeprazine hydrochloride 
Tramadol hydrochloride 
Clonidine hydrochloride, intravenous 
Tramadol & acetaminophen 
Non-narcotics: Non-NSAID analgesics 
Acetaminophen (AP AP) 
Acetaminophen combinations 
Acetaminophen products, miscellaneous 
Nonnarcotic analgesic combinations 
Butalbital 
Pamabrom & acetaminophen 
Ziconotide 
Pregabalin 
Non-narcotics: NSAIDs 
Fenoprofen calcium 
Flurbiprofen 
Ibuprofen 
Ketoprofen 
Naproxen 
Naproxen sodium 
Oxaprozin 
Diclofenac sodium 
Etodolac 
Indomethacin 
Ketorolac tromethamine 
Nabumetone 
Sulindac 
Tolmetin sodium 
Meclofenamate sodium or meclofenamic acid 
Mefenamic acid 
Piroxicam 
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Brornfenac sodium 
Phenylbutazone 
Oxyphenbutazone 
Diclofenac potassium 
Meloxicam 
Diclofenac epolamine, transdermal system 
Diclofenac sodium & misoprostol 
Naproxen & lansoprazole, delayed-release 
Non-narcotics: Skeletal muscle relaxants 
Baclofen 
Carisoprodol 
Chlorphenesin carbamate 
Chlorzoxazone 
Cyclobenzaprine hydrochloride 
Metaxalone 
Methocarbamol 
Orphenadrine citrate 
Tizanidine hydrochloride 
L-baclofen 
Dantrolene sodium 
Methocarbamol & aspirin 
Carisoprodol & aspirin 
Carisoprodol & codeine & aspirin 
Chlorzoxazone & acetaminophen 
Orphenadrine & aspirin & caffeine 
Non-narcotics: Glucocorticoids 
Cortisone acetate 
Hydrocortisone 
Hydrocortisone cypionate 
Hydrocortisone sodium phosphate 
Hydrocortisone sodium succinate 
Hydrocortisone acetate, local injectable 
Beclomethasone dipropionate, oral or dual-release, orphan drug 
Fluprednisolone 
Prednisone 
Prednisolone 
Prednisolone acetate 
Prednisolone tebutate 
Prednisolone sodium phosphate 
Triamcinolone 
Triamcinolone diacetate 
Triamcinolone hexacetonide 
Triamcinolone acetonide 
Methylprednisolone 
Methylprednisolone sodium succinate 
Methylprednisolone acetate 
Dexamethasone 
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Dexamethasone acetate 
Dexamethasone sodium phosphate, injectable 
Dexamethasone sodium phosphate with lidocaine 
Betamethasone 
Betamethasone sodium phosphate 
Betamethasone sodium phosphate & betamethasone acetate 
Prednisolone sodium phosphate & prednisolone acetate 
Paramethasone 
Non-narcotics: Patches 
Benzocaine, topical 
Dibucaine, topical 
Lidocaine, topical 
Butamben picrate, topical 
Tetracaine, topical 
Pramoxine hydrochloride, topical 
Benzocaine & calamine with or w/o camphor, topical 
Topical anesthetic combination products 
Topical skin anesthetics, anesthetics 
9.2 Analyses performed 
This section provides detail regarding data specification and structure of the analyses. 
Set 1) One service, two levels. The objectives of these analyses were to identify patterns 
of services over time and to determine whether different services had different 
patterns. The 16 services are listed in the body of the dissertation. 
Set 2) Two services, two levels. This set of analyses focuses on major services. 
Ancillary or rare services (Psychiatric, Blood Tests, Other Diagnostic Tests, 
Antidepressant, Sleep Aids, and Material Support) are not included. We 
performed the following bivariate analyses: 
1. Surgery/Injection & Painkillers 
2. Surgery/Injection & Therapy 
3. Surgery/Injection & Visits 
4. Surgery/Injection & Imaging 
5. Painkillers & Therapy 
6. Painkillers & Visits 
7. Painkillers & Imaging 
8. Therapy & Visits 
9. Therapy & Imaging 
10. Visits & Imaging 
The analytic structure had four response categories, based on whether the service 
was received by the member during the quarter: Not received/Not received; Not 
received/Received; Received/Not received; and Received/Received. 
Set 3) Three services, two levels. This set of analyses uses three ofthe four main sets of 
services in each run. We ran four models: 
1. Surgery/Injection & Therapy & Painkillers 
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2. Surgery/Injection & Therapy & Visits 
3. Surgery/Injection & Painkillers & Visits 
4. Therapy & Painkillers & Visits 
The analytic structure had eight response categories, based on whether the service 
was received by the member during the quarter. 
Variable 1 Variable 2 Variable 3 
1 Not received Not received Not received 
2 Received Not received Not received 
3 Not received Received Not received 
4 Not received Not received Received 
5 Received Received Not received 
6 Received Not received Received 
7 Not received Received Received 
8 Received Received Received 
Set 4) All 4 items combined, two levels. To avoid sparseness, all sets of three services in 
a quarter (e.g., the subject received Therapy, Painkillers, and an additional Visit) 
were combined with the classing of all four services in the quarter. The analytic 
structure had eight response categories, based on whether the service item was 
received by the member during the quarter. 
Item 1 Item2 ltem3 Item 4 
1 Not received Not received Not received Not received 
2 Received Not received Not received Not received 
3 Not received Received Not received Not received 
4 Not received Not received Received Not received 
5 Not received Not received Not received Received 
6 Received Received Not received Not received 
7 Received Not received Received Not received 
8 Received Not received Not received Received 
9 Not received Received Received Not received 
10 Not received Received Not received Received 
11 Not received Not received Received Received 
12 Received Received Received Not received 
12 Received Received Not received Received 
12 Received Not received Received Received 
12 Not received Received Received Received 
12 Received Received Received Received 
9.3 Choosing a model 
Table 9.3 displays the results ofLCA analysis specifying 2 through 5 classes for each 
variable. The resulting patterns are: 
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1. Ql Highest then Level- Response probabilities indicate some use during the 
first quarter, a steep decline to the Q2, and a steady rate for Q3 through Q9. For 
example, in the 2-class model, 94.2% subjects had a 22% probability of Surgery 
in Q1 and less than 0.5% probability of Surgery in Q3 through Q9. In the 3-class 
model, some of the subjects shifted into a different class and the probabilities 
shifted accordingly. In this model, 94.0% of subjects had a 20% probability of 
Surgery in Ql and less than 0.5% probability of Surgery in Q3 through Q9. The 
Q 1 Highest then Level pattern is apparent in every model run except sleep 
medications. 
The description in Table 9.3 presents the value in Q1 then in Q3-Q9. 
2. Decreasing- Response probabilities decline from each quarter to the next. For 
example, in the 2-class model, for 5.8% of subjects the probability of having 
surgery declined from 31% in Q1 to 14% in Q9. (Specifically: 31%, 26%, 23%, 
19%, 18.5%, 18.0%, 17%, 16%, 14 %.) The Decreasing pattern is typically 
apparent in the 2-class model and almost always emerges by the 3-class model. 
The description in Table 9.3 presents the values in Q1 and Q9. 
3. Repeated Highs- Response probabilities are lowest in Q2 and Q3 (and, rarely, 
Q4) then increase, often to levels higher than in Ql. For example, in the 4-class 
model, 5.2% of subjects had an 18% probability of a corticosteroid injection in 
Q1,just 3% in Q2, remained low in Q3, then rose, peaking at to 27% in Q8. 
(Specifically: 18%, 3%, 6%, 10%, 19%, 23%, 25%, 27%, 21 %.) The Repeated 
Highs pattern typically emerges in the 3-class or 4-class model. 
The description in Table 9.3 presents the values in Q1 , the lowest quarter, and 
the highest quarter following that. 
4. Level- Response probabilities are in a range of values, usually within 20 points, 
and do not follow a clear pattern. In some cases, the pattern is quite level. For 
example, in the 3-class model, 2.9% of subjects had a 15% to 31% probability of 
having Surgery in all quarters. In others, it is level relative to the other three lines. 
The Relatively Level pattern typically emerges in the 3-class or 4-class model. 
The description in Table 9.3 presents the values the lowest and highest values. 
For each service, the results from analyses with 2 through 5 classes specified are 
presented in Table 9.3. The results for the class that best fits each shape - Q 1 Highest 
then Level, Decreases, Relatively Level, Repeated Highs, and Other- are summarized as 
described above. 
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Table 9.3. Results of analysis of each service type, 1 to 5 classes. 
# AIC Q1 Highest then Level Decreases Level Re~eated Highs Other 
% Desc % Des c. % Desc % Des c. % Des c. 
Treatment- Surgery 
2 2136 94.2% 22 then <0.5 5.8% 31 to 14 
3 1292 94.0% 20 then <0.5 3.2% 40 to 2 2.9% 15-31 
4 1026 93.0% 20 then <0.5 3.2% 41 to 2 1.9% 27-43 11-0-24 
2.0% 
5 839 92.7% 2 then <0.5 2.8% 44 to 3 0.6% 36-49 2.2% 12-2-23 
1.7% 13-4-34 
Treatment- Injection 
2 3701 91 .1% 8 then <1 8.9% 42 to 19 
3 2219 89.0% 7 then <1 6.3% 47 to 3 4.7% 20-37 
4 1449 86.4% 7 then <1 7.3% 46 to 4 1.2% 44-59 18-3-27 
5.2% 
-~ 5 1083 87.4% 7 then <1 5.1% 53 to 4, level 1.1% 47-60 3.7% 19-4-36 ~ 
in Q6-Q9 2.7% 23-6-37 
Treatment- Surgery and Injection combined 
2 4099 90.4% 8 then <1 9.6% 44 to 19 
3 2321 88.9% 7 then <1 6.0% 53 to 3 --- --- 5.1% 35-21-39 
4 1485 85.9% 7 then <1 7.3% 51 to 4 1.4% 57-43 5.4% 18-3-28 
5 1104 86.9% 7 then <1 5.8% 56 to 5, level 1.2% 48-60 3.6% 18-3-37 
in Q6-Q9 2.4% 23-6-47 
Treatment - Thera~~ 
2 23362 82.9% 29 then <3 17.1% 66 to 37 
3 17608 79.0% 30 then <3 10.8% 81 to 38 --- --- 10.2% 33-6-39 
4 8070 70.5% 24 then <2 13.3% 75 to 6 4.9% 84 to 62 11 .3% 37-11-39 
5 5743 70.1% 25 then <2 7.1% 49-69 in 01-4 4.2% 68-84 9.6% 40-9-46 8.2% Q1 & Q2 high (74,84), then 
then decline. decline to Q4 (0.05) then 
steady increase to 5. 
,__. 
~ 
Vl 
# AIC Q1 Highest then 
Level 
Decreases Relatively Level Repeated Highs Other 
% Description % Description % Desc. % Desc. % Description 
Treatment - Psychological 
2 364 99.95% 0.05 then --- --- 0.05% 14-27 
<0.03 
3¥ 190 --- --- --- --- 99.96% 0-0.01 
4¥ 209 81 .3% 0.05 then 0.1% 18-23 in Q1-
~0. 02 Q3 then 
decline to 4%. 
5¥ n/a¥ 
Diagnostic Services -Imaging, Lumbar 
2 2133 94.3% 17 then <3 5.7% 40 to 21 
3 1521 94.4% 17 then <3 2.2% 53 to 8 --- --- 3.5% 
4 1117 89.5% 16 then <3 3.0% 47 to 7 0.7% 35-66 6.8% 
5 861 DNC 79.6% 17 then g 2.5% 53 to 8, 0.7% 34-67 3.7% 
slight n.s. 13.5% increase 
Q7-Q9 n.s. 
Diagnostic Services- Imaging, Other regions 
2 2699 92.2% 8 then <2 7.8% 38 to 14 
3 1634 91 .0% 7 then <2 5.0% 45 to 24 4.0% 21 to 37 
4 1125 87.0% 7 then <1 6.6% 41 to 4 1.2% 31 to 52 5.3% 
5 922 87.4% 7 then ~1 5.8% 44 to 4 1.1% 31-53 1.9% 
3.7% 
Diagnostic Services -Imaging, All 
2 3952 91 .3% 18 then <3 8. 7% 46 to 23 
3 2506 90.1% 17then<3 4.8% 57to6 5.1% 26-46 
4 1742 85.7% 17then<3 6.1% 54to7 1.6% 38-60 6.6% 
5 1252 79.5% 18then~2 5.1% 59to6, 1.8% 36-62 4.6% 
-incr. Q7 -Q9 
32-18-40 
22-6-24 
26-7-40 
14-3-17 
13-1-24 
17-4-51 
11-0-27 
23-7-32 
27-7-43 
18.5% Very low overall (0.01-0.08) with 
a relative peak in Q7 (0.11 ). 
0.04% Varies 8.4%-46.7%. 
9.1% Relapse (13-0-23 in Q5) then 
decline to 4. 
....... 
~ 
0\ 
# AIC Q1 Highest then Level Decr~ases Relatively Level Repeated Highs Other 
% Description % Description % Desc. % Desc. % Descrjption 
Diagnostic Services - Blood tests 
2 2796 91.8% 32 then <1 0 
3 2587 83.8% 35 then <15 
4 1823 27.7% 99.9 then <2 
5 1517 27.5% 99.9 then <2 
Diagnostic Services - Other 
2 12772 98.0% 33 then <16 --- ---
3 12109 89.7% 35then~16 --- ---
4 8994 24.9% 99.99 then ~2 --- ---
5 6761 24.8% 100 then <2 --- ---
55.2% 0.6-22 
43.6% 0. 7-26 
19.8% 34-75 
26.5% 32-62 
73.4% 9-19 
3.3% 41-60 
8.2% 
8.2% 
8.1% 
8.5% 
8.6% 
8.6% 
8.6% 
11.6 
% 
Q7 high (99.6), other 
quarters .9 
Q7 high (99.6), other 
quarters <3 
Q4 high (99.8) , other 
quarters <4 
Q7 high (99.8), other 
quarters <7 
Q4 high (99.8), other 
quarters <5 
Q7 high (99.9) , other 
quarters <7 
Q4 high (99.9), other 
quarters <5 
Q2 high (99.9), other 
quarters <4 
7.7% Q4 high (99.9) , other 
quarters <10 
0.9% Q1 Highest (84), level Q2-6 
(64-70) & 0?:9 (42-53) 
0.7% Increase 21-73 
12.2 Q1 (19) , Q2 high (99}, 
% other quarters <6 
5.1% Q1-Q31evel (3-5) then Q4-
Q9 level (18-22) 
9.2% Q3 high (99.97) then <12 
# AIC Q1 Highest then Level Decreases Relatively Level Repeated Highs Other 
% Description % Descript % Desc. % Desc. % Description 
ion 
Material Su~~orts 
2 3280 28.3% 99.95 then <5 --- --- 71.7% 5-19 
3 3036 28.2% 99.97 then <4 --- --- 62.9% 6-22 
4 3116 29.7% 99.98 then <5 --- --- 59.3% 2-21 
5 2323 28.7% 99.98 then <2 --- 48.1% 1-20 
,_.. Visits- New ~atients, all recorded (some include treatments or diagnostic services) 
~ 2 883 88.7% 9 then <2 11 .3% 20 to 6 
3 608°Nc 83.2% 9 then <2 6.1% 29 to 4 
4 498DNC 88.5% 9 then <2 
5 n/a DNC 
4.2% 19 to 3 
(level 
04-09) 
4.9% 10-2-17 
Visits- Established patients, all recorded (some include treatments or diagnostic services) 
2 7932 88.7% 20 then <6 11.4% 40 to 49 
3 4980 
4 2407 
5 1776 
DNC 
78.5% 19 to <4 
77.9% 18 to <4 
28.4% 38 to ~2 
n.s. 
19.2% 
9.1% 
9.5% 
n.s. 
34 to 23 2.4% 
53 to 8 2.6% 
46 to 10 2.3% 
n.s. 
62-83 
64-80 10.4% 20-13-41 
64-82 8.7% 24-14-46 
n.s. 
9.7% 07 high (99.8), other 
guarters <18 
1.3% 01 to 03 increase (56-99) 
then decrease to 18 
13.2 02 high (99.3), other 
% guarters <14 
8.5% 07 high (99.9}, other 
guarters <9 
1.5% 01 to 03 increase (52 to 
99} then decrease to 10 
--- ---
10.7 0.5-12 (no pattern) 
% 
2.4% 0.5-50 (no pattern) 
51 .1 01 at 8, 02 at 0.1, then 
% 03-9 steady at 4-5. 
# AIC Q1 Highest then Level Decreases Relative!~ Level Re~eated Highs Other 
% Description % Descript % Desc. % Desc. % Description 
ion 
Visits- Emergenc~ Room, all recorded {some include treatments or diagnostic services} 
2 460 98.7% 1.3 then <0.5 
--- --- 1.3% 11-22 
3 425 98.5% 1.3 then <0.5 1.0% 23 to 0 --- --- 0.5% 18-15-29 
4 364 97.0% 1.2 then <0.5 0.8% 25-0.05 0.05% 37-65 8-2-12 
DNC 2.2% 
5 n/a DNC 
Visits - New ~atient visits with no major treatment or diagnostic services 
2 576 89.2% 6 then <1 10.8% 17 to 6 
---
3 431 89.5% 6 then <1 6.7% 23 to 2 --- --- 3.9% 10-5-14 
4 371DNC 91 .1% 6 then <1 2.0 33 to 3 3-15 2.0% 11-3-23 Q1-Q2 at 33-42, declines, 
% (level 4.9% 2.0% then Q4-Q9 level _:::3 
Q4-Q9) 
- 5 ~ 
n/a DNC ___ 
00 Visits - Established ~atient visits with no major treatment or diagnostic services 
2 7765 89.3% 15then<4 --- --- 10.7% 37-44 
3 4524 80.2% 14then<2 17.8% 34 to 20 2.1% 58-82 
4 2207 80.6% 13then<3 9.8% 49 to 7 2.1% 63-81 7.6% 19-12-41 
5 1595 80.3% 12 then <3 5.6% 54 to 5 --- --- 6.2% 21-11-47 01 to as increase (64 to 
(Q2 high 1.7% 83} then decrease 72 
at 60) Q1-Q5 Level at 37-47, 
6.2% decreases 12 
Visits - Emergenc~ Room visits with no major treatment or diagnostic services 
2 403 99.0% 12 to <0.5 1.0% 22 to 12 
3 390 98.9% 11 to <0.5 0.8% 23 to 0 -- --- --- --- Q 1-05 level at 14-19 then 
0.3% Q6-Q9 level at 25-37 
4 337DNC 96.0% 10to<0.5 0.3% 33 to 0 3.7% 2-8 --- --- 0.03 No pattern, 31-78 (all n.s.) 
% 
5 n/aDNC 
# AIC Q1 Highest then Level Decreases Relatively Level Repeated____tiighs Other 
% Descrifillon % Description % Desc. % Desc. % Description 
Visits- New & established patients, visits with no major treatment or diagnostic services, combined 
2 8908 88.1% 24 then <7 --- --- 11 .9% 41-51 
3 6322 82.5% 25then<6 7.1% 64to39(1evel--- --- 10.4% 19-10-42 
01-04) 
4 2944 75.9% 23 then <5 9.9% 56 to 9 3.0% 64-76 11 .3% 21-12-41 
5 1856 79.4% 16 then <3 2.0% 67-78 6.6% 22-10-42 6.7% 01-051evel (35-48) then 
Visits- New & established patient & ER visits with no major treatment or diagnostic services 
2 8722 88.1% 25 then <7 --- --- 11 .9% 41-52 
3 6190 82.3% 26then<6 7.2% 64to40(1evel--- --- 10.5% 20-10-41 
01-04) 
4 2890 75.9% 23then<5 9.7% 57to9 3.0% 64-79 11 .5% 22-13-41 
decline to 12. 
5.3% 01 & Q2 high (64, 73), 
decr.to level 05-09 (4-6). 
~ 5 1856 78.9% 16 then ~3 5.4% 71 to 6 (level 2.0% 67-81 7.0% 23-10-47 0.7% 01-5 steady (37-50) then 
1.0 05-09) decline to 12. 
Medication - Painkillers, Narcotic, not associated with surgery or injection (2-levels: none and any during qu~rrer) 
2 14699 91 .6% 88 then <4 --- --- 8.4% 57-65 
3 6536 85.1% 7 then <2 11.3% 43 to 25 3.6% 80-92 
4 3702 85.6% 7 then <2 6.6% 55 to 11 3.3% 83-92 4.1% 30-15-53 
5 3069 83.1% 7 then <2 6.2% 56 to 11 2.5% 85-96 5.9% 21-7-35 
2.3% 47-35-81 
Medication- Painkillers, Non-narcotic, not associated with surgery or injection (2-levels: none and any during _qlJarter) 
2 16940 87.9% 12 to <3 --- --- 12.1% 46-58 
3 8288 78.4% 10 to <2 18.1% 42 to 23 3.6% 76-88 
4 4499 79.3% 10 to <2 --- --- 3.5% 76-87 
5 3316 79.4% 10 to ~2 3.2% 80-89 
7.5% 25-11-49 9.8% 
6.7% 27-10-53 5.3% 
5.4% 45-40-62 
01 to Q7 decrease (57 to 
7) then increase to 09 ( 11) 
01&02 at 67-69 then drop 
to 05 (4), incr. to 09 (9) 
# AIC Q1 Highest then Level Decreases Relative!~ Level Re~eated Highs Other 
% Descri~tion % Descri~tion % Des c. % Des c. % Descri~tion 
Medication- Painkillers, All, not associated with surgery or injection {2-levels: none and an~ during guarter} 
2 240 85.6% 17 then <5 --- --- 14.4% 58-69 
3 107 74.3% 12 then <3 19.8% 49 to 27 5.8% 84-92 
4 62 75.0% 14 then <3 10.8% 63 to 13 5.8% 84-91 33-16-55 
8.5% 
5 72.9% 12 then <3 --- --- 5.4% 86-93 
Medication - Antide~ressants 
2 9994 96.8% 0.5 then <0.2 3.2% 60 to 45 
3 7809 96.8% 0.5 then ~0 . 1 2.2% 82 to 40 --- --- 6-1-64 
1.0% 
4 2945 96.6% 0.4 then ~0 . 1 1.5% 72 to 5 78-96 11 -8-70 y 
1.0% 0.9% 
5 2423 96.7% 0.4then~0.1 1.2% 83to6, 1.0% 79-96 13-8-70 0.4% Q1-Q3increase(0.6to66) 
(-consistent) 0.7% then decrease to Q9 (3} 
t;; Medication - Sleep medications 
0 2 1045 95.5% 0.2-0.4 
0.5% 28-34 
3 819 94.3% 0.1-0.3 
4.4% 16-22 
1.3% 45-51 
4 640 93.9% 0.1-0.3 --- --- 2.8% Stead}' increase, 7 to 25 
1.9% 41-47 1.4% Q1-Q41evel (25-33) then 
decrease to 1 . 
5 657DNC --- 82.7% 0-0.2 --- --- 2. 7% Steady increase, 6 to 25 
--
1.9% 41-47 1 .4% Q 1-4 steady (range: 26-33) 
then Q5-9 decr.(18 to 0.3}. 
11 .3 01 -5 steady decr.(2.2-0) 
% then steady incr.to Q9 (2.2) 
9.4 Patterns Within Single Variables 
Careful analysis of each service demonstrates more subtlety across classes. For example, 
some Level classes displayed, when compared to other classes for the service, an arcing 
shape with a hump in the middle quarters ("Hump") or a clear decreasing trend after 
quarter 6 ("Level/Deer"). To be considered Level, the values must vary by no more than 
1 0 points and not show a distinct trend. 
This section presents and describes the set of curves for each service. Every chart 
has a y-axis from 0 to 1, and consistent use of markers (e.g., the Decreasing curve is 
always marked with a filled circle) to facilitate comparison. Table 9.4lists the classes and 
specifies the marker used. 
Table 9.4. Latent Classes Identified in Univariate Models 
Class 
Q1 Highest 
Then Level 
Decreasing 
Repeated 
Highs 
Level 
LevelNar 
Level/Deer. 
Description 
Proportion of services received after Q1 is very low, and is 
consistent across quarters 3-9. 
General decrease after Q 1 or Q2, with possible slight increase 
in late quarters. Two-thirds of services have a substantial 
decrease of 40-50 points (range 23-81). 
Decrease from Q 1 to Q2, followed by an increase across 
multiple quarters to a level higher than Q1, then a decrease in 
the fmal quarters. 
Difference between highest and lowest values is <10%. 
Difference between highest and lowest values is <20%. 
Level (within 10 points) through Q6 then a decrease through 
Q9. 
Marker 
cross 
circle, filled 
star 
line 
square, empty 
circle, empty 
Level/Hump Highest level is in the middle quarters; difference between triangle, empty 
lowest and highest values <20 points. 
Hump Highest level is in the middle quarters. The difference between triangle, filled 
lowest and highest ranges from 25 to 81 points. 
Increase Overall increase across all quarters, with a decrease Q8 to Q9. square, filled 
Other Unusual patterns. none 
The four classes are clearly seen for Injection (Table 9.5). The Quarter 1 Highest 
Then Level curve [with 87% of subjects] started at 7%, then leveled out less than 1% for 
the remaining quarters. The Decreasing [7%] curve declined steeply from 36% to 5% in 
quarter 6. For the next three quarters, it remained essentially level, decreasing one point 
twice then up one point in quarter 9. It is labeled Decreasing, rather than 
Decreasing/Level, because the decline is consistent through quarter 8. In contrast, the 
Level/Decreasing [1 %] curve displays two distinct patterns; it ranged within a 10-point 
band (49- 59%) through quarter 6 then dropped consistently by 4 points each quarter. The 
Repeated Highs [5%] curve started at 18% then, following a decline, reached a maximum 
27% before declining again. 
Surgery displays three of the common patterns. The Quarter 1 Highest then Level 
[93%] class is labeled relative to the other classes; it started at just 2% in Ql then ranged 
between 0.2 and 0.36%. The Decreasing class [3%] had probabilities of 41-43% before 
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declining to 1-2% in Q7-Q9. The Repeated Highs class' [2%] probability dropped from 
11% in Q1 to 0% in Q4 then increased to 30% in Q8. The fourth curve, which is level 
compared to the rest, displays a distinct "hump" pattern [2%], rising from quarters 2 
through 6 then dropping each quarter. Probability for surgery never reached 50% for any 
class or quarter. 
Table 9.5. 4-class model results for Injection and Surgery 
Injection Surgery 
------ -· 
-+-Ql High 87% -..Rpt . Highs5% ~Lvi/Decr. l% -+-Deer. 7% -+-Ql High 93% -.-Hump 2% -+-Deer. 3% -l!E- Rpt. Highs 2% 
1.00 ~ .. ·-· -----------~- 1.00 ---· 
0.75 -- 0.75 
~ ..... 0.50 -e-. ·--~ 0.50 ... -·---------------- . 0.25 : ::: : : ·~· 0.00 
Ql Q2 Q3 Q4 Q5 Q6 Q7 QS Q9 
Ql Q2 Q3 Q4 QS QG Q7 Q8 
Table 9.6 displays a chart ofthe 4-class model for each service, with a brief 
description. The sum of the percentage in all classes may not equal 100% due to 
rounding. 
Table 9.6. Results of 4-Class Models for Each Individual Type of Service 
Imaging-Lumbar ~Ql High 90% -.-Hump 1% -Ot cr. 396 ~Rpt. High~ 7% 
Q9 
After dropping from a 16% probability of getting 
lumbar imaging services, the Ql Highest Then 
Level class [90%] remained at 2% in Q3-Q9. 
Repeated Highs class [7%] dropped from 22% to 
6% (Q3) then increased to 24% in Q7 & Q8. 
Decreasing class [3%] is unusual in that the 
probability was 50% for three quarters before 
declining to 7% (Q7). It rose slightly to Q9. The 
Hump class [1 %] had probabilities over 45% for 
all quarters except Q9, with a peak of65-66 in 
Q5 &Q6. 
1.00 ,..----- ---------- -
. ·-·---·-.. ___ , ____ --·-·--·-- --------' 
Imaging-Other -+-Ql High 87% ~Rpt. Highs 5% ~Lvi/Decr. l% ....... Deer. 7% 
The Ql Highest Then Level class [87%] dropped 
from a 7% probability of getting imaging of an 
area other than the lumbar back to 1% in Q2-Q9. 
The Repeated Highs class [5%] dropped from 
13% to I% in Q2 then increased to a high of 24% o.so -f--<,__.....,_-e---e--e;...--~::::::- --
in Q7. The Decreasing class [7%] dropped from 
41% to 4% in Q7 -Q9. The class with the highest 
probabilities overall, Level/Decrease [1 %], had 
probabilities of 48-52 until they begin to decline 
in Q7, reaching 31% in Q9. 
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Treatment-Therapy ~Q1High 71% --Rpt High> 11% -... lvi/Oe<r. 5% --Oe<r. l3% 
The Q 1 Highest Then Level class [71%] 1.000 
remained at 1-2% probability of getting e--.e 9 e 6 ~ 0.750 therapy in Q2-Q9. The Decreases class [13%] -~ I declined steadily from 75% to 3% (Q7), with 0.500 
an uptick in Q9. The Repeated Highs class 
' 
~ = ~ ~ [11 %] dropped sharply from 37% to 11 (Q2) O.l 50 ~ ~then increased to 38-40% in Q6-Q8. The 
-Level/Decrease class [5%] stays very high (78- 0.000 Q1 Ol Q3 04 Q5 Q6 Q7 QB Q9 
84%) through Q6 before decreasing slowly to -
62%. 
Treatment-Psychiatric - Q1HiEI>81% - Other 0.04% - • - Oe<r. 0.01% ~Oth.r 19% 
Psychiatric care for low back pain was quite 1.0000 
rare in this population. One class with an 
0.7500 
unusual curve [19%] had either zero or 0.01 
probability of getting psychiatric services in 0 . 5000 ~ 
any given quarter. The Q1 Highest Then Level 
class [81 %] is relative to the other classes, 0.2500 1--/< ~--------
starting at just 0.05% in Q1 and ranging from 
0-0.02% in Q2-Q9. The other two classes have 0.0000 - I I I I ~-----=, • Q1 Q2 Q3 Q4 Q5 Q6 Q7 QS Q9 
less than 1% of subjects, one with decreasing 
and one with overall increasing likelihood of 
services. 
Medication-Narcotics ~Q1High 86% --RptHigh>4% -level 3% --Deer. 7% 
The Q1 Highest Then Level class [86%] 1.000 
remained at 1-2% for Q2-Q9 after dropping 
-
from just 7% probability of taking narcotics. 0.750 !--·----·-····- --------·---··-·--·-
The Decreasing class [7%] dropped from 55% 0.500 . ~ to just 7% in Q8 then increased to 11%. The Repeated Highs class [4%] dropped from 30% O.l50 · to 15% (Q2 & Q3) then increased to a high of 
0.000 
. . 
60% in Q8. The fourth class, Level, is fairly .. ... Q1 Ol Q3 Q4 Q5 Q6 Q7 QB Q9 
large [3%], given the very high probabilities of 
83-90% for all quarters. 
Medication-Non-narcotic painkillers ~Q1 High 79% --Rpt High> 7% - l vi/ Hump 3% --Oe<r. 10% 
The patterns of taking non-narcotic painkillers 1.000 
mirror those of taking narcotics. The Q 1 Highest ~ I!! I!! I!! I!! 0~-Then Level class [79%] remained at 1-3% in Q2- 0.7 50 . 
Q9. The Decreasing class [ 10%] also dropped 
consistently from 57% to 7% in Q7 but increased 0.500 -~ 
for the next two quarters. The Repeated Highs 
0.250 
class [7%] dropped from 25% to 12 (Q2) then ~ ~ ~ 
--: increased to a high of 48-49% in Q7-Q8. The ~~ -- I ===A-- ::::: : 0.000 j. 
Level class [3%] showed a slight hump pattern, Q1 Q2 Q3 Q4 Q5 Q6 Q7 QB Q9 
being somewhat lower in Ql (79%) and Q9 
(76%) than in the middle quarters (83-87%). 
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Medication-Antidepressants ~Q1 High 97% - lncrea$e l % ~lvi/Hump 1% -Oeu. 2% 
Antidepressants were not used by the vast 1.000 
majority of subjects; the Q 1 Highest Then Level 
0.750 ~ ~ 
class [97%] was just 0.4% in Q1 then 0.1-0.2% .. ~ / in Q2-Q9. Subjects who did use antidepressants 0.500 
had high levels of use. The Decrease class [2%] 
'/ displays a slight increase in the last two quarters 0.250 
after a drop from 78% (Ql) and 89% (Q2) to near 
-
~ ~ 
-zero. The Level/Hump class [1 %] had very high 0.000 
probabilities (78-96%). An Increased class [1 %] Ql 02 03 04 OS 06 07 08 09 
was level at 8-10% in Q 1-Q3 but increased 
rapidly to 70% in Q8. 
Medication-Sleeping AidsDNc -+-Lev•l 94% -11- lncr•••• l% -Lev•l 2% - Other 1% 
Sleeping aid medication was not taken by the 1.0000 
vast majority of subjects; one Level class [94%] 
had probabilities of just 0.1-0.3 %. Another Level 0.7500 
class [2%] ranges between 41% and 4 7%. The 
0.5000 Increases class [3%] grew slowly from 7% to : ::l;;~ :: : 25% (Q9). The last class was fairly level in Q1-Q4 (26-33%) and also Q6-Q9 (<6%), with an overall decreasing trend. 
Ql Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 
Office Visits- Evaluation & Management of -+-01Higl>81% ~R1H. High <> 8% ~lvi/Hump 296 -Decr. l O% 
Established Patient (without major treatment 1.000 
or diagnostics) 
~ I!! 6 tr--~ The Q 1 Highest Then Level class [81 %] was at 0.750 . 2-3% for Q2-Q9. The Decreasing class [10%] 0.500 
dropped from 47% to 7% then displays a slight ·~ ~-~ "-lK uptick in Q9. The Repeating Highs class [8%] 0.250 
reached twice its initial probability (19%) in Q7 ~ .... 
and Q8 ( 41% ). The Level/Hump class [2%] had a 0.000 
consistently high probability of being seen again 
Q1 Ql Q3 0 4 05 06 0 7 08 Q9 
by a provider, ranging from 63 (Q1 & Q9) to 81 
(Q5). 
Office Visits- Evaluation & Management of -+-0 1 Higl>91% --Rpt. HigllS 2% -.!!- Lvi/ Hump 5% ....... De<r. 2% 
New Patient (without major treatment or 
diagnostics )oNe 
1.000 
Subjects are less likely to see a new practitioner 0.750 . 
than one they have seen before, but with similar 
patterns. The Q 1 Highest Then Level class [91%] 0.500 ··- ··-- - - --· 
remained at <1% for Q2-Q9. The Repeated 
0.250 ~;a~ Highs class [2%] dropped from 11% to 3% (Q3) before rising to 23% in Q8. The Level/Hump 0.000 
class [ 5%] was double the Q2 (7%) rate in Q4 0 1 0 2 Ql 04 05 06 Q7 08 09 
(15%) then dropped to 3% (Q8 & Q9). It was 
also relatively high in Q1 (15%), possibly also 
reflecting a decreasing pattern. 
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Office Visits- Evaluation & Management in 
Emergency Room (without major treatment 
d . t" )DNC or 1agnos ICS 
The Q 1 Highest Then Level class [96%] had just 
a I% probability of going to the ERin Q1 and 
<0.5% in Q2-Q9. The Level class [4%] varied 
between 5% and 8% except for a low of 2% in 
Q2. The Decreases class [0.3%], after a rise from 
33% to 50% in Q2, dropped fairly consistently to 
almost zero in Q9. The smallest class [0.3%] 
generally increased, from 31% to 78%. 
Diagnostics-Blood Tests 
Two classes demonstrate the patterns found for 
other services. The Q I Highest Then Level class 
[28%] had a 99.96% probability of having a 
blood test in QI then between zero and 1.3% in 
Q2-Q9. The Level/Var class [55%] had low-
moderate probabilities (<25%) in most months 
and near zero in three. Two other classes have 
unique patterns. One [9%] had a near 100% 
probability in Q7 and the other [8%] in Q4; both 
have below 5% probabilities in all other quarters. 
Diagnostics-Other 
The largest class, Level [73%], ranged between a 
9% and I9% probability of getting other 
diagnostic services. The Q I Highest Then Level 
class [25%] remained at 1-2% for Q3-Q9 after 
declining from near 100% in Q I . The Increases 
class [ 1%] generally rose from 21% to 94% in 
Q8 before dropping to 73%. The last class [I%] 
had an unusual pattern; it starts at 84% then was 
generally level at 64-70% in Q2-Q6 and at 42-
53% in Q7-Q9. 
-+-01High 96% - lncrea<e 0.03% ...... Decr. 0.3% -Level 4% 
-+-0 1High 28% - o ther S% -Other 9% -Levei/Var. 55% 
1.000 ,-t-- -----,r--------.,-------
-+-01 High 25% -e-lncrea<el% - Other 1% -Level73% 
Material Supports -+-01High 30% -othe.- 10% -.-Hump1% -Levei/Var. 60% 
The Levei/Var class [60%] had low, but fairly 1.ooo .-r----- - .... ------.-----
consistent probabilities (:S21% ). Two classes, Q I 
Highest Then Level [30%] and Other [10%], o.75o ··1--\- +=- ----\----J 
have near 1 00% probability of getting material 
supports in one quarter but otherwise remain o.5oo +---\ ------_..)~, ____:\----
below 3%. The Hump class had probabilities 
over 50% for five consecutive quarters before o.25o 
decreasing to below 20% in Q8 & Q9. 
DNC Model did not converge in 5000 iterations. Response probabilities should be considered 
less stable than those in models that converged. 
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9.5 Results of analyses using combinations of two variables 
For bivariate analyses, we combine similar services: office visits, narcotics and non-
narcotic medications, imaging (lumbar and other, with diagnosis of LBP), and surgery or 
injection. Table 9.7 demonstrates that combined variables all have the four latent classes 
found in univariate analysis. 
Table 9.7. Results of 4-Ciass Models for Combined Types of Service 
Visits to Providers 
The Q1 Highest Then Level class [76%] 
dropped from a 16% likelihood of having a 
provider visit (that does not include surgery, 
injection, therapy, or imaging) to remain at 2-
3% in Q3-Q9. The Repeated Highs class 
[12%] dropped from 21% to 11% in Q2 then 
climbs to 40% in Q7 & Q8. The Decreasing 
class [11 %] dropped steadily from 53% to 
6% in Q8 then rose slightly. The LeveVHump 
class [3%] had no probability below 63%, 
with a hi of 80% in Q5. 
Painkillers 
The Q1 Highest Then Level class [75%] 
dropped from 13% probability of having a 
prescription for painkillers to a 2-3% 
probability in Q3-Q9. The Decreasing class 
[ 11%] dropped from 63% to 9% in Q8 before 
increasing. The Repeated Highs class [9%] 
decreased from 33% to 16% then rose to 55% 
in Q8 before declining. The Level class [ 6%] 
had a consistently very high probability, 83-
92%. 
Imaging 
The Q1 Highest Then Level class [85%] 
dropped from 17% to 2-3% in Q3-Q9. The 
Repeat Highs class [7%] dropped from 23% 
to just 7% in Q2 & Q3 before rising to 32% 
in Q7. The Decreasing class dropped slowly 
from 54% to 41% in Q3 then more rapidly, 
reaching 5% in Q7 & Q8 before increasing 
one point. The Level/Decreasing class [2%] 
remained at 55-60% through Q6 then 
declined to 38%. 
- Ql High 7696 _..Rp!. Highs 1296 -.!r-Lvi/ Hurnp 396 ...... Oe<r. l 096 
1.00 r----------------
__.Q1 High 7596 -+- Ri>!. High< 996 -Level696 ........ Oecr. l196 
1.000 I 
0.750 -r---------------
__.Ql High 86% -+-Ri>!. Highs 7% ~Lvi/Oecr. 2% ....... Deer. 696 
1.000 ,---------------
156 
Surgery/Injection 
After dropping from 7%, the Q 1 Highest 
Then Level class [86%] remained at a very 
low level, 0.4-0.5% in Q2-Q9. The Decrease 
class [7%] declined steadily from 51% to 5% 
in Q6 then remained at 3-4%. The Repeat 
Highs class [5%] dropped sharply from 18% 
to just 3% in Q2 then rose consistently but 
slowly, reaching 28% in Q8. The 
Level/Decrease class [1 %] varies between 
48% and 57% in Q1-Q8 and had a distinct, if 
slow, decrease from Q6 to Q9, ending at 
43%. 
~Ql High 86% -..Ril l. High< 5% -Lvi/ Decr. l % ...-o .. r. 7% 
1.000 ,------- ---------
0.750 -1---------------
The results include a set of four probabilities in each quarter. The probabilities are 
for subjects in the class having one kind of service only, the other only, both, or neither. 
In a given quarter, the probabilities must, of course, add up to 1.0. The probabilities for a 
given service are additive; a 10% probability of getting only getting one type of service in 
a given quarter plus a 15% probability of getting both services in the quarter adds to a 
25% probability of getting that service in the quarter. 
The bivariate models demonstrate the rate at which services were received, 
relative to the other service in the model. As expected, as every univariate model has a 
Q 1 Highest The Level class, every bivariate model has one class with a low probability of 
at least one kind of service in Q 1 and essentially no utilization in Q2-Q9. This section 
presents results for the other classes, those with the probability of services. Table 9.8 
shows the proportion of total subjects in each model. For example, in the model with 
painkillers and therapy, 54% of subjects were very unlikely to receive either service; the 
data presented below are for the remaining 46%. 
Table 9.8. Percentage of subjects included in each 2-variable model. 
%subjects Painkillers Therapy Imaging Surgery/Injection 
Painkillers 
Therapy 46% 
Imaging 42% 44% 
Surgery/Injection 25% 31% 27% 
Visits 44% 47% 43% 31% 
The total probabilities for getting any given type of service change depending on 
which service they are paired with because, of course, the set of subjects is somewhat 
different. In Q 1, therapy was highest overall, with total probabilities of 64-68%. 
Painkillers were second highest, with probabilities of 48-58%. Imaging and visits had 
similar levels, with probabilities of 35-51 and 39-44%, respectively. Surgery/injection 
was lowest, with probabilities of 31-45%. 
By Q9, the frequency of each service type had declined. Probability of painkillers 
was highest, at 30-41%. The probability of therapy was second highest, with probabilities 
of 17-21%. Imaging and surgery/injection both had similar probabilities of approximately 
10%. 
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We analyzed 2-class and 3-class models for each set of services. The 3-class 
typically improved on the 2-class model by producing three distinct classes of clinical 
interest, such as (l) very low users, (2) moderate users, and (3) high users, or (1) very 
low users, (2) patients with declining rates of use, and (3) patients with consistent rates of 
use. Statistically, the 3-class models had lower AIC statistics. 
Table 9.9 describes two sets of results in detail: (1) patterns of service types for 
each combination of services resulting from 2-class models, and (2) patterns over time 
results from the 3-class models for each combination of services. 
Table 9.9. Results of bivariate analyses, by service type and over time. 
Model 
Painkillers & 
Therapy 
Painkillers & 
Imaging 
Results 
By service tvpe: 54% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 46% the distribution was as follows. 
In Q1, subjects were most likely to have Therapy Only; 36% had Therapy 
Only, 31% both services, and 17% Painkillers Only. The probability of 
Painkillers Only increased over time. In Q2, the probabilities for Painkillers 
Only were 24%, higher than Therapy Only at 22%. In Q9, the probability 
for Painkillers Only was 23%, for Therapy Only 15%, and for both services 
5%. 
Over time: The three classes have very different patterns. A class with 39% 
of subjects had a Decreasing level of getting therapy, with or without 
painkillers in the quarter, a Level pattern of getting Painkillers Only (11-
17%), and a Q1 Highest Then Level pattern of getting both (26% then 3-
6%). Overall, its probability of getting painkillers was moderate and 
Decreasing from 40% to 10%. 
A high utilization class, with 8% of subjects, had a probability of getting 
either or both services in a given quarter that ranged from 79% to 94%. Its 
probability of getting Therapy Only, or getting both, followed the Q1 
Highest Then Level pattern, with both much higher (54% then 13-21 %) than 
Therapy Only ( 16% then 3-6% ). This class ' probability of getting 
Painkillers Only followed the Hump pattern, increasing steeply from 25% in 
Ql to 55% in Q2 and continuing to 68% in Q7, then dropping slightly to 
63%. 
53% of subjects had a low likelihood of receiving either service in any 
uarter. 
By service tvpe: 58% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 42% the distribution was as follows. 
In Q 1, subjects were most likely to have Painkillers Only; 31% had 
Painkillers Only, 23% hnaging Only, and 20% both services. The 
probabilities for Painkillers Only declined very slowly, so the differences 
became greater. In Q9, the probabilities were 27%, 8%, and 3%. 
Over time: A class with 36% of subjects demonstrated a general decline in 
services. Painkillers Only had a Decreasing pattern (27 to16%); hnaging 
Only Decreasing/Level (24% to 11% in Q3 then level at 9-11 %). 
Probabilities for both services together had a Q 1 Highest Then Level pattern 
(17 then 1-3%). 
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Model 
Painkillers & 
Office Visits 
Surgery/Injection 
& Painkillers 
Results 
A high utilization class with 8% of subjects had an 80 to 89% probability of 
getting either or both services in a given quarter. It had a Q 1 Highest Then 
Level pattern for Imaging Only and for both services together ( 10% then 2-4 
and 35% then 8-12%, respectively). It had a high Hump pattern for 
Painkillers Only, growingfrom 44% to 74-77% in Q4-Q7 (peaking in Q6) 
then declining to 50%. 
56% of subjects had a low likelihood of receiving either service in any 
uarter. 
By service type: 56% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 44% the distribution was as follows. 
In Q1, subjects were most likely to have Painkillers Only; 31% had Therapy 
Only, 22% for Visits Only, and 22% for both services. The probability for 
Painkillers Only decreased slowly; in Q9, the differences were greater with 
probabilities at 24%, 13%, and 4%, respectively. 
Over time: The three classes have very different patterns. A class with 3 7% 
of subjects had a Decreasing level of each type of service. Their probability 
of having office visits with no surgical, injection, or therapeutic services 
declined from 25% to 15%, of having Painkillers Only from 27% to 15%, 
and of having both from 19% to 3%. 
A high utilization class, with 8% of subjects, had a 79% to 94% probability 
of getting either or both services in a given quarter. Its probability of 
getting Therapy Only, or getting both, followed the Q1 Highest Then Level 
pattern, with both much higher (54% then 13-21 %) than Therapy Only 
(16% then 3-6%). This class ' probability of getting Painkillers Only 
followed the Hump pattern, increasing from 42% to 71% in Q6, and then 
dropping slightly to 64%. 
55% of subjects had a low likelihood of receiving either service in any 
uarter. 
By service type: 75% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 25% the distribution was as follows. 
In Q 1, subjects were most likely to have Painkillers Only; 42% had 
Painkillers Only, 16% both services, and 15% Surgery/Injection Only. In 
Q9, the probabilities were 38%, 3%, and 6%. 
Over time: Two classes had a Q1 Highest Then Level pattern of having 
surgery/injection, either with or without painkillers (other than those 
associated with the surgery/injection) in the quarter. 29% of subjects had a 
30% likelihood in Q1 then 8-11% in Q2-Q9 while 7% of subjects had a 25% 
likelihood in Ql then 5-8% in Q1-Q9. The probability of having Painkillers 
Only differed for the two classes, with 7% maintaining a high probability 
(60-83%) while the probability for the class with 29% of subjects declined 
from 34% to 19%. A high utilization class, with 7% of subjects, had an 80% 
to 89% probability of getting either or both services in a given quarter. 
64% of subjects had a low likelihood ofreceiving either service in any 
quarter. 
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Model 
Surgery/Injection 
& Therapy 
Surgery/Injection 
& Office Visits 
Surgery/Injection 
& Imaging 
Results 
By service type: 69% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 31% the distribution was as follows. 
In Q1 , subjects were most likely to have Therapy Only; 47% had Therapy 
Only, 16% both services, and 12% Surgery/Injection Only. In Q9, the 
probabilities were 24%, 6%, and 2%. 
Over time: Two classes had a Q 1 Highest Then Level pattern of having 
surgery/injection, either with or without therapy in the quarter. 28% of 
subjects had a 28% likelihood in Q1 then 8-18% in Q2-Q9 while 8% of 
subjects had a 21% likelihood in Q1 then 4-7% in Q1-Q9. The probability 
of having Therapy Only differed for the two classes, with 8% maintaining a 
fairly high probability (51-69%) while the probability for the class with 
28% of subjects declined from 49% to 12%. 
By service type: 69% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 31% the distribution was as follows. 
In Q1, subjects were most likely to have Visits Only; 31% had Visits Only, 
20% Surgery/Injection Only, and 12% both services. In Q9, the probabilities 
were 20%, 7%, and 1%. 
Over time: Two classes had a Q 1 Highest Then Level pattern of having 
surgery/injection, either with or without office visits with no surgical, 
injection, or therapeutic services in the quarter. 28% of subjects had a 33% 
likelihood ofhaving surgery/injection in Q1 then 8-14% in Q2-Q9. 4% of 
subjects had a 23% likelihood of having surgery/injection in Q1 then 4-6% 
in Q2-Q9. The probability of having office Visits Only differed for the two 
classes. It declined from 31% to 14% for the class with 28% of subjects. 
The class with 4% of subjects demonstrating the Hump pattern at a 
moderate level (38% to 67% in Q5 to 53%). 
By service type: 73% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 27% the distribution was as follows. 
In Q1, subjects were most likely to have Imaging Only; 32% had Therapy 
Only, 22% Surgery/Injection Only, and 13% both services. In Q9, the 
probabilities were 13%, 9%, and 1%. 
Over time: A class with 20% of subjects demonstrated a general decline in 
services. Both Surgery/Injection Only and with imaging had a Q 1 Highest 
Then Level pattern (24% then 3-5% and 9% then 0.5-2%, respectively). 
Imaging Only had an overall Decreasing trend from 25%, level at 19-21% 
in Q2-Q6, then declining gradually to 16%. 
A class with 8% of subjects had Ql Highest Then Level patterns for 
Imaging Only and both (45% then 4-7% in Q3-Q9 and 22% then 2-4% in 
Q2-Q9, respectively). The pattern for Surgery/Injection Only was an almost 
flat Hump pattern, increasing from 12 in Q I then remaining level at 19-
24%. 
72% of subjects had a low likelihood of receiving either service in any 
quarter. 
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Model 
Therapy & 
Imaging 
Office Visits & 
Imaging 
Therapy & Office 
Visits 
Results 
By service type: 56% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 44% the distribution was as follows. 
In Ql , subjects were most likely to have Therapy Only; 42% had Therapy 
Only, 23% both services, and 15% Surgery/Injection Only. Probabilities for 
imaging decreased moderately, but Therapy Only remained highest in Q9. 
In Q9, the probabilities were 18%, 2%, and 9%. 
Over time: A class with 39% of subjects demonstrated a general decline in 
services. Imaging Only had a Decreasing pattern (14 to 9%); Therapy Only 
Decreasing/Level (14% to 10% in Q5 then level through Q9). Probabilities 
for both services together had a Q 1 Highest Then Level pattern ( 14 then 1-
2%). 
A high utilization class with 7% of subjects had a 60 to 82% probability of 
getting either or both services in a given quarter. It had a Ql Highest Then 
Level pattern for Imaging Only and for both services together (12% then 2-4 
and 28% then 5-9%, respectively). It had a high Hump pattern for Therapy 
Only, growing from 42% to 67% in Q5 and Q6 then declining to 50%. 
54 % of subjects had a low likelihood of receiving either service in any 
uarter. 
By service type: 57% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 43% the distribution was as follows. 
In Q I, subjects were equally likely to have Visits Only (26%) or Imaging 
Only (25%), and less likely to have both services (16%). The probability of 
visits declined slowly. In Q1, probabilities were 16% for Visits Only, 9% 
for Surgery/Injection Only, and 2% for both services. 
Over time: A class with 41% of subjects demonstrated a general decline in 
services. Office visits with no surgical, injection, or Therapy Only had a 
Decreasing pattern (26 to 13%); Imaging Only Decreasing/Level (25% to 
11% in Q3 then level at 9-11% ). Probabilities for both services together had 
a Ql Highest Then Level pattern (15 then 1-3%). 
A high utilization class with 4% of subjects had a 63 to 7 5% probability of 
getting either or both services in a given quarter. It had a QI Highest Then 
Level pattern for Imaging Only and for both services together (22% then 3-
6% and 25% then 6-10%, respectively). It had a high Hump pattern for 
Visits Only, increasing quickly from 29% to 48% in Q2 then steadily to 65% 
in Q5 & Q6 then declining to 52%. 
By service type: 53% of subjects had a low likelihood of receiving either 
service in any quarter. Of the other 47% the distribution was as follows. 
In Q 1, subjects were most likely to have Therapy Only; 41% had Therapy 
Only, 25% both services, and 14% Visits Only. In Q9, the probabilities were 
closer between Therapy Only, with a Decreasing pattern (16%), and visits, 
with a Level pattern (14%). The probability of both services was 3%. 
Over time (2 class model) : 46% of subjects demonstrated a Decreasing 
pattern of receiving Therapy Only, without office visits with no surgical, 
injection, or therapeutic services ( 41% to 16% ), a Level pattern of having 
office Visits Only (14-16%), and a Ql Highest Then Level pattern of 
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Model Results 
receiving both (25% then 3%-6%) in the quarter. 
54% of subjects had a low likelihood of receiving either service in any 
uarter. 
The most significant result from these analyses is that a small set of subjects with 
very high utilization emerged with the following ranges of probabilities of getting 
services across quarters: 
• 8% of subjects in the Therapy & Painkillers analysis (79-94%); 
• 8% of subjects in the Imaging & Painkillers analysis (80-89%); 
• 8% of subjects in the Therapy & Imaging analysis (79-94%); 
• 7% of subjects in the Surgery/Injection & Painkillers analysis (80-89%); 
• 7% of subjects in the Surgery/Injection & Therapy analysis (60-82%); and 
• 4% of subjects in the Surgery/Injection & Imaging analysis (63-75%). 
The high utilization class received all four types of service. 
10 APPENDIX 4: ADDITIONAL DATA FOR COST OF TREATMENT STUDY 
Table 10.1 presents the observed-to-expected ratios for each sensitivity analysis, and its 
rank compared to the other three tests within each analysis. 
Table 10.1. Observed values compared to expected values of each theoretical distribution. 
Lognormal Weibull Gamma Exeonential 
%ile OlE Rank OlE Rank OlE Rank OlE Rank 
1% 0.188 1 4.590 3 5.615 4 0.377 2 
5% 0.098 1 1.023 3 1.036 4 0.225 2 
10% 0.055 1 0.408 4 0.338 2 0.345 3 
MRI 25% 0.022 1 0.054 2 0.144 3 0.422 4 
Base plus 50% 0.094 1 0.114 2 0.197 3 0.313 4 
Chiropractic 75% 0.041 1 0.107 2 0.158 3 0.164 4 
90% 0.007 1 0.056 3 0.048 2 0.134 4 
95% 0.121 2 0.094 0.123 3 0.261 4 
99% 0.259 1 0.380 2 0.513 3 0.788 4 
1% 0.399 2 3.451 3 5.690 4 0.353 1 
MRI 5% 0.010 1 1.230 3 1.503 4 0.407 2 
Medical, 10% 0.033 1 0.417 2 0.426 3 0.508 4 
only if 25% 0.024 1 0.040 2 0.131 3 0.515 4 
primary 50% 0.107 1 0.125 2 0.228 3 0.388 4 
diagnosis of 75% 0.074 1 0.077 2 0.152 3 0.165 4 
LBP, and 90% 0.015 1 0.070 3 0.049 2 0.169 4 
Pharmacy 95% 0.170 3 0.098 1 0.125 2 0.322 4 
99% 0.350 1 0.354 2 0.514 3 0.913 4 
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5% 
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5% 
10% 
25% 
50% 
75% 
90% 
95% 
99% 
1% 
5% 
10% 
25% 
50% 
75% 
Lognormal 
OlE Rank 
0.289 2 
0.098 1 
0.077 1 
0.026 1 
0.100 1 
0.087 2 
0.054 3 
0.185 
0.304 
0.121 
0.075 
0.093 
0.050 
0.063 
0.074 
0.042 
0.095 
0.257 
0.044 
0.117 
0.030 
0.037 
0.019 
0.021 
0.069 
0.040 
0.129 
0.677 
0.546 
0.312 
0.258 
0.250 
0.015 
0.147 
0.269 
0.519 
0.185 
0.063 
0.006 
0.037 
0.041 
0.002 
3 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
3 
1 
1 
1 
2 
1 
3 
2 
1 
3 
3 
2 
1 
1 
1 
Weibull 
OlE Rank 
3.439 3 
0.899 3 
0.311 3 
0.031 2 
0.113 2 
0.055 
0.018 2 
0.048 
0.355 
7.721 
1.209 
0.406 
0.070 
0.145 
0.093 
0.073 
0.107 
0.367 
10.542 
2.360 
0.904 
0.038 
0.193 
0.170 
0.010 
0.138 
0.775 
2.186 
0.072 
0.866 
0.078 
0.083 
0.123 
0.044 
0.182 
0.460 
12.742 
2.286 
0.870 
0.046 
0.212 
0.191 
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1 
2 
3 
3 
3 
2 
2 
2 
3 
2 
2 
3 
3 
4 
2 
2 
2 
1 
2 
2 
3 
1 
3 
2 
2 
2 
2 
1 
3 
3 
4 
2 
2 
2 
Gamma 
OlE Rank 
4.226 4 
0.922 4 
0.257 2 
0.113 3 
0.188 3 
0.102 3 
0.014 1 
0.077 
0.480 
10.379 
1.313 
0.359 
0.165 
0.239 
0.158 
0.057 
0.135 
0.514 
14.690 
2.488 
0.791 
0.110 
0.316 
0.260 
0.033 
0.143 
0.959 
11.154 
0.853 
1.360 
0.029 
0.279 
0.282 
0.043 
0.179 
0.728 
18.432 
2.468 
0.771 
0.106 
0.337 
0.284 
2 
3 
4 
4 
2 
3 
3 
3 
2 
3 
3 
4 
4 
3 
3 
3 
3 
2 
3 
3 
4 
3 
4 
1 
3 
3 
1 
1 
3 
4 
4 
3 
3 
3 
3 
Exponential 
OlE Rank 
0.210 1 
0.219 2 
0.354 4 
0.385 4 
0.297 4 
0.108 4 
0.092 4 
0.201 
0.732 
0.625 
0.302 
0.439 
0.487 
0.373 
0.167 
0.161 
0.304 
0.851 
0.505 
0.177 
0.384 
0.505 
0.459 
0.272 
0.077 
0.344 
1.476 
0.929 
0.923 
0.775 
0.733 
0.573 
0.329 
0.150 
0.571 
1.643 
0.629 
0.247 
0.427 
0.519 
0.482 
0.297 
4 
4 
2 
2 
4 
4 
4 
4 
4 
4 
4 
2 
2 
2 
4 
4 
4 
4 
4 
4 
2 
4 
2 
4 
4 
4 
4 
4 
4 
2 
2 
2 
4 
4 
4 
Lognormal Wei bull Gamma Ex~onential 
%He OlE Rank OlE Rank OlE Rank OlE Rank 
90% 0.043 3 0.023 1 0.069 4 0.042 2 
95% 0.021 1 0.106 2 0.108 3 0.312 4 
99% 0.142 0.778 2 0.964 3 1.509 4 
1% 0.710 2 22.153 3 40.787 4 0.674 
5% 0.215 1 3.020 3 3.743 4 0.348 2 
10% 0.017 1 0.984 3 0.992 4 0.540 2 
NoMRI 25% 0.161 2 0.088 0.223 3 0.652 4 
Medical 50% 0.022 1 0.210 2 0.356 3 0.534 4 
Only 75% 0.030 1 0.184 2 0.301 3 0.321 4 
90% 0.152 4 0.069 2 0.002 1 0.143 3 
95% 0.104 1 0.196 3 0.185 2 0.457 4 
99% 0.069 1 0.705 2 0.902 3 1.570 4 
* This dataset does not clearly fit one distribution over the others. 
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